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Abstract 
Aims: Mature podocytes are terminally differentiated and their turnover is very low under 
physiological conditions. This suggests that they are maintained by an endogenous survival 
signal. Vascular endothelial growth factor (VEGF) is known to promote survival in 
endothelial cells via activation of the P13-Kinase/AKT survival pathway. VEGF is highly 
expressed by podocytes, which are known to express a co-receptor for VEGF-receptor 2. The 
aim of this thesis was to investigate if VEGF could promote survival in cultured podocytes. 
Results and conclusions: Exogenous and endogenous VEGF significantly reduced 
cytotoxicity in cultured podocytes in an autocrine manner via a reduction in apoptosis. The 
reduction in cytotoxicity was dependent on VEGF-RI (and possibly VEGF-R3) and P13- 
Kinase activation. VEGF165 also induced the phosphorylation of nephrin, a cell adhesion 
molecule associated with the slit diaphragm of podocytes and linked to survival signalling in 
podocytes. The reduction in apoptosis induced by VEGF in podocytes was also shown to be 
dependent on normal nephrin expression. This was demonstrated with the use of two 
podocyte cell lines, one with a mutation in the extracellular domain of nephrin, the other 
which was nephrin deficient. VEGF-C, expressed by podocytes, also significantly reduced 
cytotoxicity in cultured podocytes and was shown to induce the phosphorylation of VEGF- 
receptor 3 and nephrin. VEGF165b, a novel VEGF isoform shown to be anti-angiogenic by its 
action on endothelial cells, dose dependently reduced cytotoxicity in cultured podocytes, but 
in the presence of VEGF dose dependently increased cytotoxicity. In conclusion members of 
the VEGF family are expressed in podocytes and play a role in promoting their survival, yet 
they may also antagonise each other under pathological conditions. 
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Introduction 
1.1 Renal Disease 
Renal disease is relatively uncommon in the general population (Feest et al., 1990). Despite its 
relative rarity however, it is a very significant health care problem. Approximately 30% of all 
cases of glomerular disease progress to end stage renal failure and renal replacement therapy 
(long term dialysis or renal transplantation). Renal replacement therapy is associated with 
significant increased mortality -a5 year survival rate of 50% (2001). This equates to the 
survival figures for grade II stomach cancer. In addition, renal replacement therapy costs the 
NHS approximately 13 0,000 per patient/per year (200 1) and most centres have in the region of 
400 such patients. 
A greater understanding of glornerular function in health and disease is therefore warranted 
since any potential therapeutic interventions that result would have profound clinical and 
financial implications. 
1.2 Podocytes 
The glomerulus is a unique ultra filtration unit (Berrie and Levy, 1992). It is a network of 
capillaries supplied by the afferent arteriole and drained by the efferent arteriole. These 
capillaries are covered by a basement membrane, which in turn is covered by epithelial cells or 
podocytes (Beme and Levy, 1992) (figurel. 1). Mesangial cells sit between the capillaries and 
provide them with structural support, secrete extracellular matrix, and exhibit phagocytic 
activity (Beme and Levy, 1992). Three clearly defined barriers are believed to determine 
permeability in the glomerulus; the basement membrane, endothelial and epithelial cells. 
These are highly permeable to water, small solutes and small proteins, however large proteins 
23 
are generally retained. These layers are collectively known as the glomerular filtration barrier 
(Berne and Levy, 1992) (figure 1.1). 
Permeability is partly determined by the presence of 700 A fenestrations in the endotheliurn 











Figure I. I. A transmission electron micrograph of the glomerular fillration harrier. 
The glomerular filtration barrier consists (if fenestrated endothelial cells (FEC) which lack diaphragms, a 
glomerular basement membrane (GBM) and podocYtes, with interdigitating foot processes, i% hich together 
regulate permeabilitil (Berne and Levil, 1992). 
The (jBM is a heteropolymetric network, cornposed of type IV collagen, larninin and 
libronectin (Ilavenstadt, 2000). This network creates a negative charge of matrix proteins 
(Deen et al., 2001), which act to repel positively charged molecules. It is the podocytes 
(figurel 
. 
1), however that account for 40% of hydraulic resistance of the filtration barrier 
(Deen et al., 200 1 ). They differ from normal vascular epithelial cells (pericytes) because they 
cease to proliferate and diffierentlate to form foot processes when they reach maturity. The 
foot processes are separated by slit diaphragms that contain pores ot'dimensions 40 x 140A 
(Berne and Levy, 1992). The foot processes interdigitate around the GBM surrounding the 




and the podocytes effectively retain molecules over 36A through size selectivity, and even 





Figure 1.2. Scanning electron micrograph of podocytes surrounding glomerular capillaries. 
Primary podocyte foot process extend from the podocyte cell body, branch into secondary foot processes 
and finally into tertiary foot processes (enlarged area). The tertiary foot processes interdigitate with 
tertiary foot processes of the same cell or of neighbouring podocytes (Berne and IRvy, 1992). 
Podocytes are the last line of defence against macromolecular leakage, and therefore 
disruption of podocytes for example through disease, would have profound consequences on 
filtration control. Many types of glomerular disease are characterised by podocyte injury 
(Gassler et al., 2001), but humans do not usually present until glomerular disease is well 
established. The pathological characteristics of glomerular disease with time are unknown, 
therefore the following sequence for progressive renal disease was attempted using a fa/fa 
Zucker rat model, originally a rat model for non-Insulin-dependent diabetes mellitus. The 
authors described the sequence of podocyte injury (Gassler et al., 2001). Firstly, there is foot 
process effacement defined as retraction of foot processes and loss of foot process and slit 
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diaphragm organisation, a process that can be reversed if the cause of injury is acute rather 
than chronic (Schwartz, 2000). Secondly, lipid droplets and lysosomal elements accumulate 
in the podocyte cytoplasm presumably from podocyte endocytosis of GBM macromolecules. 
Thirdly, podocytes are lost, which has a direct correlation with glomerulosclerosis (Kim et al., 
2001) resulting in denuded areas of the GBM. Fourthly, tuft adhesions form at denuded areas 
of GBM to the Bowman's capsule (Gassler et al., 2001), which leads to loss of glomerular 
filtration capacity (Schwartz, 2000). Excessive leakage of plasma proteins into the proximal 
tubule follows and the proximal tubules reabsorb these proteins until they reach saturation 
levels. In response to this mediators are released from the tubules towards the interstitium, 
giving rise to interstitial proliferation and matrix deposition (as discussed in (Gassler et al., 
2001)). This leads to the sclerosis of the entire nephron unit, which is often situated in close 
proximity to healthy nephrons, or those that have already gone through this process 
independently (Gassler et al., 2001). Such a sequence of putative events in humans would be 
one "planation of primary podocyte injury progressing to end stage renal disease. A greater 
understanding of the factors that influence podocyte maintenance and survival may provide 
novel therapeutic avenues designed to enhance podocyte survival and minimise subsequent 
nephron loss and reduction of GFR. The terminally differentiated, growth arrested phenotype, 
of the podocyte may provide a clue to the susceptibility of podocytes to injury. 
I. ZI Podocyte differentiation 
Cell cycle completion (cytokinesis) is controlled by cyclin activation of partner cyclin 
dependent kinases (CDKs). Cell cycle arrest is controlled by cycle dependent kinase 
inhibitors (CDKIs) (Barisoni et al., 2000), which bind to specific cyclin complexes 
(Petermann et al., 2002) (figure 1.3). During human glomerulogenesis immature podocytes 
are proliferative, but from the capillary loop stage of glomerulogenesis expression of cyclins 
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change from that of cyclin A to cyclin D and there is upregulation of CDKIs p57 and p27. 
The podocytes then exit the cell cycle, become terminally differentiated and quiescent 
(Barisoni et al., 2000). 
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Figure 1.3. The cell cycle. 
Each phase of the cell cycle is controlled by specific cyclin/CDK complexes. Upregulation of the CDK 
inhibitors, p27 and p57, prevent cyclin activation by CDKs at the GI phase of the cell cycle. This is the 
stage of the cell cycle in which podocytes are held at differentiation (Nagata et al., 1998). 
A natural response of cells to injury is to proliferate and recover but this is rarely the case with 
podocytes (Shankland et al., 2000). In fact it is thought that this may underlie the 
development of glomeruloscicrosis (Griffin et al., 2003). It is widely accepted that the 
expression of p27 and p57 ensures that the podocyte does not re-enter the mitotic phase of the 
cell cycle (Barisom et al., 2000), However Bailey et al (Bailey et al., 1998) demonstrated that 
human podocytes can enter S-phase using in situ hybridisation for histone mRNA, (a reliable 
marker of S phase of the cell cycle). This leads to podocytes undergoing DNA synthesis, but 
not cytokinesis and therefore it is not uncommon to find podocytes with polyploid nuclei. One 




is an early feature of the disease: Podocytes become hypertrophic and hyperplastic due to a 
loss of CDKIs and cyclin A is re-expressed (Barisoni et al., 2000). For the most part, however, 
if podocytes are lost then the neighbouring podocytes have a limited capacity to cover the area 
of denuded basement membrane (Nagata et al., 2003a) and it has been suggested, as discussed 
earlier, that this exposed area of GBM commonly leads to proteinuria. Therefore, to ensure 
the integrity of the glomerular filtration barrier it is vital that terminally differentiated 
podocytes are maintained in the mature glomerulus. Other cell types provide clues as to how 
this may be achieved in podocytes. For example, myoblasts are similar to podocytes in that 
they tenninally and irreversibly differentiate into myotubes and some also have polyploid 
nuclei. This phenotype is resistant to apoptosis. It is thought that withdrawal from the cell 
cycle facilitates the induction of a cell signalling pathway, which involves AKT 
phosphorylation, and promotes survival (Fujio et al., 1999). It has also been considered that 
Insulin-like growth factors may activate AKT phosphorylation through activation of 
phosphatidylinositol 3-kinase (P13 Kinase) in an autocrine manner (Fujio et al., 1999). In 
vitro assays using sense oligonucleotides to p2l CDKI mRNA showed that endogenous AKT 
induction is p2l dependent. Human podocytes do not express p2l (Griffin et al., 2003), 
however this same paper has shown that forced expression of p27 (expressed in podocytes) 
can compensate for p2l. The link in this cell type between mitotic activity and apoptosis 
provides a clue to prolonged survival of podocytes. It may be possible that growth factors, 
expressed by podocytes, also play a role in maintenance of differentiated podocytes. One 
paradox of podocyte biology is that podocytes appear to express a high level of vascular 
endothelial growth factor (VEGF) mRNA and protein. 
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1.3 VEGF in endothelial cells 
VEGF is a powerful endothelial cell migration, vasodilator, mitogen, angiogenic and 
permeability factor and has permeability properties more potent than histamine (Aiello and 
Wong, 2000). The importance of this molecule was outlined by Ferrara et at, who 
demonstrated that a loss ofjust one VEGF allele is embryonically lethal in mice (Ferrara et al., 
1996). The VEGF gene has eight exons from which alternate splicing can form a number of 
different active disulphide linked homodimer isoforms (Ferrara, 2001, Neufeld et al., 1999). 
The isoforms are named according to their length of amino acids; they all have different 
properties encoded for by different exons (Neufeld et al., 1999). The most common isoforms 
are VEGF189, VEGF165and VEGF121, all of which have different binding affinities for heparin- 
sulphate proteoglycans. The longer isoforin is cell associated due to its high affinity for 
proteoglycans and may be activated by protease activation and cleavage (Ferrara, 2001), while 
the two shorter isoforms are secreted. VEGF165 binds heparin and therefore can bind to the 
cell surface or the extracellular matrix, but VEGF121 has no heparin binding ability and 
therefore is freely diffusible (Ferrara, 2001, Simon et al., 1995). Due to its widespread 
expression VEGF165 is the most studied of the VEGF isoforms. VEGF-C, which will be 
discussed later in detail, is a member of the VEGF family of growth factors and has an N 
terminal and a C-terminal extension flanking a VEGF homology domain (Joukov et al., 1997). 
It is a ligand for both VEGF-R2 (with a lower binding affinity than VEGF) and VEGF-R3 (see 
figure 1.4), is pre-dominantly expressed in the lymphatic system and is thought to function in 
lymphangiogenesis (Joukov et al., 1997) as oppose to VEGF in angiogenesis. 
The VEGFs act through three class III tyrosine kinase receptors: VEGF receptor I (VEGF- 
RI), VEGF receptor 2 (VEGF-R2) and VEGF receptor 3 (VEGF-R3) all of which have seven 
extracellular immunoglobulin-like domains (Neufeld et al., 1999), a single transmembrane 
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domain and an intracellular tyrosine kinase domain (figure 1.4). VEGF binds to both VEGF- 
RI and VEGF-R2 causing dimerization and auto-phosphorylation. There is, however, no 
evidence to suggest that it can directly bind to VEGF-R3: a receptor expressed on lymphatic 
endothelial cells, which is known to bind VEGF-C (Jussila and Alitalo, 2002). VEGF-RI 
binds VEGF165 with a greater affinity than VEGF-R2, although it has been suggested that it 
acts mainly as a decoy receptor by competitively binding VEGF (Neufeld et al., 1999). 
Various studies have suggested it is likely that VEGF-R2 is the sole mediator of VEGF- 
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Figure 1.4. Growth factors and receptors of the VEGF family. 
The three signalling class III tyrosine-kinase receptors of the VEGF family (VEGF-RI, VEGF-R2 and 
VEGF-R3), the accessory isofrom specific receptors neuropilin-I and neuropilin-2, and VEGF binding 
heparin-sulphate proteoglycans are displayed with general structural features. VEGFI&,; is able to bind to 
every receptor except VEGF-R3 (adapted from ligyurc 1, (Neufeld et al., 1999)). 
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VEGF activates a diverse range of signalling pathways in endothelial cells via VEGF-R2. For 
example auto-phosphorylation of VEGF-R2 by VEGF activates phospholipase CY (PLC), 
which leads to diacylglycerol (DAG) generation and consequently an increase in [C21i, 
probably due to an external influx via transient receptor potential (TRP) channels in the 
plasma membrane, resulting in an increase in vessel permeability (Bates and Curry, 1997) 
(Pocock et al., 2000). An increase in [Ca2+]i also leads to nitric oxide activation by nitric 
oxide synthase, resulting in vessel vasodilatation (as reviewed in (Bates et al., 1999)). VEGF- 
R2 auto-phosphorylation also activates a PLCy, PKC, Raf, mitogen activated protein kinase 
kinase (MEK), p42/44 mitogen activated protein kinase (MAPK), dependent signalling 
cascade, which results in endothelial proliferation and migration (Wu et al., 2000) (Ilan et al., 
1998). Activation of P13-Kinase, by VEGF-R2, induces AKT phosphorylation and promotes 
survival, as discussed below (Gerber et al., 1998b). An increase in permeability, cell 
proliferation and migration are all part of the VEGF induced angiogenesis sequence in 
endothelial cells of capillaries. The aspect of VEGF signalling that is most applicable to 
potential VEGF signalling in podocytes, however is VEGF induced survival signalling. 
1.3.1 VEGF and survivalpathways 
To understand if VEGF can promote survival in podocytes, a basic understanding of VEGF 
survival signalling in endothelial cells is required. The actions of VEGF16s on VEGF-R2 have 
been well documented, mostly in vascular endothelial cells due to the original, but erroneous 
concept that VEGF was endothelial cell specific. VEGF has been shown to act as a survival 
factor in these cells via a pathway well recognised in a variety of cell types, which is 
independent of VEGF mediated vasodilatation, permeability and migration pathways. VEGF, 
via VEGF-R2, induces the phosphorylation of P13-Kinase by binding the SH2-domain of the 
P13-Kinase p85 regulatory subunit. This is probably via an adapter molecule, because the 
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motif to bind the SH2 domain is not present on VEGF-R2 (Gerber et al., 1998b). This 
increases intracellular levels of phosphatidylinositol-3,4,5 bisphosphate (PI(4,5)P2) and 
phosphatidylinositol-3,4,5 trisphosphate (Pl(3,4,5)P3). These positively regulate the serine- 
threonine protein kinase AKT by binding to its pleckstrin homology (PH) domain (Gerber et 
al., 1998b) (figure 1.5). The VEGF survival pathway is P13-kinase/AKT dependent (Gerber et 
al., 1998a, Gerber et al., 1998b) and has been associated with increased levels of two anti- 
apoptotic proteins: Bcl-2 and Al (Gerber et al., 1998a). The Bcl-2 family of proteins consists 
of both pro- and anti-apoptotic proteins. Examples of pro-apoptotic proteins are BAX, BAK 
and Bcl-Y, Examples of anti-apoptotic molecules are Bcl-2, Bcl-XL and Al (Oltvai et al., 
1993). These proteins have the ability to form homo- and heterodimers with each other and, 
depending on the ratio of proteins from each pro- and anti-apoptotic family, can compete with 
and neutralise the effects of the other (Gross et al., 1999). The phosphorylation of pro- 
apoptotic proteins by activated AKT proteins sequesters them to the cytosol where they cannot 
insert into the mitochondrial membrane to release cytochrome c (Gross et al., 1999), which 
would result in apoptosis (programmed cell death) (see figure 1.5). Surprisingly, VEGF can 
also stimulate a pathway that can induce apoptosis. As well as activating the P13-Kinase/AKT 
pathway VEGF also stimulates the activation of stress-activated serine/threonine protein 
kinase p38 mitogen activated protein kinase (MAPK) (Gratton et al., 2001). Using a cell 
culture model it was shown that the blockade of the P13-Kinase/AKT pathway attenuated 
VEGF stimulated MAPK kinase kinase 3 (MEKK3) phosphorylation thereby increasing Src 
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Figure 1.5. Schematic (of VEGF survival signalling in endothelial cells. 
Activation of VEGF-R2 by its ligand, VEGF, induces its autophosphorylation, which activates P13-Kinase. 
This converts PI(4, '9)2 to PI(3,4,5)P3, which induces the translocation of AKT to the plasma membrane 
where it is phosphorylated. Phospho-AKT induces the phosphorylation of members of the pro-apoptotic 
proteins, which inactivates them. If these proteins are not inactivated then they insert into the 
mitochondrial membrane and induce the release of cytochrome c, which forms an apoptosome with 
caspase 9 and Apaf I (apoptotic protease activating factor, a caspase recruitment domain). This cleaves 
and activates caspase 9, which cleaves and activates the effector caspases, 3 and 6. These cleave nucleases, 
which translocate to the nucleus and induce DNA fragmentation and death due to apoptosis. There is 
cross-talk between two VEGF signalling pathways, which balances pro- and anti-apoptotic signalling in 
endothelial cells. Activated related focal adhesion tyrosine kinase (RAFTK), by VEGF-R2, activates Src, 
which results in the phosphorylation of MEK (p-MEK), which then phosphorýylates p38 MAPIC This is 
linked to an increase in apoptosis, but can be inhibited by phosphorylated AKT. Thus, phosphorylated 
AKT is anti-apoptotic through two separate pathways. 
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This resulted in increased apoptosis in these cells. If this pathway was blocked then the P13- 
Kinase/AKT pathway was upregulated and apoptosis was reduced. This showed that the two 
pathways were physiologically linked to apoptosis and survival in endothelial cells (Gratton et 
al., 2001) (figure 1.5). The hypothesis that VEGF could induce survival signalling in 
podocytes was initiated due to the high expression of VEGF by podocytes. 
1.4 VEGF in the glomerulus 
In Situ hybridisation studies of human kidney tissue demonstrated the expression of VEGF 
mRNA by podocytes (see figure 1.6) and the expression of VEGF-R1 and VEGF-R2 on 
glomerular endothelial cells in both fetal and adult tissue (Simon et al., 1995). The potential 
for VEGF signalling in the glomerulus therefore originally lay with the endothelial cells. 
Vascularisation of the human kidney occurs during development, in the S-shaped body during 
the fifth gestational week. This coincides with the time VEGF is first expressed (Eremina et 
al., 2003), and also the time endothelial cells migrate into the developing glomerulus (Simon 
et al., 1995). It is thought that the VEGF expressing, de-differentiated podocytes situated next 
to the endothelial cells during the development of the vascular cleft provide the migratory cues 
to the endothelial cells to establish the glomerular vascular structure (Saxen and Sariola, 1987, 
Simon et al., 1995). VEGF therefore plays a specific paracrine role in angiogenesis during 
human kidney organogenesis (Simon et al., 1995). At maturity, it is thought that VEGF 
expression ensures the maintenance of the fenestrated endothelium (Simon et al., 1995) and 
also plays a role in maintaining the filtration barrier (Eremina et al., 2003). This was 
supported by Eremina et al using a Cre-loxP system, which allows switching on and off of 
specific genes, whereby the VEGF gene was switched off at various stages of murine 
development. It was shown that a reduction in VEGF at establishment of the vascular beds led 
to a loss of endothelial fenestrations (Eremina et al., 2003). Four isoforms of VEGF mRNA 
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are expressed in the cortex of the human kidney: VEGF121, VEGF165 VEGF189 (Simon et al., 
1995) and VEGF148 (Whittle et al., 1999), of which VEGF165 is predominantly expressed 
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Figure 1.6. Non-isotopic, in situ hybridisation for VEGF mRNA in the glomerular tuft (Bailey et al., 1999). 
Human renal cortex sections were probed with labelled VEGF mRNA. This section demonstrates that, 
within the glomerulus, dark staining for labelled VEGF mRNA was detected in cells at the periphery of the 
glomerular tuft, which, because of their micro-anatomy are known to be podocytes. Hence podocytes are 
the site of VEGF production in the healthy, mature human glomerulus. (Bailey et al., 1999). 
The same pattern of isoform expression has been seen in the mouse kidney, although each of 
these lack one amino acid compared to the human isoforms (Kretzler et al., 1998). Mouse and 
rat glomerular endothelial cells express VEGF-RI and VEGF-R2 and have also been shown to 
express neuropilin-1 (Np-1) (Robert et al., 2000) (Villegas and Tufro, 2002). Np-I is a co- 
receptor for receptors of the plexin family (Neufeld et al., 2002). Together these bind the 
ligand Sema-3A, a member of the class III semaphorin subfamily (Neufeld et al., 2002), which 
stimulates collapse of neural growth curves and repels axons (Neufeld et al., 2002). Np-I is 
also a co-receptor for VEGF-R2 and binds VEGF 165 at the protein sequence encoded by exon 7 
(Soker et al., 1998). It was first described as VEGF165R (Soker et al., 1997) in relation to 
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VEGF signalling until Soker et al discovered that it was identical to Np-I (Soker et al., 1998). 
Over expression of Np-I can cause abnormalities in the development of both the vascular and 
nervous system (Neufeld et al., 2002) and Np-l knock out mice do not survive past embryonic 
day 12.5 (Takashima et al., 2002). Np-I enhances the binding of VEGF165 to VEGF-R2 4 to 6 
fold compared to VEGF-R2 expression alone, it also enhances chernotaxis of porcine aortic 
endothelial (PAE) cells expressing VEGF-R2 and Np-I to VEGF165 2.5 fold compared to 
VEGF-R2 expression alone (Soker et al., 1998). Np-l is also first expressed in mouse and rat 
glomerular endothelial cells at the S-shaped body of development (Villegas and Tufro, 2002). 
This indicates that co-expression of Np-I and VEGF-R2 on glomerular endothelial cells aids 
glomerular vascular development and enhances VEGF signalling in these cells. Np-2 is also 
expressed on glomerular endothelial cells at the same time point (Villegas and Tufro, 2002) 
and can bind both VEGF165 and VEGF145 (a rarer isoform) (Gluzman-Poltorak et al., 2001). 
Little is known about its function in the vascular system although it is thought to form 
complexes with Np-I and VEGF-RI (as reviewed in (Neufeld et al., 2002)). 
Recently, it has been shown that human podocytes express mRNA and protein for Np-I and 
mRNA for Np-2 (Harper et al., 2001), which gave rise to the potential for VEGF signalling in 
podocytes. Neuropilins lack a cytoplasmic signalling domain (Soker et al., 2001) (Harper et 
al., 2001) and were not thought to be able to signal independently, but by associating with 
tyrosine kinase receptors it is thought they could function as signalling complexes (Gluzman- 
Poltoraketal., 2001). It is therefore surprising that there is no evidence to date to suggest that 
podocytes express VEGF-RI or VEGF-R2. In mice heterozygous for VEGF there was a 
dramatic loss of podocytes by week nine of development following endotheliosis and 
proteinuria (Eremina et al., 2003). The authors have suggested endothelial cells signal back to 
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podocytes to maintain them. Another interpretation is that VEGF signals directly to the 
podocytes, epithelial in origin, to maintain their survival. 
1.5 VEGF signalling in non-endothelial cells 
Work in recent years has uncovered a role for VEGF in cell types other then endothelial cells, 
despite the fact that it was thought to be endothelial specific, and these studies provide clues to 
potential VEGF signalling pathways in podocytes. Haernatopoietic stem cells express VEGF, 
VEGF-R1 and VEGF-R2 (Gerber et al., 2002). Using a cre-loxP system in mice to knock 
down VEGF Gerber et al elucidated that VEGF regulated haernatopoiefic stem cell survival 
through an internal autocrine loop, not generally seen to operate in endothelial cells (Gerber et 
al., 2002). This was demonstrated by the lack of effect of external acting inhibitors, although 
VEGF-R2 still plays a role in internal VEGF signalling. A similar mechanism was seen in 
VEGF expressing leukaemia cell lines. Although they express and signal through VEGF-R2 
there appear to be two independent autocrine VEGF signalling pathways: an external and an 
internal (Rosa Santos and Dias, 2004). Interestingly it appears that the internal autocrine 
pathway has a greater effect on cell survival. They suggest that VEGF-R2 is not exclusively 
membrane bound although it is still constitutively activated. This provides an interesting 
insight to the expanding signalling potential of VEGF. Taking this novel concept a step 
further Bachelder et al demonstrated, using anti-sense VEGF oligonucleotides in metastatic 
breast carcinoma cell lines, that VEGF promotes survival in a P13-kinase/AKT dependent 
manner (Bachelder et al., 2001). Not only are these cells not endothelial but they do not 
express VEGF-Rl or VEGF-R2. They do however express Np-1, as do podocytes, and the 
authors have shown that Np-1 is associated with elevated levels of survival. It is not known 
how VEGF can signal independently through Np-1, but this is not an isolated case. Miao et al 
have shown that overexpression of Np-I in rat prostate carcinoma AT2.1 cells, which express 
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VEGF but not VEGF-RI and VEGF-R2, led to an increase in tumour angiogenesis and 
reduced apoptosis (Mao et al., 2000). These authors have also postulated that VEGF165 may 
stimulate cells directly via Np-I binding, which would have relevance to VEGF signalling in 
podocytes independently of other VEGF receptors. This contradicts previous workers, who 
postulated that the intracellular domain of Np-I does not contain a signalling domain. Recent 
work by Wang et al, however, indicates that Np-I may be able to signal independently. They 
created a chimeric receptor by fusing the extracellular domain of epidermal growth factor 
receptor (EGFR) to the transmembrane and intracellular domains of Np-I (Wang et al., 2003). 
This was then transduced into human umbilical vein endothelial cells (EIUVECs) using a 
retroviral expression vector. It was shown that epidermal growth factor (EGF) stimulated Np- 
I dependent migration of HUVECs via a P13-kinase dependent pathway (Wang et al., 2003). 
From this they deduced that Np-I alone could mediate VEGF induced endothelial cell 
migration via activation of the intracellular domain of Np-l. This research encourages the 
theory that VEGF may signal in podocytes, despite VEGF receptor expression limited to Np- 
1, although conclusions drawn from the work done by Wang et al may be premature. 
HUVECs express VEGF-RI, VEGF-R2 and Np-1, so the signalling pathway studied may not 
have been isolated to the chimeric receptor. Also, the 3-dimensional conformation of EGF 
bound to its extracellular domain would probably be completely different to that of VEGF 
binding to the extracellular domain of Np-l. This may affect the conformational change of the 
intracellular domain of Np-I and therefore its auto-phosphorylation sites. Therefore, it seems 
that the intracellular domain of Np-l may be capable of signalling independently, but not 
necessarily in response to VEGF in a non-artificial system. The literature on the effects of 
VEGF on non-endothelial cells is growing fast however, and apart from podocytes examples 
of cell lines expressing VEGF and Np-1, but not VEGF-Rl and VEGF-R2 seems limited to 
carcinoma cell lines. The function of isolated Np-I expression may be to sequester VEGF165, 
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or to enhance actions of VEGF through some unknown mechanism (Soker et al., 1998). This 
could potentially allow VEGF signalling in podocytes to promote survival, but in order to 
understand the potential of VEGF survival signalling in podocytes, current understanding of 
survival signalling in podocytes should be examined. 
1.6 Podocyte maintenance 
1.6.1 Extern alfactors 
Despite the obvious importance of differentiated podocyte survival and maintenance, the 
literature on it is very limited. There is a lot of information in the literature on the causes of 
pathological apoptosis, and effacement of podocytes, but an understanding of what makes 
podocytes so robust in vivo and in vitro is warranted. Many types of cells receive external 
survival stimuli from various growth factors or cytokines. Work by Fornoni et al has shown 
that cultured podocytes are protected from cyclosporin A induced apoptosis by hepatocyte 
growth factor. This was dependent on Bcl-XL regulation and is postulated to be P13-kinase 
dependent (Fornoni et al., 2001). Despite the similarities seen between this pathway and the 
apoptosis pathway described earlier these authors believe that the same growth factors may 
stimulate different apoptosis pathways in podocytes. Indeed, they show that DNA 
fragmentation is an early event in podocytes (Fornoni et al., 2001), detectable before a 
decrease in cell number. Apart from this piece of work there is little to link other growth 
factors with survival in podocytes. 
L 6.2 Internalfactors 
Much of the evidence for podocyte survival in the literature is based on intracellular 
I 
observations. There is growing evidence linking podocyte survival with its actin cytoskeleton, 
found in the podocyte foot processes (figure 1.7). Reorganisation of the podocyte actin 
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cytoskeleton leads to retraction and effacement of foot processes (Reiser et al., 2000b), which 
invariably leads to proteinuria; the hallmark of many glomerular diseases (Huh et al., 2002). 
The link between podocyte survival and its cytoskeleton has been outlined by work done by 
Smoyer et al. Heat shock protein 27 (hsp27), a low molecular weight, rapidly phosphorylated 
protein that is upregulated in response to exposure to toxicants and oxidative stress Qia et al., 
2001), has been associated with increased cell survival and recovery Qia et al., 2001). Hsp27 
was shown to inhibit actin polymerisation in podocytes (Smoyer and Ransom, 2002); 
transfection of an immortalised mouse podocyte cell line with hsp27 sense DNA caused cell 
retraction, detachment and death (Smoyer and Ransom, 2002). Podocyte hsp27 levels also 
correlated with resistance to puromycin aminonucleoside (PAN) induced cell death (Smoyer 
and Ransom, 2002). This indicates that podocyte survival is maintained if the actin 
cytoskeleton is not disrupted. Therefore, an understanding of the podocyte cytoskeleton is 
critical to the elucidation of how the cytoskeletal structure affects podocyte survival. 
1.6 ZI Organisation ofpodocyte cytoske leton 
The podocyte is composed of three compartments, consisting of the cell body, the major 
processes and the foot processes (Ichimura et al., 2003) (figure 1.2). Both the cell body and 
the major processes contain cytoplasmic microtubules and intermediate filaments (vimentin 
and tubulin), but the foot processes only contain microfilaments (Vasmant et al., 1984), 
namely actin and cc actinin (Drenckhahn and Franke, 1988) (figure 1.7). These proteins 
generate the contractile force that resists the high intraluminal hydrostatic pressure from the 
capillaries, and it has been speculated that they actively modify their surface area for filtration 
(Drenckhahn and Franke, 1988). The podocyte actin cytoskeleton appears to be associated 
with the plasma membrane, and can communicate externally via numerous contact proteins, 
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Figure 1.7. A schematic representation of actin filament organisation in the podocyte foot process. 
There are two distinct sub populations of actin filaments in the foot processes; the actin bundle, 
concentrated in the apical region of the foot processes, which includes proteins such as (xactinin and 
synaptopodin and the cortical actin network spread throughout the cytoplasm, which contains proteins 
such as cortactin and ZO-1. Adapted from (Ichimura et al., 2003). GBM= glomerular basement 
membrane, FEC = fenestrated endothelial cells. 
1.6 3 Potlocalyxin 
Podocalyxin is a sialylated transmembrane protein found in the podocyte cell body and in the 
apical plasma membrane of the foot processes. It carries a highly negative charge and is 
thought to prevent normal cell-cell aggregation in culture by charge repulsion (Takeda et aL, 
2000). Similarly, when podocyte tight junctions transform into slit diaphragms during the S- 
shaped body stage of glomerulogenesis it is thought to be due to the charge repulsion of 
proteins such as podocalyxin. This maintains the open slits between neighbouring foot 
processes (Takeda et al., 2000). Podocalyxin has been shown to form complexes with ezrin 
(Orlando et al., 2001) (figure 1.8). This is a phospho-tyrosine protein locallsed to the apical 
membrane region of the cytosol (Kurihara et al., 1995), which is known to bind to the actin 
cytoskeleton (Tsukita and Yonemura, 1997). Any stimuli that modify podocalyxin expression 
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may therefore influence its intracellular interactions with cytosolic proteins (Orlando et al., 
2001) and are likely to affect the morphology of the foot processes. 
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Figure 1.8. A schematic representation of the anatomy of the actin cytoskeleton in the podocyte. 
The morphology of the podocyte is maintained via communications between the plasma membrane and 
actin cytoskeleton. Communicative proteins, such as nephrin, podocalyxin and dystroglycan provide a 
link from the outside of the cell to the actin cytoskeleton via actin binding proteins, such as (x actinin 4, 
utrophin and ezrin. In some instances a large complex is formed, such as at the slit diaphragm, which 
provides an indirect link between the communicative proteins and the actin binding proteins. 
1.6.3.1 Dystroglycans 
The podocytes govern the topography of the GBM matrix proteins using actin-guided 
dystroglycan (DG) complexes (Regele et al., 2000) (figure 1.8). Dystroglycan ot and P are 
expressed in the basal cell membranes of the podocyte foot processes (Regele et al., 2000), It 
has been postulated that they provide a link with the cytoskeleton of the podocytes (via 
utrophin, an intracellular binding partner of DGs (Regele et al., 2000)) and the GBM to help to 
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stabilise the podocytes to the GBM (Regele et al., 2000); thus they oppose podocyte 
detachment and may contribute to function. Expression of dystroglycans is reduced in renal 
biopsies of minimal change nephropathy patients, a disease characterised by flattened or 
effaced foot processes (Regele et al., 2000). 
1.6.3.2 Nephrin 
Nephrin is a transmembrane, cell adhesion protein of the immunoglobulin family (Holzman et 
al., 1999). It was first localised to the slit diaphragm of the podocyte foot processes by 
Ruotsalainen et al (Ruotsalainen et al., 1999) and is suggested to be associated with size 
selectivity (Simons et al., 2001). Nephrin is fundamentally important in maintaining the 
function of the slit diaphragm. This was outlined by the identification and sequencing of the 
gene NPHS I that encodes nephrin, in which common mutations are known to cause congenital 
nephrotic syndrome of the Finnish type (Kestila et al., 1998). The abnormalities of this 
disease are limited to an effacement of podocyte foot processes and massive proteinuria 
resulting in death within the first two years of life unless a kidney transplant is received 
(Kestila et al., 1998). An alteration of nephrin expression is not just isolated to genetic 
mutations-it can also be acquired and is associated with many other types of renal disease. A 
reduction in nephrin expression was noted in areas of effaced foot processes in human renal 
biopsies of various chronic glomerulonephritides (Huh et al., 2002), membranous 
glomerulonephritis, minimal change glomerulonephritus and focal and segmental 
glomerulosclerosis (Doublier et al., 2001). It is interesting to note that there was no change in 
nephrin expression in biopsies from patients with IgA nephropathy, which is a disease in 
which proteinuria tends to be a less prominent feature. This indicates that nephrin expression 
is related to the proteinuric state rather than the specific disease (Doublier et al., 2001). 
Nephrin has an extracellular domain probably involved in cell adhesion, a transmembrane 
domain and an intracellular domain with nine putative tyrosine phosphorylation sites (Kestila 
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et al., 1998), which suggests that nephrin may function as a signalling molecule (Doublier et 
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Figure 1.9. A schematic representation of putative nephrin protein structure and function 
The extracellular domain of nephrin has a total of 8 Ig motifs, although Ig motifs 6 and 7 are separated by 
a spacer domain, which may allow flexibility. Heterophilic interactions, mediated via cysteine residues, 
are postulated to be Ig motif 1-3 dependent, whereas homophilic interactions, mediated via cysteine 
residues, are postulated to be Ig motif 1-6 dependent There is a fibronectin type 111-like domain and a 
transmembrane domain. The cytoplasmic domain contains 9 putative tyrosine residues, which are 
implicated in nephrin signalling. 
During podocyte development, apical tight junctions migrate down the lateral aspect of the 
plasma membrane and are eventually replaced by the slit diaphragm. These earliest slit pore 
regions were often densely labelled with anti-nephrin antibodies in electron microscopy 
studies (Holzman et al., 1999), which demonstrates that nephrin complexes associate when 
podocytes transdifferentiate into mature cells and this is thought to be aided by lipid rafts 
(Simons et al., 2001). Lipid rafts are regions of the plasma membrane enriched in 
glycosphingolipids and cholesterol. They organise the cell membrane into different 
compartments and function in a variety of cell biological processes such as cell adhesion and 
signal transduction (Simons et al., 2001) and are highly concentrated in transduction 
molecules (Huber et al., 2003b). The oligomerized form of nephrin has been shown to 
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associate with these lipid rafts and is redistributed via the cytoskeleton to the slit diaphragm 
(Simons et al., 2001). These lipid rafts may also be important in the conversion of the apical 
fightjunctions to slit diaphragms (Simons et al., 2001). 
It is possible that nephrin can induce a change in the cytoskeleton and also that the 
cytoskeleton can induce a change in nephrin distribution. For example it has been shown that 
angiotensin-H can induce redistribution of nephrin from the slit diaphragm and also induce the 
shedding of nephrin (Doublier et al., 2003). This occurred on a time course ofjust 30 minutes, 
which suggests that this is independent of mRNA expression. On the contrary it has been 
shown that angiotensin-II directly stimulates the F-actin cytoskeleton. This nephrin 
redistribution and shedding is thought to be an early effect of type I and type 2 diabetes in 
diabetic nephropathy (Doublier et al., 2003). Angiotensin-II has been shown to depolarise the 
podocyte in intact glomeruli via its receptor (AT, ). This results in an increase in [Ca2li 
(Nitschke et al., 2000) (which causes the cytoskeleton to contract) and ultimately stimulates an 
increase in extracellular matrix production, which determines matrix deposition in glomerular 
disease (Candiano et al., 2001). Other studies investigating the effect of angiotensin-11 on 
glomerulonephropathies have shown that there is a time dependent reduction in nephrin 
mRNA in chronic injury correlated with increased proteinuria. Histological sections from a 
rat model of human membranous nephropathy (passive Heymann nephrifis) showed reduced 
glomerular expression of nephiin mRNA (using in situ hybridisation) and also nephrin protein. 
The effects on nephrin expression and distribution could be fully blocked using inhibitors to 
angiotensin-II converting enzyme and the receptor of angiotensin-II (Losartan), which also 
blocked chronic injury (Benigni et al., 2001). This indicates, at least in this rat model, that 
angiotensin-II dependent chronic renal injury is dependent on changing expression and 
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distribution of nephrin, in addition to any haemodynamically-dependent angiotensin-11 
induced changes in single nephron glomerular filtration rate (Durvasula et al., 2004). 
1.63.3 Podocin 
Podocin is an integral membrane hairpin protein of the raft-associated stomatin family with a 
short N-terminal domain, a transmembrane region and a C-terminal domain (Huber et al., 
2001, Huber et al., 2003b). It is encoded by the gene NPHS2, mutations in which cause a 
subset of childhood steroid-resistant nephrotic syndrome with focal and segmental 
glomerulosclerosis (Boute et al., 2000). This disease follows a milder clinical course than that 
caused by mutations in the NPHS1 gene (Huber et al., 2001). It is localised to the slit 
diaphragm (Simons et al., 2001) in mature podocytes (Huber et al., 2001) and forms homo- 
oligomers involving the amino and carboxy-terminal domains (Huber et al., 2003b) to form a 
widespread structure (Boute et al., 2000, Huber et al., 2003b). Podocin binds to the 
cytoplasmic tail of nephrin by forming oligomers (Huber et al., 2001) (figure 1.8) and 
immunoprecipitation studies on transfected human embryonic kidney (HEK) 293T cells 
involving podocin mutants show that it plays a role in recruiting nephrin into the lipid raft 
microdomains (Huber et al., 2003b). 
1.63.4. CD2AP 
Another molecule shown to play a vital role in the slit diaphragm is CD2 associated protein 
(CD2AP). CD2AP is an adapter protein containing three SH3 domains and multiple 
polyproline motifs that was originally shown to bind to the cytoplasmic domain of CD2 
(which is a transmembrane protein of an immunoglobulin family expressed on T-cells) (Dustin 
et al., 1998). CD2AP supports a role as molecular scaffolding and may polarise the 
cytoskeleton (Dustin et al., 1998). Homozygous CD2AP knock out mice died by weeks 6 or 
7, and surprisingly, one symptom revealed by histological examination was severe kidney 
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pathology (Shih et al., 1999). The initial defect was isolated to the podocytes using electron 
microscopy showing obliterated slit diaphragms. CD2AP was also shown to be co- 
immunoprecipitated with a nephrin fusion protein and was localised in the lipid rafts by the 
slit diaphragm along with podocin and nephrin (Schwarz et al., 2001, Shih et al., 1999). This 
study and others demonstrate that foot processes can develop in the absence of CD2AP and 
that CD2AP-nephiin interactions are not necessary for the accumulation of nephrin, therefore 
it may function to anchor nephrin to the cytoskeleton (Li et al., 2000, Shih et al., 1999). 
Nephrin and CD2AP develop together in the capillary loop stage of kidney development and 
CD2AP binds to the cytoplasmic tail of nephrin (Li et al., 2000). The interaction of podocin 
with CD2AP and nephrin independently of each other via the COOH-terminus of podocin has 
also been shown (Schwarz et al., 2001). CD2AP is co-localised with F-actin of the cortical 
actin network and cytochalasin D studies demonstrated that the two are physically associated 
(Welsch et al., 2001). It appears that both CD2AP and podocin play a role in clustering 
nephrin-containing rafts; providing a secure scaffolding for the slit diaphragm, and anchoring 
the complex to the actin cytoskeleton (Schwarz et al., 2001)[Dusfin, 1998 #345 (figure 1.8). 
1.63.5. a-Actinin-4 
(x-Actinin-4 is an F-actin cross linking protein, which has been localised to the podocyte foot 
processes within the glomerulus where it is highly expressed (Kaplan et al., 2000). ACTN4 is 
the gene that encodes it and mutations in this gene are the cause of an autosomal dominant 
form of focal and segmental glomerulosclerosis (Kaplan et al., 2000), originally mapped to a 
region of chromosome 19ql3 (Mathis et al., 1998). The disease is defined by a mild onset of 
proteinuria in the teenage years with slow but progressive loss of renal function and the 
development of end stage renal failure in later life (Michaud et al., 2003). FSGS associated 
mutations in ACTN4 are associated with a greater binding affinity of cc-Actinin4 to actin 
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filaments (Kaplan et al., 2000). This leads to the development of sclerotic lesions as a result 
of the dysregulation of the actin cytoskeleton (Michaud et al., 2003). Using a mouse model 
with a high affinity mutated form of (x-Actinin-4 expressed specifically in the podocytes 
Michaud et al found that by 10 weeks 3/8 mice developed proteinuria and had reduced renal 
function. These mice had reduced nephrin mRNA expression suggesting a cause and effect 
relationship between dysregulation of the actin cytoskeleton by (x-Actinin-4 and the 
deterioration of the slit diaphragm complex (Michaud et al., 2003). 
1.6.3.6. ZO-1 
Zonula occludin-1 (ZO-1) is a membrane associated multi-adapter polypeptide whose 
expression was thought to be restricted to tight junctions (Huber et al., 2003a). There is 
growing evidence, however, that it is involved in the slit diaphragm complex. ZO-1 is present 
early in podocyte development at the time when they express fight junctions (Schnabel et al., 
1990). In fact ZO-1 is involved in the conversion of the slit diaphragms back to tightjunctions 
seen in podocyte effacement (Schnabel et al., 1990). The function of ZO-I at podocyte 
differentiation has remained elusive until recently. ZO-1 contains three PSD95/Dlg/ZO-l 
(PDZ) domains, which are protein-binding modules that recognise short peptide PDZ domain 
binding motifs within their protein targets (Huber et al., 2003a). In the slit diaphragm region 
ZO-I is the only protein to express these PDZ domains, which provides the clue to its function 
(Huber et al., 2003a). It binds to an isoform of a recently discovered family of proteins related 
to nephrin named Nephl, which contains a putative PDZ domain binding motif (Huber et al., 
2003a). Nephl is a member of three structurally related proteins: Nephl, Neph2 and Neph3, 
all of which consist of five immunoglobulin-like repeats, a transmembrane domain and a 
cytoplasmic domain (Sellin et al., 2003). The cytoplasmic domain of Nephl has been shown 
to bind the carboxy-terminus of podocin, which it is co-localised with in the podocyte foot 
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processes (Sellin et al., 2003). Nephl and nephrin also interact via their cytoplasmic domains 
in a cis-interacting hetero-oligomeric complex (Barletta et al., 2003). Nephrin is shown to 
form heterodimers, as is Nephl, in promiscuous interactions (Gerke et al., 2003). 
Furthermore, Nephl and nephrin have also been shown to interact via their extracellular 
domains in an in vivo mouse model, although murine Nephl only has four immunoglobulin- 
like domains and lacks a transmembrane domain (Liu et al., 2003) (figure 1.9). A head to 
head assembly of human nephrin has been postulated using the first six Ig domains of 
opposing nephrin molecules (Gerke et al., 2003) (Figure 1.9). A combination of antibodies to 
Nephl and nephrin injected into mice also resulted in a dramatic reduction in expression of 
ZO-I (Liu et al., 2003). As with other components of the slit diaphragm Nephl plays a pivotal 
role: Nephl-/- mice died between 3 and 8 weeks of age and electron microscopy revealed 
effacement of foot processes (Donoviel et al., 2001). The clinical phenotype is similar to that 
of mutated podocin but not as severe as that of mutated nephrin. 
Hence, there are many proteins that link the transmembrane integrins to the actin cytoskeleton 
in podocytes. Disruption of any one of these complexes would have a similar effect on 
morphological changes in podocytes leading to proteinuria and foot process effacement. The 
slit diaphragm complex is the area most targeted in human glomerular disease. It plays a vital 
role in maintaining a physical barrier to filtrate, but there is growing evidence to suggest that 
this is also the site of signal transduction. Evidence to support this latter function was first 
presented in 1995 with the observation that there were increased levels of tyrosine 
phosphorylation of proteins at newly formed tight junctions of the foot processes and also at 
the induction of foot process effacement (Kurihara et al., 1995). 
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1.6.4. Signalling at the slit diaphragm conWlex 
1.6 4.1. Nephrin 
It has been shown that nephrin mRNA expression can be upregulated in HEK A293 cells, 
which constitutively express nephrin, by protein kinase C (PKC) (Wang et al., 2001). PKC is 
a large family of serine/threonine kinases involved in the phosphorylation of a variety of intra- 
cellular proteins (Wang et al., 2001). It was suggested that PKC phosphorylated the 
intracellular domain of nephrin either directly or indirectly. Nephrin also mediates signalling 
pathways including those of p38 protein kinase and c-Jun N-terminal protein kinase QNK). 
Podocin was shown to synergistically augment this activation almost 40 fold more than 
nephrin alone (Huber et al., 2001). Recently, members of the Src family kinases have been 
implicated in nephrin signalling. Src family kinases are regulated by their SH3 and SH2 
domains, which repress kinase activity by interacting with amino acids within the catalytic 
domain. The kinase is activated when a protein phosphatase dephosphorylates the COOH- 
terminal tyrosine (as reviewed in (Thomas and Brugge, 1997)). These were initially 
implicated in kidney damage and loss of renal filtration barrier in a study done by Yu et al. 
Homozygous knock out mice for Fyn, Lyn (Src family kinase members) and both together 
were developed. Fyn-/- and Lyn-/- mice excreted moderate levels of albumin, but Fyn-/- Lyn- 
/-mice suffered from chronic kidney damage and a high death rate (Yu et al., 2001a). Itwas 
shown that Fyn can bind directly to nephrin both in vitro and in vivo via its SH3 domain 
(Verma et al., 2003). This induced the phosphorylation of nephrin. Deletion of Fyn in a 
knockout mouse model resulted in attenuated nephrin phosphorylation and coarsening of the 
foot processes (Verma et al., 2003). Nephrin was also shown to interact with Yes, another 
member of the Src family kinases but the consequences of this are not yet clear (Verma et al., 
2003). The nephrin signalling pathway was further clarified by work done by Huber et al. 
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Co-immunoprecipitation studies showed that the carboxy-terminal cytoplasmic tail of both 
nephrin and CD2AP interact with the p85 regulatory subunit of P13-kinasc (Huber et al., 
2003c). This interaction was inhibited by incubation with genistcin; a broad-spectrum 
tyrosine kinase inhibitor with some preference for members of the Src family kinases. P13- 
kinasc activation by nephrin and CD2AP was associated with a strong activation of AKT and 
phosphorylation of the anti-apoptotic protein Bad, correlated with reduced apoptosis (Huber et 
al., 2003c). The phosphorylation of nephrin induced by Src can activate the P13-kinase/AKT 
pathway resulting in inhibition of apoptosis, shown in three independent cell models including 
differentiated podocytcs; HEK 293 cells, canine kidney cpithelial cells and differentiated 
mouse podocytes (Huber ct al., 2003c). Clustering of nephrin on the surface of transfected 
HEK293 cells (that express the same Src family kinascs as podocytes) by anti-nephrin 
antibodies induced auto-phosphorylation of ncphrin (Lahdenpera et al., 2003). Inhibition by 
PP2, a Src inhibitor, showed that nephrin phosphorylation was Src family kinase dependent 
and more than one was involved: Fyn, Src, Yes and possibly Lyn. Tyrosine phosphorylation 
of nephrin is thought to create binding sites for other signalling proteins stimulating a signal 
cascade (Lahdenpera ct al., 2003). Clustering of nephrin on the cell surface mimics clustering 
at the slit diaphragm and this is shown to be a very dynamic process, suggesting that 
podocytes have an ability to rapidly rearrange the actin cytoskeleton in the foot process 
(Lahdenpera et al., 2003). This is potentially possible if the tyrosine phosphorylation induced 
by Src is multiple and processive (i. e. the enzyme remains bound to the peptide substrate 
during multiple phosphorylation events) (Scott and Miller, 2000). This theory was tested by 
Scott ct al using a synthetic peptide system and found that Src remained bound to its substrate 
until it completed all its phosphorylations, so only one Src/substrate collision was necessary 
(Scott and Miller, 2000). The affinity of Src to its substrate increased with multiple 
interactions via SH2 and SH3 and the catalytic domains. This ensures that there is rapid 
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multiple phosphorylation, which is needed in vivo for the slit diaphragm to be so dynamic. 
Although the signalling dynamics of nephrin are still under investigation it is clear that the 
intracellular domain of nephrin can be phosphorylated (i. e. by PKC and Src family members), 
which induces various signalling pathways such as P13-Kinase and p38/c-Jun. 
1.6.4.2 Neph I 
Nephl contains a SH2 binding site and is also thought to be a signalling protein. Incubation 
with v-Src (a viral form of Src) reduced the interaction between Nephl and podocin at the 
carboxy-terminal domain, indicating that tyrosine phosphorylation of the Nephl podocin 
binding motif regulates the interaction between the two proteins (Sellin et al., 2003). This 
could potentially disrupt the slit diaphragm complex. Itk, a member of the Tec; kinase family, 
resulted in a four-fold increase in Nephl mediated AP-1 activation (a transcription factor 
complex that modulates a variety of signalling pathways such as survival and apoptosis (Eferl 
and Wagner, 2003)), demonstrating downstream signalling of Nephl. Tec kinases are present 
in the lipid rafts of the podocyte foot processes (Sellin et al., 2003) and are the second largest 
family of cytoplasmic protein tyrosine kinases after Src (Smith et al., 2001). They contain a 
pleckstrin homology (PH) domain and Src homology 3 (SH3), SH2 and SHI domains and lack 
a C-terminal tyrosine, so have an auto-inhibitory function in their phosphorylated state (Smith 
et al., 2001). Activation of P13-kinase generates PIP3, which recognises proteins with PH 
domains such as AKT (figure 1.5). It can also bind to and activate Tec kinases and these have 
been linked to the transcriptional control of complex survival and differentiation events (as 
reviewed in (Smith et al., 2001)). 
1.6.4.3. ZO-1 
ZO-1 was the first molecule shown to be tyrosine phosphorylated at the slit diaphragm region 
of the rat kidney (Kurihara et al., 1995). In fact tyrosine phosphorylated proteins were not 
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detected in normal rat podocytes, but two tyrosine phosphorylated protein bands were detected 
in Western blots for protamine sulphate treated rat glomeruli. Protamine sulphate neutralises 
the negative charges between podocytes and is thought to induce tight (occluding) junction 
formation, which eventually leads to denuded areas of basement membrane (Caulfield et al., 
1976). Two bands were detected, one at 225kDa, which was found to be ZO-1, and one at 
180kDa, which was co-immunoprecipitated with ZO-I (Kurihara et al., 1995) (although this 
was not shown in the blot probed with anti-ZO-1). This protein was not identified, however it 
is the same MW as nephrin. The reason that no phospho-tyrosine proteins were detected in 
normal rat podocytes may have been because the expression levels of the proteins concerned 
were too low to be picked up by the antibody or enhanced chemiluminescence kit used. The 
tyrosine phosphorylation occurred only 15 minutes after the initiating the perfusion of 
protamine sulphate, which demonstrates the speed at which the podocyte can rearrange its 
cytoskeleton (Kurihara et al., 1995). ZO-I can also induce the tyrosine (and serine) 
phosphorylation of Nephl and accelerate Nephl -mediated AM activity (Huber et al., 2003a). 
The function of this may be to induce the clustering of Nephl into homo/heterodimers. 
Tyrosine phosphorylation at the slit diaphragm has been associated with podocyte dysfunction 
(i. e. transition of slit diaphragms to tight junctions) and also with podocyte function (i. e. 
clustering of the slit diaphragm proteins and survival pathways). Therefore, it is wise to study 
each tyrosine phosphorylation pathway separately, not associate it with one consequence. 
1.6. S. Suminary of survival nwchanisnis in podocytes 
There appear to be three potential mechanisms by which podocytes can maintain their 
survival: 
1. Upregulation of cyclic dependent kinase inhibitors such as p27 and p57 at the point of 
differentiation onwards, which may upregulate the P13-Kinase/AKT survival pathway. 
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2. Maintenance of the actin cytoskeleton within the foot processes through cell-cell contact 
and adherence to the glomerular basement membrane. 
3. Activation of signalling complexes at the slit diaphragm or glomerular basement 
membrane. 
1.7 Potential of VEGF-nephrin signalling 
VEGF has been shown to increase phosphorylation of tight junctions in bovine retinal 
epithelial cell (BREC) cultures and in an in vivo model in the rat eye vitreous cavity (Antonetti 
et al., 1999). Of the seven tight junction proteins both occludin and ZO-I were 
phosphorylated by VEGF; occludin by serine/threonine phosphorylation and ZO-1 by tyrosine 
I 
phosphorylation. These changes were rapid (15 minutes post injection of VEGF into the 
vitreous cavity) (Antonetti et al., 1999) and in a time frame consistent with a VEGF induced 
increase in the microvascular permeability barrier in vivo (Pocock et al., 2000). It is known 
that: 1) VEGF is expressed in differentiated podocytes as is its co-receptor Np-1; 2) the slit 
diaphragm contains ZO-1; a protein associated with tight junctions and indeed slit diaphragms 
are thought to transform from them (Reiser et al., 2000a); 3) VEGF can induce the 
phosphorylation of proteins at tight junctions; 4) the slit diaphragm contains proteins that can 
be phosphorylated; and 5) podocytes are terminally differentiated and have prolonged 
survival. Therefore, it is possible that the role of VEGF in the podocyte may, at least in part, 
be to act in an autocrine manner in podocytes to positively maintain the slit diaphragm, and 
cell survival. 
In endothelial cells VEGF-R2 is highly enriched in caveolae, where VEGF signalling is 
initiated (Labrecque et al., 2003). Caveolae are defined as specialised membrane 
microdomains that appear as flask shaped invaginations (Feng et al., 1999). In fact they could 
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be described as vesicular lipid rafts. They are found in many cell types, particularly in 
terminally differentiated cells (Labrecque et al., 2003). Caveolae are expressed in the 
podocyte foot processes (Sorensson et al., 2002): Caveolin-1, the protein that defines caveolae, 
was co-immunoprecipitatcd along with CD2AP and nephrin in mouse glomerular lysates 
suggesting that caveolae are localised to the slit diaphragm. Surprisingly, caveolin-I deficient 
mice showed normal podocyte foot process ultrastructure (Sorensson et al., 2002). 
Interestingly, both caveolae and CD2AP have been implicated in internalisation of 
ligand/receptor complexes by endocytosis. VEGF stimulation of the caveolin/VEGF-R2 
complex, which contains many types of signalling proteins, caused the translocation of the 
caveolin complex to the nucleus (Feng et al., 1999). Similarly epidermal growth factor (EGF) 
stimulation of EGF receptor induced cortactin recruitment (an actin linking protein) to CD2AP 
and led to epidermal growth factor receptor endocytosis and trafficking (Lynch et al., 2003). 
This suggests that the dynamic slit diaphragm is also capable of endocytosis of growth factors, 
although none have yet been implicated in signalling at the slit diaphragm. Localisation of 
VEGF-R2 to caveolae in endothelial cells also implies the localisation of Np-I because it acts 
as a co-receptor for VEGF-R2, however there is no evidence yet to show this. It is known 
that; 1) caveolae are localised to the slit diaphragm; 2) nephrin is localised to the slit 
diaphragm; 3) caveolae express VEGF-R2 in endothelial cells; 4) nephrin and VEGF are 
implicated in cell survival; 5) VEGF induces the phosphorylation of Src family kinases in 
endothelial cells and 6) Src family kinases induce the phosphorylation of nephrin. Therefore, 
it is possible that VEGF can signal at the slit diaphragm to phosphorylate nephrin and promote 
survival in differentiated podocytes. To investigate these effects, human cultured podocytes 
were used as experimental models. 
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1.8. Experimental Podocyte models 
There are many animal models of renal disease, however although these models can provide 
valuable insight into podocyte pathology they bear limited resemblance to human kidney 
diseases. Animal renal disease tends to be acute, overwhelming and falminant whereas most 
human renal diseases are chronic, modest and intermittent. Therefore animal models have 
limited uses, which is why cell culture of human podocytes is becoming more attractive. 
Using primary culture podocytes (PCPs) can present their own difficulties. Major criticisms 
of the isolation technique used are that the resulting cells (podocytes) isolated from the 
glomeruli almost never form pure populations and may also change phenotype in culture 
(Yaoita et al., 2001). To overcome difficulties related to primary culture of podocytes 
different groups have tried to develop conditionally immortalised podocyte cell lines. This 
was first successfully described in 1996 by Mundel et al using podocytes originally isolated 
from mouse glomeruli. A transgenic mouse cell line, H-2K b_tsA58, was developed that carries 
a thermolabile mutant of the SV40 large T antigen-tsA58 under the control of a y-interferon 
inducible promoter, H-2K b (Mundel et al., 1997b). This allowed the cells to be proliferative 
when incubated at 330C with y-interferon and growth arrested and differentiated when 
incubated at 37"C without y-interferon, to inactivate the immortalising SV40 Tag. This 
development changed the dynamics of podocyte investigations. Despite this advancement a 
human model of cell culture was still needed because rat and mouse podocytes, although very 
similar to human podocytes, do express some different proteins (e. g. megalin is expressed in 
rats but not human podocytes), therefore podocyte functions may differ between species. 
Saleem et al developed the first temperature sensitive SV40 human conditionally transformed 
podocyte cell line in 2002. Similarly to the mouse podocyte cell line the human podocytes 
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were infected with an SV40 large T-antigen gene containing tsA58/UI9 mutations. They are 
therefore also temperature sensitive, and when incubated at the permissive temperature of 
33"C are proliferative and de-differentiated, but when incubated at the non-permissive 
temperature of 37*C for a fortnight they became non-proliferative and differentiated (Saleern 
et al., 2002). 'These cells have been fully characterised and at differentiation express the 
podocyte specific markers of maturity nephrin, podocin and synaptopodin amongst others. Of 
note, these cells were originally cloned from podocytes isolated in the same way as primary 
cultured podocytes. Although primary culture podocytes (PCPs) were initially used, their use 
in this investigation was limited to assays where the specific quality of these cells was needed, 
such as the ability to proliferate. Otherwise, once it was established that the two types of 
cultured podocytes responded in a similar manner, human conditionally immortalised 
podocyte cell lines were used as models to investigate the effects of VEGF on podocyte 
biology. 
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1.9 Hypotheses and Aims 
This study will test the hypotheses that; 1) VEGF can act in an autocrine manner in podocytes; 
2) VEGF promotes survival in differentiated podocytes; 3) VEGF can signal at the slit 
diaphragm; 4) VEGF directly or indirectly induces the phosphorylation of nephrin; 5) VEGF 
and nephrin interact synergistically to protect differentiated podocytes. 
Using various human podocyte cell lines, both primary and conditionally immortalised, I will 
invesfigate: 
1. If VEGF can stimulate a change in intracellular calcium in podocytes, a common signal 
transduction pathway of VEGF; 
2. The possible effects of VEGF on podocytes via established mechanisms already known in 
endothelial cells such as proliferation, cytotoxicity and apoptosis; 
3. The ability of nephrin to promote podocyte survival using nephrin deficient and nephrin 
mutated cell lines; 
4. The ability of VEGF to induce phosphorylation of nephrin and the consequences on 






All chemicals are from Sigma-Aldrich (Ayreshire, UK) unless otherwise stated. 
2.2 Solutions 
10 x Phosphate buffered saline solution (PBS): 1.37M NaCl, 27mM KCI, IOOMM Na21HP04 
and 30mM KH2P04, pH 7.4 (autoclaved). 
Ix PBS: 1: 10 dilution 10 X PBS in de-ionised water 
All others are as described in the text. 
2.3 Cell culture 
All tissue culture was carried out in a sterile laminar flow hood. All human tissue was taken 
with ethical committee approval (see appendix). 
23.1 Prinutry culture podocyles (PCTs) (as described by (Mundel et aL, 1997a)) 
A section of renal cortex was taken from the unaffected pole of a human nephrectomy 
specimen with renal carcinoma. The tissue was macroscopically normal and such tissue has 
been shown to be microscopically normal on previous preliminary studies (Whittle et al., 
1999). The tissue was transported in sterile lxPBS on ice for a maximum of 30 minutes. 
Instruments and solutions used were sterilised either by autoclaving or using 70% ethanol 
(Fisher Scientific, Leicestershire, UK). Scissors and forceps were used to remove the kidney 
capsule and the cortex was chopped finely. Three brass sieves with mesh sizes of 425Am, 
180Am and 125Am (Endecotts, London, UK) were stacked on top of each other. The cortex 
was placed in the top sieve and gently but firmly pressed through using a sterile syringe 
plunger. Sterile room temperature lxPBS was used intermittently to wash the tissue through. 
The 180ptm mesh sieve retained some glomeruli and tubules whilst the 125ptm mesh sieve 
retained glomeruli and debris. The glomeruli from the 125Am mesh sieve were washed three 
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times with complete RPMI (Roswell Park Memorial Institute) media (containing inorganic 
salts; lg/L Ca(N03)2-4H20,0.049 g/L MgS04,0.4g/L NaHC03,6g/L NaCl and 0.8g/L 
Na2I1PO4 with additional 0.10/ýo insulin transferrin selenite, and 10% fetal bovine serum (FBS)) 
in a 50ml Falcon tube (Fisher Scientific, leicestershire, UK): glomeruli were centrifuged at 
10OOrpm, the supernatant was aspirated off, resuspended in complete RPMI and repeated 
twice more. The glomeruli were resuspended again in complete RPMI and transferred to a 
vented 75cm 3 tissue culture flask (Greiner, Fickenhausen, Germany) and placed in an 
incubator at 37"C with 5% C02 (Sanyo, Bensenville, USA), for 14 days allowing the primary 
cultured podocytes, which are proliferative to grow out from the glomeruli. The glomeruli 
were then washed away using sterile 1xPBS and the media replaced three times a week. Cells 
were passaged when they achieved 100% confluency and were only used for a maximum of 
four passages as the cells become senescent. 
23.2 Huinan conditionally immortalisedpodocytes (hCIPs) 
Two hCIP cell lines were developed and characterised by Dr M. Saleem, at the Academic 
Renal Unit, Southmead Hospital, Bristol. Nephrectomy specimens were taken from a three- 
year old child with hydronephrosis (hCIPa) (Saleem et al., 2002) and a four year old child with 
a Wilms Tumor (Saleem et al, unpublished). Glomeruli were isolated and primary culture 
podocytes grown out as above. The cells were passaged after 14 days once they had reached 
confluency (Saleern et al., 2002). Saleem et al then transfected the cells with a retroviral 
construct consisting of an SV40 large T antigen gene containing containing the temperature 
sensitive A58 (tsA58) mutation. The use of hCIPs, kept at 33"C, ensures a uniform population 
of de-differentiated podocytes. After infection with the retrovirus containing the SV40 T 
antigen, the virions translocate to the nucleus where they are uncovered and the viral 
chromatin is released (Pipas and Levine, 2001). The cells enter S phase a few hours after 
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infection and the large T antigen initiates viral DNA replication by binding to its origin and 
recruiting cell replication apparatus. The large T antigen contributes to cell transformation in 
a number of ways. For example it binds to and stabilises (and therefore inactivates) p53 by 
blocking the ability of p53 to bind to its DNA consensus sequence, thereby blocking its ability 
to act as a transcription factor (Pipas and Levine, 2001). p53 transactivates genes that lead to 
growth arrest, therefore inactivation of p53 allows proliferation. The replication of the 
retrovirus, containing the SV40 T antigen, is impaired at high temperature by the tsA58 
mutant (Sompayrac and Danna, 1983). This ensures that, at the tsA58 permissive temperature 
of 33*C the hCIPs remain proliferative and de-differentiated, but at the tsA58 non-permissive 
temperature of 37*C, p53 is activated and hC1Ps become differentiated. Infection, selection 
and continuous culture were carried out in an incubator kept at 33C. Cells were subcloned by 
seeding at increasing densities in the presense of irradiated NIH 3T3 mouse fibroblast cells, 
provided as nondividing feeder cells. Cells were then selected using plastic cloning rings 
(Saleem et al., 2002). Differentiation was induced by thermoswitching the cells from the 
permissive temperature of 33'C to the non-permissive temperature of 37"C, for 14 days to 
inactivate the SV40 T antigen. These cells stained positively for WT-I at both de- 
differentiation and differentiation and stained for synaptopodin, P-cadherin, nephrin and 
podocin at differentiation (Saleern et al., 2002). Cells were used between passages 10 and 20. 
23.3 Nephtin nmtated conditionally immortalisedpodocytes (NMh CIPs) 
These cells were developed and characterised as above by Saleem et al (unpublished) except 
that the cells were isolated from a nephrectomy specimen taken from a patient with a 
homozygous R460Q mutation at nucleotide 1379 in exon II of the NPHS I gene that encodes 
nephrin (Figure 2.1). This mutation leads to a missense reading in the part of the nephrin 
protein that corresponds to immunoglobulin (1g) 5 of the extracellular domain, where arginine 
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is replaced by glutamine (Koziell et al., 2002). This protein is expressed at the slit diaphragm 
but still causes a classically severe congenital nephrotic syndrome (Koziell et al., 2002). 
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Figure 2.1. A schematic of the putative NPHSI gene structure. 
The location of the mutations that define the NMhCIP and the NDhClIP cell lines are indicated in the 
nephrin gene, and the corresponding putative amino acid sequences of the protein, encoded by each exon 
(Ex) are also indicated. 
2 3.4 Nephrin deficient huntan conditionally iminortalisedpodocyles (NDhCIPs) 
These cells were developed and characterised by Saleem et al (unpublished) as above except 
that the cells were isolated from a nephrectomy specimen taken from a patient with a Fin.,, j, 
mutation in the NBPSI gene. This is a two base pair deletion in exon 2 at nucleotide 121 
(figure 2.1), which results in a truncated protein of 90 amino acids and a complete absence of 
protein expression (Patrakka et al., 2000). This also leads to a severe congenital nephrotic 
syndrome. 
23.5 Passaging cells (adaptedfrom (Saleem et al, 2002)) 
Both primary culture podocytes and conditionally immortal podocyte cell lines were passaged 
using the same protocol as follows. At 100% confluency serum was washed from the cells 
using sterile IxPBS then incubated for 5 minutes at 371C with 3ml Ix trypsin. 7ml of 
complete RPMI media was added to stop the reaction and pipetted over the flask surface to 
wash off the cells. Cells were then centrifuged at approximately 30OOrpm for 5 minutes, the 
supematant aspirated off and the cell pellet resuspended in complete RPMI media. Cells were 
divided 1: 4 (primary culture podocytes) into new 75CM3 tissue culture flasks or 1: 5 (podocyte 
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cell lines) to freeze down a cryovial of cells (see below). 10ml media was also added to the 
flasks of podocyte cell lines that were split even though there were few cells remaining, this 
was kept as the stock flask and achieved 100% confluency weekly. The cell lines were kept at 
33*C for 2-3 days until they achieved 100% confluency and then transferred to 37"C to 
differentiate. The primary culture cells were kept at 37C constantly and were slow to 
proliferate. They achieved confluency once every one or two weeks depending on the age of 
kidney they were isolated from. 
23.6 Freezing down and bringing up cells 
Cell lines were frozen down at every passage up to passage 18 to keep stocks replenished. 
Freezing media consisted of 20% DMSO (a cryoagent) and 80% FBS. 500gI of this was 
added to 5OOgI of podocyte cell suspension (of trypsinised cells) in complete RPMI (see 
passaging above). This was transferred to cryovials (Simport plastics, Quebec, Canada), 
which were frozen down in the -80'C freezer. To thaw, the cryovials were taken out and run 
under wann water to avoid formation of crystals in the cells. The cells were quickly 
transferred to a 75CM3 flask containing 9.5mls of complete RPMI to prevent cytotoxicity due 
to the high DMSO concentration. The cells were mixed into the media and were then grown 
in the same way as passaged cells. 
2.4 Immunohistochemistry 
24.1 I-Issueprocessing andfkation 
Whole rat kidneys were dissected from Male Wistar rats (200-300g), anaesthetised by 
inhalation of 5% halothane and maintained on 3% halothane (Merial, animal health ltd, Essex, 
UK). Kidney tissue was fixed in 10% buffered formalin at room temperature overnight. 
Tissue was then processed-each step included gentle agitation of samples in each solution for 
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four hours. Tissue was first dehydrated in 70%, 90% and 100% Methanol and two steps of 
100% Ethanol. The alcohol was then displaced with xylene (0) and then embedded in melted 
paraffin wax at -40*C in three separate steps, the last one in a vacuum. Wax blocks were then 
placed into cassettes and kept in the fridge ready for cutting. Blocks were cut on the 
microtome (Leica, Milton Keynes, UK) in 7gin sections and flattened using warni water and 
100% ethanol onto gelatin/poly-L-lysine coated glass slides to ensure tissue adherence (see 
below). Tissue and slides were then left to dry in a slide rack and then baked overnight at 
37'C to further ensure that the tissue had firmly adhered. 
24.2fflidepreparafion 
2g gelatin (BDH, Pool, UK) was dissolved in 400ml (1: 200 dilution) heated distilled water and 
0.2g of chromium potassium sulphate then dissolved into it. Racks containing clean slides 
were dipped into this solution for five minutes and then dried overnight in an incubator at 
37'C. lOmM Tris-HCI was made up in water and adjusted to pH 7.6.25mg of Poly-L-lysine 
was dissolved in a small amount of lOmM Tris-HCI and then added to the rest of the solution. 
The gelatin-coated slides were then placed in the solution as before and again left to dry 
overnight at 37'C. 
2 4.3 Cellf"alion (adaptedfrom (Marlow and Lane, 1998)) 
Primary culture podocytes were grown to confluency on 10% collagen (Autogen Bioclear, 
Wiltshire, UK)/PBS coated 22mm diameter glass coverslips (BDH, Pool, UK) in a six well 
plate (Coming, Birmingham, UK). They were then washed twice with IxPBS and fixed in 
Iml 10% formaldehyde (Fisher Scientific, Leicestershire, UK) for 10 minutes. The 
formaldehyde was washed off twice with IxPBS and the cells then permeabilised in 0.2% 
Triton XAPBS for 15 minutes. This was washed off again four times with IxPBS. 
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2 4.4 Ininmnohislochendstry (adaptedfrom (Harlow and Lane, 1998)) 
Microscope slides with tissue sections on them were dewaxed in histoclear for 5 minutes and 
rehydrated in graded ethanol: 100,95 and 70% (Fisher Scientific, Leicestershire, UK) for 2 
minutes each. They were then washed twice in distilled water for 5 minutes each and washed 
once in IxPBS for another 5 minutes. Half of the slides were microwaved in IOOmM Tris- 
HCl/2mM ethyl enedi aminetetraaceti c acid (EDTA) buffer for 2x4 minutes at full power to 
promote antigen retrieval, then left to cool for 20 minutes. The non-microwaved slides were 
left in IxPBS and used to compare efficiency of immuno-staining. All slides were treated 
with 3% hydrogen peroxide (BDfL Pool, LJK) for 5 minutes to block endogenous peroxidases 
and then washed twice for 5 minutes with IxPBS. Slides were then incubated with a 1.5% 
normal serum (Vecta, California, USA)/PBS blocking solution from the animal in which the 
secondary antibody was raised for 30 minutes in a humid chamber to block non-specific 
binding sites. Slides were split into microwaved and non-microwaved groups and treatment in 
one group was paired with treatment in the other. They were then incubated with 40AI of an 
optimised dilution of primary antibody (when using an antibody for the first time it was used 
in various concentrations, as was the secondary antibody). Each primary antibody treatment 
had a matched IgG control of the same concentration (an isotype control) diluted in the 
blocking solution described above. The tissue was protected from drying out by covering with 
a glass coverslip and was incubated in a humid chamber at 4"C overnight. The following day 
the coverslips were removed in 0.1% PBS/Tween and washed twice in IxPBS. Slides were 
treated for a second time with 1.5% normal serum/PBS blocking solution for 30 minutes in a 
humid chamber. All slides, including the controls, were treated with 5gg/ml biotinylated 
secondary antibody (Vecta, California, USA)/blocking solution to the species in which the 
primary was raised for 30 minutes in a humid chamber. They were then washed twice in 0.1% 
PBS/Tween (a more stringent wash solution than lxPBS) and then incubated in a pre-prepared 
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BRP conjugated avidin-biotin complex (ABC) solution (Vecta, California, USA) for 30 
minutes in a humid chamber. This bound to the biotinylated secondary antibodies. The slides 
were washed twice for 5 minutes in 0.1% PBS/Tween and were then incubated with 
diaminobezidine (Vecta, California, USA), which provided the substrate for the HRP 
conjugated to the ABC, until brown colour was visualised. The reaction was stopped by 
washing twice in distilled water for 5 minutes and counter-stained with haematoxylin (a 
nuclear dye) for 5 minutes before leaving in gently running tap water (to aid the "bluing") for 
5 minutes. The tissue was then dehydrated in 70,90 and 100% ethanol for 2 minutes each, 
cleared in xylene for 10 minutes and finally mounted with DPX, glass coverslips and nail 
varnish. Immunostaining was visualised using a light microscope and images were captured 
using a digital camera (Leica, Milton Keynes, UK), downloaded and saved as an 
AdobePhotoshop file. 
2 4.5 Ininmnocytochentistry (adaptedfrom (Harlow and Lane, 1998)) 
Fixed cells on coverslips were treated in a similar manner as tissue on slides except that they 
were not rehydrated as they were not dehydrated or wax embedded. They were treated for 
endogenous peroxidase and from that stage forward, the methodology was the same (although 
they were covered with a slide overnight) until the last stages where they were not dehydrated 
and cleared. 
2.5 PCR 
Z5.1 Ribonucleic acid (RNA) extraction (as described by Gibco BRL Life Technologies 
TRIzol Data sheet) 
Cells were grown to confluency in a 75CM3 tissue culture flask. Media was aspirated off and 
the cells were lysed with 0.3ml TRIzol (Invitrogen Life Technologies, California, USA) 
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/10cm 2 surface area, which was washed over the cells then left at room temperature for 5 
minutes. This lysate was transferred to a 15ml Falcon tube, 0.2ml chloroform (BDH, Pool, 
UK) /0.75mlTrizol added and the tube shaken vigorously. This was left at room temperature 
for 2-15 minutes and then centrifuged at 12,000g (Annita IIR, ISTCP, New Jersey, USA) for 
15minutes at 4"C. This separated the solution into an aqueous phase, which contained the 
RNA and an organic phase. The top aqueous phase was transferred to a clean tube and 0.5ml 
isopropanol/0.75ml TRIzol was added and left at room temperature for 10 minutes to 
precipitate the RNA. This was centrifuged at 12,000g for 10 minutes at 4'C, the supernatant 
removed and washed once with I ml/0.75ml TRIzol 75% ethanol/ Dep. H20 (RNAse treated). 
The solution was vortexed (Jencons, Leighton Buzzard, UK) and then centrifuged at 7,500g 
for 5 minutes at 4C. The supernatant was removed and the RNA pellet air dried for 5 
minutes (but not completely). Subsequently it was dissolved by adding 50gl 
DiEthylPyroCarbonate water (Dep. H20) (RNAse free treated water) and incubated at 60'C 
for 10 minutes. RNA was only briefly kept on ice otherwise kept in the -80"C freezer to 
prevent the breakdown by RNAses (New Brunswick Scientific, Hertforshire, UK). 
2 5.2 Quantifying RNA 
RNA was diluted in Iml Dep. H20 at various dilutions, starting at 1: 200 and mixed well 
before being transferred to a quartz cuvette (Fisher Scientific, Leicestershire, UK). Iml Dep. 
H20 was used to calibrate the spectrophotometer (Shimadzu, Duisburg, Germany) and RNA 
was quantified at 260nm, protein was also quantified simultaneously at 280nm, so that the 
ratio of the two measurements could be used. If the ratio was over 1.5 then there was little 
protein contamination so the quality was deemed adequate. It was assumed that one optical 
density (OD) unit read by the spectrophotometer was equivalent to 40Aglml RNA (Sambrook 
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and Russell, 2001a). Tberefore to find the volume of starting solution needed to yield Igg of 
RNA the following equations were used: 
((OD260 x 40ýLg/ml) D)/l 000 = Xgg/gl RNA 
IgI /(Xgg/gl) RNA= volume containing lptg RNA 
Where D is the dilution factor used and X is the unknown quantity. Of note, this can only 
provide overall RNA concentration, notjust mRNA concentration. 
Z5.3 Reverse transcription -polymerase chain reaction (RT-PCR)(adaptedjrom (Sambrook 
and Russell, 2001a)) 
lAg of RNA from each sample was added to IAI 50AM Oligo (dT) (Promega, Wisconsin, 
USA) (a universal primer, which anneals to the 3' poly A tail of mammalian mRNA) and Dep. 
H20 to bring the volume to I OAL -This was incubated at 65"C for 5 minutes to denature the 
RNA, followed by rapid chilling on ice. To this, I OAl of solution was added containing: 2PLI 
Dep. H20; 4AI 5x first strand synthesis buffer (Roche, Mannheim, Germany) (a buffer for 
reverse transcriptase); IgI O. IM dithiothreotol (DTT) (Roche, Wisconsin, USA) (a reducing 
agent that prevents secondary folding of RNA); IgI 25mM dNTPs (nucleotides for the 
reaction); IýLl RNA guard (Roche, Wisconsin, USA) (an RNAse inhibitor) and IAI 50u/Al 
expand reverse transcriptase (Roche, Wisconsin, USA) (RNA dependent DNA polymerase to 
catalyse the synthesis of complementary DNA). This reaction was incubated for 60 minutes at 
420C. The first strand synthesis of cDNA from mRNA was primed by the Oligo (dT), which 
creates a DNA: RNA hybrid. 
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ZS. 4PCR 
Complementary DNA (or cDNA) was amplified at this stage. IgI cDNA (made above) was 
added to a solution containing: 13.5gl Dep. H20; 2gl lOx amplification buffer (Abgene, 
Surry, UK); lgl 25mM MgCl2 (Abgene, Surry, UK) (to control the pH of the solution); 0.3gl 
25mM dNTPs; IgI sense primer, IgI antisense primer (Invitrogen Life Technologies, 
California, USA) and 0.2gl Taq (Abgene, Surry, UK) (a thermostable DNA polymerase 
enzyme to amplify the cDNA). Each reaction had a positive cDNA control (i. e. tissue cDNA 
or a plasmid containing the cDNA in question), a positive primer control (i. e. GAPDFI) and a 
negative primer control (i. e. Dep. H20). These reactions were run in a PCR thermal cycler 
(Hybaid, Thermo-Electron, Basingstoke, UK) on a standard cycle: 35 cycles of 94"C for 3 
minutes; 55'C for 30 seconds; 72"C for I minute; 94*C for 30 seconds then one cycle of 72"C 
for 3 minutes, then held at 4'C . This cycle of temperature change 
induced denaturation of the 
double stranded cDNA template (high temperatures), primer annealing to the single stranded 
DNA and extension of the desired portion of cDNA (dictated by the sense and antisense 
primers used) by the DNA polymerase, which was again denatured in the next cycle. 
Z 5.5 Prinwr design (Sambrook and Russell, 2001a) 
Primer sequences were either taken from the literature or designed. Primers were designed 
with the following criteria: a G-C content of 50-55%, G-C base pairs have three bonds 
whereas A-T base pairs only have two so the G-C content ensures that the sequence is not 
bound too tightly or too loosely during the amplification cycles. Triplicates and quadruples 
were avoided for the same reason; the primer sequence was required to end in GC, CG, CC or 
GG to secure the binding. The amplicon length of 250-500 base pairs (bp) was required and 
the length of the primer was 18-25 nucleotides. Members of primer pairs did not differ in 
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number by more then 3 bp. The melting temperature of the primers was above 72"C, for the 
Taq to work optimally and was calculated using the following equation: 
2(A+T)+4(G+C) 
The primers were designed in such a way that the 3' sequence of one primer could not bind to 
a site on the other primer. All primer sequences were checked for specificty using BLAST in 
PubMed. 
Z 5.6 Agarose gel (Sambrook and Russell, 2001b) 
2% agarose (Roche) was added to 40mM Tris-acetate/ImM EDTA (BDI-L Pool, UK) (TAE) 
buffer. This was heated in a conical flask in the microwave for 20 seconds at a time until the 
powder dissolved. It was left to cool, then 5% ethidium bromide (Invitrogen Life 
Technologies, California, USA) was added to decrease the negative charge of the double 
stranded DNA, increase its stiffness and length and allow visualisation under UV light. The 
solution was poured into a cast with a comb (BioRad, Hertforshire, UK) and left to set. 5gl of 
Dep. H20 was added to 5gl of PCR reaction with 2gl of 6x loading buffer (0.25% 
bromophenol blue, 0.25% xylene cyanol FF and 30% glycerol/dep. water). This increased the 
density of the samples, allowed visualisation of the samples and migrated through the gel at a 
predictable rate. Once the combs were removed and the cast put in the gel tank with a good 
covering of Ix TAE buffer a 100 base pair ladder was loaded into the gel so that the size of the 
cDNA bands could be assessed accurately. The PCR reaction samples with loading buffer 
were loaded into the gel. The gel then had 70 volts applied through it, which caused the 
proportional migration of the linear DNA. The size of DNA was inversely proportional to the 
rate of migration therefore the length of time the gel ran for depended on the size of DNA 
band expected. A 2% agarose gel was chosen because the molecular size of the cDNA used 
was relatively small (150-500 base pairs). 
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2 S. 7 Visualisation 
Bands were visualised on an UV transilluminator (Gibco Life Technologies, Maryland, USA) 
with 100% UV light applied. A Polaroid picture was taken using a Polaroid gel cam and hood 
(Fisher scientific, Leicestershire, UK) using black and white film. 
2.6 Intracellular calcium ([Ca2+Jj) measurements 
2 6.1 Calcium Rig set up (adaptedfrom methods used in (Pocock et al, 2000) and (Glass, 
2003)) 
A calcium rig has been set up in this laboratory to measure [Ca2+]i changes in in vitro and in in 
vivo models. A schematic of the in vitro set-up is shown in figure 2.2. A glass coverslip with 
a monolayer of cells sits in a coverslip holder on an epifluorescence microscope (Leica, 
Milton Keynes, UK). The cells, loaded with Fura 2AM (see below) are excited by three 
different wavelengths of light emitted from a xenon light source via a filter wheel containing 
340,360 and 380nm filters that spins at 50 Hz, controlled by the filter wheel controller. Each 
filter position is synchronised to channels 14 respectively on the spectrophotometer (Cairn, 
Kent, UK). The filtered light passes through a 400nm dichroic mirror, which reflects light 
below 400nm and allows greater wavelengths to pass through. The mirror is set at 45* to the 
light path, so it reflects light up to the specimen. This light excites the Fura 2 in the cells. 
When bound to calcium this emits a wavelength of 510±35nm. The 510nni emitted light 
passes through the 400nm dichroic mirror and the light can then be guided down one of two 
pathways by an adjustable prism. In one position it allows the light to be viewed through the 
eyepiece, to visualise the cells, in the other position the light is directed to the photomultiplier 
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Figure 2.2. In vitro schematic of the calcium rig 
White light is filtered through 340,360 and 380nm filters and passes through a dichroic mirror that 
2+ 
reflects light <400nm up to the Fura-2 loaded cells. The [Ca li bound Fura-2 is exited by light at 340,360 
and 380nm and emits light at 510nm. This light passes through the 400nm dichroic and is either visualised 
in the microscope eyepiece, or is directed, by the adjustable prism, to the PMT, where the signal is 
amplified. The signal is then converted by the spectrophotometer and is recorded by PowerLab/4sp, which 
synchronises emitted light to the wavelength of light it was excited by, i. e. 340,360, or 380nm. 
The PMT amplifies the signal and relays this to the spectrophotometcr, which converts the 
light signal to voltage. This unit also controls the PMT output and gain (amplitude). The 
fluorescence intensity for each filter is displayed and recorded by the PowerLab/4sp (AD 
Instruments, Oxfordshire, UK) software on the computer. 
262 Fura 2-AM 
Fluorescence intensity is measured using the fluorescence calcium indicator Fura 2, which 
forms aI-. I complex with calcium. Both free and bound forms of the dye fluoresce but when 
bound to calcium the fluorescence has a shorter excitation wavelength (Poenie, 1990). [Ca 2+] i 
can be calculated from the ratio of the fluorescent intensity measured at 340nm to that 
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measured at 380nm. The fluorescent intensity measured at 340nm is proportional to an 
increase in [Ca 2 ']i and the fluorescent intensity measured at 380nm is proportional to a 
decrease in [Ca 2+]i (figure 2.3). To calculate the [Ca 21], it must be related to the minimum and 
maximum values of this ratio termed R. in and R,,.,. These can be calculated using thin films 
of Fura-2 solutions containing saturated calcium concentrations (R. Ix) or zero calcium 
concentrations (R .. in) chelated by EGTA. This is best done in water rather than in cells as the 
fluorescence intensity can be affected by the viscosity of the cytoplasm (Poenie, 1990). 
Ern 510 nrn 
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Figure 2.3. The Fluorescence intensity of Fura-2. 
The fluorescence intensity of Fura-2 is proportional to an increase in calcium when excited at wavelength 
340nm and is inversely proportional to an increase in calcium when excited at wavelength 380nm. 
Emission (EM) is at wavelength 510nm. Adapted from Molecular Probes' calcium calibration buffer kits 
data sheet. 
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Fura-2 is used in this project in two forms, pentapotassium. salt and Fura-2 acetoxymethyl 
(AM). Fura 2 pentapotassium salt is used to calibrate the dissociation co-efficient (Kd) (see 
below) and is not cell permeant. Fura 2 AM is an ester of Fura 2 and is cell permeant. 
2.6.2.1 Calcium calibration andKdp 
The Kdp describes the dissociation of bound calcium to free calcium and this can be calculated 
by plotting emissions of a range of known calcium concentrations at both 340nm and 380nm 
and was done on a regular basis. The fluorescence intensity is proportional to Fura 2 bound 
[C21i levels at wavelength 340nm and is inversely proportional to Fura 2 bound [C2']i 
levels at wavelength 380nm (figure 2.3). Light emitted at 360nm from the loaded cells is 
directly proportional to the concentration of Fura 2). Fura-2 pentapotassium salt was diluted 
to a final concentration of lOgM in calibration buffers (Molecular Probes, Leiden, 
Netherlands) ranging from 0 to lOmM Ca-EGTA (39gM free calcium) and mixed thoroughly. 
60ptl of water was pipetted onto a 50 x 50mm glass coverslip (no. 0 thickness, Menzel-Glaser, 
Braunschweig, Germany), which had an enclosed area of approximately lcm 2 sealed off with 
three layers of Biohazard tape. This was then covered with a 22 x 22mm glass coverslip 
(Menzel-Glaser, Braunschweig, Germany) and placed on the microscope stage of the 
epifluorescence microscope. The level of fluorescence intensity was recorded in complete 
darkness for approximately 10 seconds to make sure the reading was unchanging. This was 
then repeated with 60gl from all 10 calcium buffer solutions. The data was analysed (see 
below) and the KdP plotted as the fluorescence intensity ratio against free calcium 
concentration (see figure 2.4). The KdP is defined as the calcium concentration at which it 
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Figure 2.4. An example of a calibration curve for the Kdo. 
Kd P= 2050.41 
600 700 800 
R. j. and R..,, are the ratios 1134011080fOr zero Ca2+ and saturated Ca2+ respectively. 
Kdo is calculated from 
the gradient of the line m demonstrated on the graph. 
2 6.3 Fura 2 Calibration 
Fura 2 was also optimally calibrated to check the consistancy of the system, although a 
concentration of 10ýM was always used. Fura 2 pentapotassium salt was dissolved at various 
concentrations ranging from 1-20ýtM in 5mM Ca-EDTA calibration buffer (number 5 of 11). 
Fluorescence intensity was recorded as before and the fluorescence intensity plotted against 
the concentration of Fura 2. 
26.4R .. i,, and R,,. calibration 
At the beginning of each day the system was calibrated using OmM calcium and lOmM Ca- 
EGTA calibration buffers. This was necessary to work out the R .. in and R,,,,, for each set of 
experiments (see analysis below). The fluorescence intensity of water, R. in and Rax were 
measured in the same way as above. 
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2 6.5 Loading the cells 
Primary cultured and differentiated human conditionally immortalised podocytes were grown 
to confluency on 10% collagen/PBS coated 22mm diameter glass coverslips in a six well 
plate. Cells were washed once with serum free RPMI then incubated in I ml serum free RPMI 
media containing lOgM Fura 2 AM and 0.006% pluronic (Molecular Probes, Leiden, 
Netherlands), which was mixed thoroughly to reduce Fura 2 crystals. The Fura 2 AM is 
cleaved by intracellular esterases into Fura 2, which is sensitive to calcium ions, and pluronic 
helps to disperse the AM esters. Cells were light protected and incubated at 37*C for between 
1_ and 2hrs. The Fura 2 solution was aspirated off and the cells washed once in phenol red free 
Hanks' Balanced Salt Solution (HBSS, Gibco Life Technologies, Maryland, USA). The 
HBSS contained either minimal (approximately 200ýIM) calcium (with 0.4g/L KCL, 0.06g/L 
KH2P04,0.35g/L NaHC03,8g/L NaCL, 0.048g/L Na2f]PO4, lg/L D-glucose) or 1.3mM 
calcium (i. e. physiological extracellular calcium concentration) (with 0.185g/L CaC12-21120, 
0.098 g/L MgS04,0.4g/L KCL, 0.06g/L KH2P04,0.35g/L NaHC03,8g/L NaCL, 0.048g/L 
Na2HP04, Ig/L D-glucose) depending on the experiment. The coverslip was handled with 
forceps and the cells carefully wiped off the underside using tissue. Surplus solution was 
drawn off and the coverslip placed in a coverslip holder, which was covered in a thin film of 
silica paste with a Perspex plate placed firmly on top to achieve a good seal. The area above 
the coverslip was exposed and Iml HBSS was pipetted into a lip that allows gradual spill-over 
onto the coverslip. The coverslip was slotted into a Perspex tray on the epifluorescence 
microscope. The cells were brought into focus in the light and then the Fura 2 loaded cells 
were fine focussed in complete darkness. An appropriate view was found with confluent cells, 
high fluorescence intensity and minimal Fura 2 background. A stable baseline was established 
over a minimum of 2 minutes and in most cases recordings were taken for approximately I 
minute prior to treatment. If fluorescence intensity was too low or the recordings not regular 
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then another view was found. To add the treatment to the cells the PNIT was closed to protect 
it from white light a torch was shone over the coverslip, the treatment was pipetted carefully 
into the BBSS without disturbing the cells, the torch was turned off and the PMT reopened. In 
this manner recording could continue and changes in [Ca 21, could be detected as soon as the 
PMT was turned back on. [Ca2'1j changes were recorded for approximately 5. At the end of 
each experiment lOgM ionomycin was added, which is a calcium ionophore that perforates all 
cell membranes causing a heavy influx of calcium both extracellularly and from intracellular 
stores. This was used as a positive control followed by 5mM Manganese chloride (MnCl2) to 
quench the Fura 2 bound calcium. This last reading was used as the Rin to calculate actual 
calcium concentrations (see analysis below). 
2 6.6 Data analysis 
Voltage readings for all three wavelengths plus the time since the start of the experiment were 
recorded using the Chart V3.6 MacLab system. This was opened in Excel as a txt document 
and was converted into individual data points. Actual calcium was calculated using the 
following equation: 
[Cä21i = Kd [(Rnorrn - 0.85) / (0.85 x R. «norm)-Rnorm]) 
Where 0.85 represents the correction value to account for cytoplasm viscosity (Poenie, 1990), 
R is the normalised ratio of fluorescence intensity (If) calculated as: 
R= Fv / Rj. 
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Where &v= (If34o-B340)/(If380-B380)- If34o is the If measured during excitation at 340nm, If38o is 
the If measured during excitation at 380nm and B34o and 113go are the background If values 
measured during excitations at 340nm and 380nm respectively (measured as the If after Mn2+ 
quenching). Rninis the in vitro ratio for zero [Ca2jj concentration calculated where Rj. - 
(If340-W340)/(1f380-W380)- W34o and W38o are the background If values during excitations at 
340nin and 380nm of water. R.. norm is the ratio of R.. Ain and R.,,, is the in vitro ratio 
for saturated [C2+]i and is calculated by Rmax=(If340-S340)/(If380-S380), where S34o and S38o are 
the If values of saturated [Ca2jj. Rnorm is the Ratio normalised to Rmk Actual calcium was 
used as well as the Rnorm. This was to compare between sets of experiments where the 
calcium levels were variable. [C21i was plotted against time of treatment introduction. 
Changes in [Ca2jj were measured by taking the average of select data points representative of 
a baseline reading and a peak or trough reading after treatment. To look for significance within 
an experiment these were compared using a paired Mest. To check for significance between 
experiments the ratio of the experimental over baseline reading was taken and the averages of 
these compared using an unpaired t -test. P<0.05 was accepted as statistically significant. 
2.7 Proliferation 
This assay was adapted from the one described in (Bates et al., 2002). It uses the principle 
that DNA replicates during proliferation and if Methy 1_3 H labelled thymidine is present it will 
be incorporated into the DNA. Therefore the radioactive signal will be directly proportional to 
DNA replication. Only primary culture podocytes were used in this assay because they are 
proliferative. 200gl of a podocyte cell suspension was seeded onto a 24 well plate (Nunc, 
Fisher Scientific, Leicestershire, UK) with 800gl complete RPMI. Cells were left for 48 hrs 
or until 70% confluent then media was removed and replaced with serum free RPMI media. 
Treatment was added to half the cells and half were left untreated. 24hrs later IgCi/ml 
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Methyl-3H thymidine (Amersham Pharmacia, Buckinghamshire, UK) was added to each well 
and mixed. Afterjust 4 hrs the wells were washed once with IxPBS and then 0.2ml Ix trypsin 
was added to each well and left for 5 minutes. 0.2mls complete RPMI was added to each well 
to stop the reaction and remaining cells were pipetted into 1.5ml tubes (Eppendorf, Hamburg, 
Germany) from which a cell count was taken using a students' haemocytometer (Neubeaur, 
Weber, UK). The samples were spun at 300g for 10mins (Biofuge, Hereaus, Hanu, Germany). 
The supernatant was removed and 0.2ml NaOH was added to lyse the cells at room 
temperature for 30 minutes. Cells were then pipetted into scintillation vials (Fisher Scientific, 
Leicestershire, UK) and 5ml of biodegradable scintillation fluid (Amersham Pharmacia, 
Buckinghamshire, UK) was added before counts per minute (cpm) were read by a scintillation 
counter (1217 Rackbeta, Perkin Elmer, Boston, USA). Data was expressed as cpm/treatment 
and 3H thymidine incorporation/cell for each treatment. A paired I-test was used to test for 
significance. 
2.8 Cytotoxicity (adapted from LDH kit instruction manual, Roche) 
18.1 Principles 
Percentage cell death (cytotoxicity) was measured using a colourimetric assay to detect lactate 
dehydrogenase (LDH) activity released from the cytosol of damaged cells into the supernatant 
(Roche). Released LDH reduces nicotine adenine dinucleotide (NAD+), a coenzyme for 
oxidation, to NADH/H+ by the oxidation of lactate to pyruvate. Then a second catalyst 
(diaphorase) transfers two hydrogen ions from NADFVH+ to the yellow iodotetrazolium. 
chloride (INT), which forms red formazan as shown in figure 2.5. Therefore the amount of 






Figure 2.5. Principle of LDH assay 
LDH release induces the reduction of NAD+ to NADH/H+. This allows the transfer of two hydrogen ions 
from NADH/H+ to iodotetrazolium chloride (yellow) to form formazan (red). The colour of the media is 
therefore directly proportional to the amount of LDH release and the percentage of cytotoxicity can be 
calculated from this. 
2 8.2 Notocol 
On day one a 96 well plate (Coming, Birmingham, UK) was seeded with 20%d/well primary 
culture or conditionally immortal podocyte cell suspensions in complete RPMI media and left 
for 48hrs or until confluent. On day three the media was removed using a multichannel 
pipettor, washed once with sterile IxPBS and 200ýtl serum free RPMl added. On day 4 100gl 
from each well was transferred to a similarly labelled 96 well plate. For a full 96 well plate 
11.25ml of solution containing diaphorase/NAD' from the LDH kit (Roche, Manheim, 
Germany) was mixed with 250ýd of solution containing INT and sodium lactate. 100ýtlofthis 
solution was added to each well and light protected for 30 minutes at room temperature. It 
was then quantified using a Bichrometric Multiscan plate reader (Bioscan, Washington, USA), 
using an absorbance spectra at wavelength 492nm. This was the low control reading (min). 
The test 96 well plate was divided into non-treatment and treatment(s) and I OOPI of serum free 
RPMI containing either treatment (double final concentration) or not was added to the I 00gl 
media left in the 96 well plate. On day 5 100gi of the 200gi from each well was transferred to 
a similarly labelled 96 well plate and the LDH assayed and quantified as above. This was the 
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experimental reading (exp). Finally 100gl of 2% Triton XIlx PBS (final concentration 1%) 
was added to each well and left for 10 minutes to lyse the adherent cells and enable the 
maximum LDH from each well to be determined. 100gl was removed from each well 
transferred to a similarly labelled 96 well plate and the LDH assayed and quantified as above. 
This was the high control reading (max). From these readings the % cytotoxicity (T. ) can be 
calculated: 
T. = (exp-(min/2A))/(max + ((exp/21)-(min/4c))) x 100 
A. Nfin values are divided by 2 because the control media still left in the 96 well plate was 
diluted twice by day two. B. Exp values are divided by 2 because the exp, media in the plate 
was diluted twice by day three. C. By the third day the low control was diluted twice more 
and therefore was a quarter of the original reading. The max and exp readings were combined 
to allow for differences between treatments in the high control readings. Data were expressed 
as changes in % cytotoxicity and significance was tested within experiments using a paired I- 
test and between experiments using an unpaired I-test (two samples) or unpaired ANOVA 
(more than two samples). 
2.9 Apoptosis Assay 
Z9.1 Principles 
Apoptosis is programmed cell death that can be initiated through a number of different stimuli 
via a number of different pathways. This assay uses the principle that the plasma membrane 
fatty acid residues are normally polarised with phosphatidylserine (PS) residues on the 
cytoplasmic side. During apoptosis this polarity is lost and the PS residues are "posed to the 
extracellular fluid. This, is just one of the cell surface residues that are recognised by 
phagocytotic cells. Annexin V is a member of a family of calcium dependent phospholipid- 
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binding proteins involved in cytoplasmic signal transductions, whose preferential cytosol- 
binding partner is PS. FITC conjugated recombinant annexin V protein has been developed to 
bind to PS residues of apoptotic cells. This assay also uses the principle that during necrosis 
(pathological cell death) the plasma membrane loses its integrity allowing propidiurn iodide, 
which is a hydrophilic polar nuclear binding dye and therefore not normally able to cross the 
plasma membrane, entry into the cell, which is taken up by the nucleus. Necrotic cells have 
very low cell surface exposure of annexin V. Apoptotic cells do not lose their membrane 
integrity until late in the process when apoptotic bodies are formed, just before phagocytosis. 
Z 9.2 Protocol 
Confluent conditionally immortal podocyte cell lines in 75CM3 tissue culture flasks were 
serum starved for 4,16 or 48hrs to induce growth factor withdrawal induced apoptosis, then 
treated or left untreated for a further 4hrs. Cells were then scraped into suspension using cell 
scrapers (Nalge Nunc, Fisher Scientific, Leicestershire, UK) and left in a 15ml falcon tube on 
a roller (Stuart Scientific, Watford, UK) for 4 hrs more to ensure cells did not re-adhere. This 
was also to promote anoikis, which is apoptosis induced by disturbance of cell surface 
integrins. Cells were then spun for 5 minutes at approximately 30OOrpm, the supernatant 
discarded and each pellet resuspended in Iml Ix binding buffer (Bender Medsystems, Vienna, 
Austria) (final concentration lOmM Hepes/NaOH, pH 7.4,140mM NaCL, 2.5 mM CaC12). 
Each ml was divided four ways into: 1) a background sample; 2) an annexin V only treated 
sample; 3) a propidium iodide (PI) only treated sample and 4) a sample treated with a 
combination of annexin V and PI. 10 gl of FITC conjugated recombinant (rh) annexin V 
protein was added to the annexin V sample (sample 2) and the combination sample (sample 4). 
All samples were protected from light and incubated at room temperature for 15 minutes on a 
roller to mix and stop cell re-adherence. The unbound annexin V was washed away by 
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centrifuging at 600g for 5 minutes, discarding the supernatant, adding 250ýtl IxPBS, 
resuspending the cell pellet and centrifuging again at 600g for 5 minutes. 5ýd of 20ýtl/ml PI 
was added to the PI only (sample 3) and the combination sample (sample 4) and mixed. 
Samples were then immediately assayed using a flow cytometer. Samples not immediately 
used were kept in the fridge under gentle agitation until ready for use. Samples were used in 
no specific order. 
2.9.3 Flow cytometer 
The cell suspension sample was taken up into the flow cell of the flow cytometer (Beckman 
Coulter, Buckinghamshire, UK) where hydrodynamics focused the cells into a single stream. 
An argon laser emitted light at 488nm, which excited the samples in the flow cell. Light was 
scattered from the sample and captured at 90', termed the forward scatter and at 450, termed 
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Figure 2.6. Flow cytometer optics from Beckman Coulter tutorial slide 
The cell suspension is taken up by the flow cytometer and excited by light at 488nm. Light scattered 
forward gave an indication of granularity of events, and light scattered sideways gave an indication of size 
of events. Side scatter light passed through dichroics of various limits and light shorter then the dichroic 
limit was reflected up to various light filters of 525nm, 575nm and 600nm. 
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The wavelength of forward scatter light represented size of the particles (events) hit by light 
and the wavelength of side scatter represented the granularity of particles (events) hit by light. 
The beam of side scatter light was filtered through a series of dichroic mirrors and filters for 
different wavelengths as shown in figure 2.5. Emission collected at 525nm (filter 1, green) 
picked up FITC-conjugated AV labelled cells and emission collected at 600nm picked up PI 
labelled cells (filter 3, red). The PMT amplified the signal. This was then controlled by the 
voltage, which acts as a fine control and by the gain, which acts as a coarse adjustment. 





Figure 2.7. Flow Cytometer data display. 
B 
D 
A. Forward scatter and side scatter light from each event is displayed, and the gated region defines cells 
depending on their size and granularity. B. A scatter plot of events detected at 525nm (AV) and at 600nm 
(PI), showing subpopulations defined by four different regions. C. Count of events with AV binding, 
showing a linear region to divide the AV bound population from the autofluorescent, or low level AV 
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bound population. D. Count of events with PI staining, showing a linear region to divide the PI stained 
population from the autolluoreseent, or low level " bound population. 
Data from the cell sample are displayed in four graphs. Firstly, a dot plot of forward scatter 
against side scatter, which is used to gate an area representative of size and granularity of 
events (data points) therefore discarding debris (figure 2.7 A). The discriminator was also set 
on the machine to discard readings below a certain size in order to count only whole cells. 
Secondly, a scatter plot of events from filter I (annexin V) (X axis) was plotted against events 
from filter 3 (PI) (Y axis) (figure 2.7 B). This histogram separates the entire population of 
events into sub-populations characterised according to whether they are labelled with neither 
AV nor PI (viable), PI alone (necrotic), AV alone (apoptotic) or both PI and AV (late 
apoptotic), as described below. Thirdly, a one parameter histogram displaying wavelengths 
from filter I (annexin V) against events count (figure 2.7 Q and a fourthly a one parameter 
histogram displaying wavelengths from filter 3 (PI) against events count (figure 2.7 D). These 
show quantity of events that have picked up the dyes. The sub-populations in histogram two 
were defined into separate regions very carefully using an untreated sample that was 
subdivided into background, PI only, annexin V only and both PI and annexin V incubated 
cells as described in figure 2.8. The background sample was run through the machine and the 
population seen on histogram two was isolated by drawing a region around it as indicated in 
figure 2.8 A. This isolated the population that was auto-fluorescent from the cells that had 
picked up either dye. The same was done with each sample and each new population was 
isolated by a new region (figure 2.8 B-D). Once the first three samples were run through, the 
population defined by the last sample was the population that had picked up both PI and 
annexin V. This inferred that either the cells (events) were in late apoptosis and had lost some 
membrane integrity (apoptotic cell bodies) or that some necrotic cells (events) had low 
exposure of PS residues on the surface (figure 2.8 D). The population from the combined 
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stain sample (figure 2.8 D) that fit into the autofluorescence region (figure 2.8 A) described a 
viable population, as well as autofluorescent cells, because this cell population picked up 
neither annexin V nor PI. 
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A. A cell suspension sample was assayed by the flow cytometer and the population shown by the scatter 
plot was defined as an autofluorescence/viable population. B. A cell suspension incubated In P1 only was 
assayed by the flow cytometer and the population shown by the scatter plot outside of the autofluorescence 
region was defined as the necrotic population. CA cell suspension Incubated In FITC conjugated annexin 
V only was assayed by the flow cytometer and the population shown by the scatter plot outside of the 
regions already defined was defined as the apoptotic population. D. A cell suspension incubated In both 
PI and annexin V was assayed by the flow cytometer and the population shown by the scatter plot outside 
of the regions already defined was defined as the late apoptotic population. 
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Background sample 
Annexin V and PI Annexin V 
A linear region was also fitted to the last two histograms using the background sample to show 
auto-fluorescence, defining the region from there onwards. A protocol was set up in this 
manner for different cell types. Once it had been set up then the populations of all of the 
samples should fit in the regions defined unless the laser loses its alignment (see calibration 
below). 
2 9.5 Calibration 
Every time the flow cytometer was used it was calibrated using fluorescent spheres that 
fluoresce equally at all three filter wavelengths (Beckman Coulter, Buckinghamshire, UK). 
They were run through as a sample would be and the data was displayed on a pre-set up "start- 
up protocol". This data indicated whether there was a blockage in the flow cell or if the laser 
was out of alignment. Each parameter was tested on a histogram against sphere count. The 
computer measured the half peak co-efficient of variation of these peaks, which showed that 
the excited light from the laser did not vary by more than 0.5%. 
Z9.6Analysis 
The computer on the flow cytometer quantifies the events in the gates and regions and this 
data was analysed in Excel with the assumption that all events were cells. Each subpopulation 
was calculated as a percentage of the total population given by the statistics on the Flow 
cytometer as follows: 
Viable population (background) = POPcv/POPT 
Necrotic population (PI) ý (POPCN-POPOA)/POPT 
Apoptotic populafion (Annexin V) ý (POPCA-POPON)/POPT 
Late apoptotic population (PI and Annexin V) -ý (POPCLA-(POPOA+POPON))/POPT 
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Where POPT describes the total population calculated as the sum of populations in each 
region. POPxv depicts the population in the viable region just as POPXA, POPxN and POPx" 
depicts the populations in the apoptotic necrotic and late apoptotic regions respectively. 
POPcx and POPox describe this populations from combined incubation or incubation with one 
dye only respectively. An unpaired ANOVA with a Bonferroni post hoc test was used to test 
for significant differences between cell populations. 
2.10 Western Blotting 
Z 10.1. Protein extraction (adaptedfrom (Wen et al, 1999)) 
Protein was extracted from confluent cells in a 75CM3 tissue culture flask that had been 
serum starved for 24hrs and then incubated with treatment for various times. Cells were 
washed once with cold Ix PBS and then scraped into suspension using a cell scraper. 
Cells were centrifuged at 30OOrpm for 5 minutes, the supernatant removed and lysis buffer 
added depending on the pellet size (-IOOAI). The lysis buffer contained RIPA buffer 
consisting of detergents and salts including 1% Nonidet P-40 (ICN Biomedicals, 
California, USA), 0.5% Sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS) 
/water, Ix PBS. It also contained a cocktail of proteinase and phosphatase inhibitors 
added fresh to the RIPA buffer consisting of ImM PMSF/isopropanol, ImM 
Na3VO4/water and 20Ag Aprotonin/ml water. The samples were left to rock at 4C for 20 
minutes to mix and then incubated on ice for 60 minutes to lyse the cells. The samples 
were spun at 130OOrpm at 4C for 15mins and the supernatant transferred to clean 
Eppendorf tubes. Protein was kept at -20"C until ready to use. Protein extraction from 
tissue was done in much the same way except that the tissue was chopped finely and 
homogenised using plastic homogenisers (Fisher Scientific, Leicestershire, UK) then 
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incubated in lysis buffer and centrifuged in the same way. The lysis buffer added equated 
to the weight of the tissue. 
ZIO. Z Protein quantification (Bradford assay using Bio-Rad guidelines) 
Protein was quantified from samples that were thawed on ice. A protein standard curve was 
prepared using normal mouse IgG protein at various dilutions in milli Q ranging from 0 to 30 
ýtg/ml in (total volume 30gi) made up in 7ml sterilised polystyrene containers (Biby Sterilin, 
Staffordshire, UK). Protein was diluted at 1: 10,1: 50 and/or 1: 100 in water (total volume 
30gl). The Bio-Rad dye was made up 1: 5 in water (containing ethanol and phosphoric acid) 
and 1.5ml added to each of the samples, including the standard curve samples, vortexed and 
left at room temperature for -10 minutes. The samples were transferred to plastic 1.6ml 
cuvettes (Fisher Scientific, Leicestershire, UK). The standard curve absorbence was read on a 
spectrophotometer at 595nm in order of increasing protein concentration using the 0 Ag/ml 
protein sample to calibrate the machine, then the samples were read. The protein standard 
curve was then plotted using the optical density (OD) reading against concentration (jig/ml) 
and the protein quantity of the diluted samples determined from the line of best fit. This 
concentration of protein was multiplied by the dilution factor used, then divided by 1000 to 
achieve gglAl. 
2 10.3. SDS Polyacrylandde gel electrophoresis (PA GE) 
Proteins were run using SDS PAGE to separate them according to charge and molecular size. 
First the proteins for each gel were diluted with up to 8gl Ix PBS so that each sample had an 
equal quantity of protein (70-100gg) and were then diluted in 8gl Ix SDS loading buffer. 
This contained IOOmM Tris/Cl pH 6.8,4% SDS, 20% (v/v) glycerol (BDH, Pool, UK), 5% 0- 
mercaptoethanol and 0.2% (w/v) bromophenol blue. The 0-mercaptoethanol reduces any 
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disulphide bonds stabilising the protein, the glycerol gives density to the samples when loaded 
into the gel and the bromophenol blue dye enables visualisation of samples as they run 
through the gel. The samples were then boiled at 100'C for 5 minutes to denature the protein 
and expose the entire length of the polypeptide chain to the detergent. The samples were put 
on ice to stop the reaction. A polyacrylamide gel was made (by the polymerisation of the two 
monomers acrylamide and NN-methylene-bis-acrylamide (Sambrook and Russell, 2001c)). 
The percentage bis-acrylamide varied depending on the molecular weight of the protein in 
question (i. e. 7.5,12 and 15%) because the pore size of the gel decreases with increasing 
proportions of bis-acrylamide. 5ml resolving gel solution was made for each gel using water 
30 % bis-acrylamide (BioRad, Hertfordshire, UK) (final concentration varies), 375mM Tris, 
0.1% SDS, 0.05% ammonium persulphate, to catalyse the reaction and 0.05% 
tetramethylethylene diamine (TEMED) to initiate the reaction. The gel was cast using Bio- 
Rad (Hertfordshire, UK) equipment and allowed to set with a layer of ethanol at the surface to 
exclude air, which inhibits the reaction. When it had set, a 4% bis-acrylamide stacking gel 
was made as above but using 125mM Tris, and 0.1% TEMED. The ethanol was drained away 
from the resolving gel, the stacking gel added and combs put in place. Once the gel had set it 
was transferred to the electrophoresis tank (Bio-Rad, Hertfordshire, UK) and set up using SDS 
running buffer (25mM Tris, 250mM glycine (electrophoresis grade BDH, Pool, UK) 0.1% 
SDS and water). 15ýil kaleidoscope ladder (BioRad, Hertfordshire, UK) was loaded on the 
right hand side of each gel and then each sample was loaded and a current of 90V was run 
through the gel for -60-90 minutes until it had separated proteins according to the band size of 
interest. The gel was trimmed and kept in transfer buffer (5OmM Tris, 38mM glycine 




The protein was transferred from the gel to a polyvinylidine fluoride (PVDF) membrane 
(Fisher Scientific, Leicestershire, UK) using electrophoresis. Transfer was carried out 
perpendicular from the direction of travel of proteins. The PVDF membrane was cut to the 
size of the gel. It was soaked in methanol because it is hydrophobic, then soaked in transfer 
buffer until use. The PVDF membrane was placed on top of the gel and sandwiched between 
a set of filters (BioRad, Hertfordshire, UK) and a set of sponges (BioRad, Hertfordshire, UK) 
pre-soaked in transfer buffer (see above). This was held together in a cassette and placed in 
the transfer module (BioRad, Hertfordshire, UK). The transfer module was kept at 4"C and 
the protein was transferred at a constant current of 250mA for 4hrs. 
ZIOJIMmnodetection 
This procedure was used to identify and measure the size of proteins that are recognised by the 
specific antibodies. The PVDF membrane was incubated in 10% low fat powdered 
milk/0.05% PBS-tween blocking solution or filter sterilised 3% bovine serum albumin 
(BSA)/0.05% PBS-tween depending on the primary antibody used: For example, when 
probed with an anti-p-Y antibody membranes were blocked with 1% BSA instead of non fat 
milk, as the latter has been described to provide much greater background, due to endogenous 
phosphotyrosines. It was incubated for Ihr at room temperature on a roller to block non- 
specific binding sites on the membrane and suppress non-specific adsorption of antibodies. 
The membrane was then incubated with the primary antibody that recognises the antigen of 
the protein of interest diluted by 50% in the required blocking solution in 0.05% PBS-tween 
and incubated at 4*C overnight under gentle agitation. Unbound primary antibody was 
washed away with 5 washes of at least 5 minutes each using 0.05% PBS-tween at room 
temperature. The membrane was then incubated for one hour at room temperature on a roller 
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in horseradish peroxidase (HRP) conjugated secondary antibody (Pierce) diluted by 50% in 
the required blocking solution. The membrane was washed again as above. The luminol 
enhancer solution and the peroxide solution from an enhanced chemiluminescent kit (ECL) 
(SuperSignal West Femto Maximum Sensitivity Substrate, Pierce, Cheshire, LJK) were mixed 
1: 1 allowing 0.125ml of total solution per CM2 of membrane. The membrane was exposed to 
the ECL for between 5-15 minutes (depending on optimisation for each primary antibody) and 
light protected. In the presence of hydrogen peroxide HRP it triggers a cyclical 
chemiluminescent reaction that results in the oxidation of luminol to an excited form of 3- 
aminophthalate. When this compound returns to ground state it emits blue light that was 
captured on X-ray film (Sambrook and Russell, 2001c). In a dark room the membrane was 
laid flat against cling film and taped in place in a film cassette (GRI Molecular Biology, 
Essex, UK). The membrane was exposed for various amounts of time to X-ray film 
(Amersham Biosciences, Buckinghamshire, UK) ranging from I second to 5 minutes 
depending on the signal given off and was run through the developing machine (X-ograph 
Imaging Systems). Membranes were kept in clingfilm at 4"C for long term storage. 
Z 10.6 Stripping blots 
Membranes that had been probed once were stripped of that antibody detection complex so 
that they could be re-probed with further antibodies. This allowed experiments to be paired. 
Membranes were wetted with methanol if they had dried out, then incubated at 50*C for 30 
minutes with occasional gentle agitation in stripping buffer. This contained IOOmM P- 
mercaptoethanol, 2% SDS, IM Tris and water. The membrane was then washed twice for ten 
minutes in 0.05% PBS-tween and then blocked and probed as before. 
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Z10.7Analysis 
The bands on the film were scanned into the computer (SnapScan 1236, AGFA, Middlesex, 
UK) and opened in the NIH image software package. This was used to compare the pixel 
density of each band in question, using an identical area each time. The bands were compared 
within a membrane using an unpaired I-test (comparing two bands) or an unpaired ANOVA 
(more than two bands) and bands between the same re-probed membrane using paired mest or 
paired ANOVA. 
2.11 Immunoprecipitation 
This procedure was used to establish protein association. It used proteins A and G, which are 
expressed on the surface of gram positive bacteria (different species) and enable the bacteria to 
invade the host system. They do this by binding to immunoglobulins (Igs) without stimulating 
an immune response. Protein G only recognises IgGs where as Protein A recognises other 
types of Igs such as IgM and IgE. Protein A/G can bind to the Fc portion of antibodies so can 
be used in combination as a binding reagent when conjugated to beads. Protein was extracted 
from the cells and quantified as above. 
211.1. Cell lysatepre-cleating 
The protein A/G slurry (Santa Cruz Biotechnologies, Heidelberg, Germany) was pre-washed 
in the lysis buffer used in protein extraction. It was washed twice, centrifuged at 100OOrpm 
for 30 seconds and resuspended in lysis buffer. The lysate was then pre-cleared of non- 
specific contaminants by incubating it in 2% (v/v) pre-washed protein A/G slurry at 41C for 
lhr under gentle agitation. The sample was then centrifuged at 130OOrpm for 15 minutes at 
4'C, the supernatant transferred to a fresh Eppendorf and the bead pellet, containing the non- 
specific contaminants and protein A/G beads discarded. The lysate was incubated again as 
above, also adding 0.25ptg of appropriate control IgG corresponding to the host species of the 
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primary antibody used in the next step. The sample was spun down as above and again the 
supernatant kept and the pellet discarded, the slurry was resuspended in lysis buffer Iý1. 
2.11.2 Inintunoprecipitation 
The lysate was incubated overnight at 4'C under gentle agitation with a total of Ipg of' 
primary antibody to react with the antigen of the protein of interest. 1 ý25 of the 50% protein 
A/G slurry was added to the lysate and incubated for a further 2hrs at VC under gentle 
agitation to bind to the primary antibody. The lysate was centrifuged at 130OOrpm for 15 
minutes at 4'C, the supernatant transferred to a fresh Eppendorf and the bead pellet containing 
the protein of interest was washed three times in lysis buffer, as described for pre-clearing. 
The pellet and supernatant were kept at -20'C until use. The pellet was resuspended in l0lt] 
Ix SDS loading buffer and the lysate diluted to a standard concentration with lxPBS and 
samples were boiled as before. The samples were then subjected to SDS PAGE, transferred to 
a PVDF membrane and immunodetected as described above. 




Figure 2.9. A PVDF membrane (of WIP lysate immunoprecipitated ith an anti-p-V antilmdý. 
A number of t. ýrosine phosphorylated protein hands ha%e been picked up at variteus molecular weights. 
The bands are more intense in the precipitate (ppt) compared to the supernatant (s/n). 
An example ol'a PVDF membrane, containing hClP lysate that had been immunoprecipitated, 
using an anti -phospho-tyrosl ne antibody and probed with anti -phospho-tyrosine, is shown in 
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figure 2.9. This demonstrates that tyrosine phosphorylated proteins were successfully pulled 
down in the precipitate. 
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Chapter 3 
Characterisation of primary cultured podocytes (PCPs) and the expression 
of VEGF receptors 
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3.1 Introduction 
To investigate the effects of VEGF on podocytes I chose to study them in isolation from the 
glomerulus since the glomerulus is a complex microenvironment and may introduce many 
extraneous variables. Podocytes can be isolated from glomeruli, originated from kidney 
cortex, from various species including mouse, rat, pig and human. In order to understand the 
relevance of this study to human physiology the best species from which to isolate podocytes 
is human. As with any primary cell culture isolation the possibility of contamination by other 
cell types is a problem and research groups have tried to address these criticisms in primary 
culture podocytes (PCPs). Yaoita et al outline the main criticism of PCPs isolated from 
glomeruli: a pure population is dubious and podocytes may change their phenotype in culture 
(Yaoita et al., 2001). A typical protocol to isolate PCPs from glomeruli was used by Parry et 
al, 2000: Chopped kidney cortex was pushed through sieves of progressively smaller pore 
sizes, e. g. sieves with pore sizes of 425gm, 180gm and 125gm. Encapsulated glomeruli were 
retained in the 125gm pore sieve and cultured in complete RPMI-1640 media containing 
insulin for a fortnight, to provide the conditions for podocyte outgrowth (Parry, 2000). Using 
this technique two types of cells have been described as podocytes with similar characteristics; 
the first are cobblestone polygonal cells, which form outgrowths in the first 6 days of 
incubation and replicate rapidly. The second are irregular, multinucleated cells with long 
cytoplasmic extensions that have limited proliferative capacity (Yaoita et al., 2001). The first 
cell type, however, were suggested to be parietal epithelial cells (PECs) that line the 
Bowman's space (Yaoita et al., 1991). Instead of pushing the kidney through the sieves, as 
described above, Yaoita et al rinsed the kidney sections gently with PBS. Individual glomeruli 
were isolated and decapsulated to avoid PEC outgrowths. They concluded that podocytes 
isolated under these conditions retained their phenotype, but those grown from encapsulated I I) 
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glomeruli were derived from PECs or tubular epithelial cells (Yaoita et al., 2001). These 
authors, therefore, recommend that encapsulated glomeruli should be avoided when isolating 
PCPs. When isolating PCPs for cell culture, however, encapsulation of each glomerulus is 
impractical because of the number required. I therefore chose to follow the protocol described 
by Parry et al, 2000 and to characterise PCPs from each isolation. 
6 
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Figure 3.1. Identification of VEGF expression by immuno-gold transmission electron micrograph in a 
normal human glomerulus. 
Sections of human renal cortex were probed with immuno-gold labelled anti-VEGF. Gold particles were 
clearly seen on the edge of the podocyte foot processes (BS= Bowman's Space, GBM=Glomerular 
Basement Membrane, PFP = Podocyte Foot process (done by Rachel Hole). 
VEGF is thought to play a paracrine role in the glornerulus, acting on the glornerular 
endothelial cells (Simon et al., 1995) even though there is no overt angiogenesis in the mature 
kidney. VEGF may be able to act on endothelial cells without causing angiogenesis, due to 
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the presence of other endogenous factors. It may, however, also be possible that VEGF plays 
an autocrine role. VEGF is highly expressed in podocytes, which also express Np-I (Harper 
et al., 2001), a co-receptor for VEGF-R2. Circumstantial evidence presented itself during an 
electron microscopy (EM) study investigating VEGF expression in the glomerulus by 
immuno-gold particles by Rachel Hole at the Academic Renal Unit, Southmead Hospital, 
Bristol. Immuno-gold labelled anti-VEGF, which was thought to act specifically on 
glomerular endothelial cells, appeared to be tightly associated with the podocyte plasma 
membrane (figure 3.1). To confirm these observations, the distance of the immuno-gold 
labelled anti-VEGF from the plasma membrane was measured and shown in the results. 
Plasma membrane associated VEGF excreted from the podocytes would be expected to be 
sequestered to the podocyte glycocalyx, due to the heparin binding abilities of VEGF, 65- If 
VEGF were bound by the glycocalyx, however, then it would not be expected to be quite so 
consistently tightly membrane bound as shown in figure 3. L This suggested that podocyte 
plasma membrane bound VEGF was binding to the plasma podocyte plasma membrane by 
some other means, potentially VEGF specific receptors. Therefore, investigations were made 
into VEGF receptor expression on podocytes, as well as Np-I. This work possibly may have 
been overlooked in the past because investigations into VEGF activity in the glomerulus 
concentrated mainly on glomerular endothelial cells and VEGF activation on epithelial cells 
was thought to be limited. 
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3.2 Methods 
3-ZI Cell culture-PCP isolation 
PCPs were isolated as previously described: Human renal cortex was pushed through 
successive sieves of progressively smaller pore sizes, and the encapsulated glomeruli were left 
at 37"C in complete RPMI media (for composition see p. 60 of methods) for a fortnight to 
allow the outgrowth of podocytes. Encapsulated glomeruli were used because it was too time 
consuming to decapsulate individual glomeruli, as the number required for sufficient podocyte 
culture was too great. The PCPs were, therefore, characterised for protein and mRNA of 
podocyte specific markers. 
3.22 Imnwnocytochemishy - characterisation ofPM 
Expression of Wilms Tumour-I (WT-1) and pan endothelial cell adhesion molecule (PECAM- 
1) protein was examined using immunocytochemical techniques on PCPs and rat glomeruli 
tissue sections. 5Ag1ml rabbit polyclonal IgG anti-WT-1 (C-19) antibody (Santa Cruz 
Biotechnology, Heidleberg, Germany) was used to detect WT-I protein and 5ptg/ml 
biotinylated goat anti-rabbit IgG (Vector, California, USA) secondary antibody was used to 
label the primary antibody. 5gg/ml normal rabbit IgG was used to control for non-specific 
staining of the secondary antibody (an isotype control) and goat serum was used in the 
blocking solution. 8Ag/ml goat polyclonal IgG anti-PECAM-1 (M 20) antibody (Santa Cruz 
Biotechnologies, Heidleberg, Germany) was used with 5Ag/ml biotinylated horse anti-goat 
IgG (Vector) secondary antibody. 5Aglml normal goat serum (Vector, California, USA) was 
used to control for non-specific staining, and horse serum (Vector, California, USA) was used 
in the blocking solution. Both were microwaved in TrisHcl/EDTA buffer (pH9). 
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3. Z3 PCR- characterisation ofPCPs and expression of VEGF receptors 
RNA was extracted from PCPs, hCEPs, human umbilical vein endothelial cells (RUVECs) and 
human liver tissue by extraction with phenol: chloroform: guanidine isothiocyanate as 
described in the methods. RNA was quantified and Igg RNA was reverse transcribed. PCR 
was carried out using the primers described in table 3.1. 
Table 3.1. Sense and anti-sense primer sequences showing location of primers relative to ATG site 
himer Sense 5'-3' Location Anti-scnse 5'-3' Location 
CD45 AGAATACTGGCCGTCAAT +1811 GGAGAGTGAATGCCTTCA +2044 
GG GC 
vWF AAGGAGTTCATGGAGGA +4551 AACCTGGTCTACATGGTC +4823 
GGT AC 
VEGF-RI ATGATGCCAGCAAGTGG +2444 CCAACTACCTCAAGAGCA +2776 
GAGTTTGC AACGTG 
VEGF-R2 GCATCTCATCTGTTACAG +2003 CTTCATCAATCTTTACCC +2335 
C 
VEGF-R3 "TC AACATCACGGAGGAGTC +97 CGCTCTTGGTCAACAGGA +455 
ACACG AGGA 
Np-I AAAAGCCCACGGTCATA +1888 GGATTGCTGTGGATGACA +2392 
G 
GAPDH GTCTTCACCACCATGGAG +301 GCCAAGGCTGTGGGCAA +659 
GGT 
The amplicon length of each primer is as follows; CD45 233bp (Whittle et al., 1999), vWF 
272bp (designed by Dr Bates), VEGF-RI 332bp (designed by Dr Bates), VEGF-R2 332bp- 
(Fakhari et al., 2002), VEGF-R3 358bp (Shushanov et al., 2000), Np-I 504bp (Fakhari et al., 
2002) and glyceral dehyde-3 -phosphate dehydrogenase (GAPDH) 358bp (designed by Dr 
Bates). The annealing temperature for each primer pair was 550C. 
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3.2.4 VEGF-immunogold labelling EM analysis 
I did the analysis on the immuno-gold labelled anti-VEGF probed EM sections, kindly 
provided by Miss R. Hole. Podocyte (intracellular or membrane associated), glomerular 
basement membrane and glomerular endothelial cell associated VEGF labelled gold particles 
were counted in 16 random fields from 4 different kidneys. Colloidal gold particles were 
considered membrane associated if they were within 2 particle widths (i. e. 30nm) of the 
membrane on either side. Data were presented as mean + standards effors. Two tailed paired I- 
tests were used to compare paired data on the same cells, unpaired Mests to compare separate 
cell populations treated differently. ANOVA was used to compare distribution of gold 
particles. 
3. Z5 Western blotting- expression of VEGF receptors 
Serum starved PCPs were treated with InM recombinant VEGF protein (a kind gift from 
Professor N. Ferrara, Genetec) for 20 minutes and serum starved hCIPs were treated with I nM 
recombinant VEGF-C protein (a kind gift from Professor K. Alitalo). VEGF-C protein was 
then quantified and subjected to SDS PAGE, transfer to PVDF membrane and 
immunodetection. The membrane containing VEGF treated PCP protein was probed with 
0.6Ag/ml goat polyclonal IgGanti-Flt-I (C-17)-G (VEGF-Rl) (Santa Cruz Biotechnology, 
Heidleberg, Germany) and 0.03Ag/ml IIRP conjugated donkey polyclonal anti-goat IgG 
secondary antibody (Santa Cruz Biotechnology, Heidleberg, Germany) in 5% non-fat milk 
blocking solution. The membrane containing VEGF-C treated hCIP protein was probed with 
0.5Ag/ml rabbit polyclonal IgG anti-Flt-4 (C-20) (VEGF-R3) (Santa Cruz Biotechnology, 
Heidleberg, Germany) and 0.03Aglml IIRP conjugated goat polyclonal anti-rabbit IgG 
secondary antibody in 5% non-fat milk blocking solution. 
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3.3 Results 
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Figure 3.2. PCPs stain positively for WT-1. 
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A. Podocytes were incubated with an antibody specific to the podocyte marker, WT-I, showed brown 
nuclear and cytoplasmic staining (shown by arrows), confirming the expression of this molecule. Cells 
incubated with the normal isotype control (IgG) were counterstained with haematoxylin (inset top RH 
corner), which is the blue nuclear stain (shown by the arrowheads), and did not show any brown staining. 
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The anti-WT-1 antibody was optimised using rat glomeruli tissue sections. B. An example of brown 
nuclear staining (shown by arrow) of podocytes within the rat glomerulus, demonstrating specificity of the 
antibody. C. An example of rat glomeruli tissue sections incubated with the normal isotype control (IgG) 
and counterstained with haematoxylin (arrows), which did not show any brown staining (50prn scale bar). 
The use of PCPs is widespread but remains controversial. It was necessary to test that in my 
hands the cells isolated and grown under the conditions described (see methods) were 
characteristic of podocytes. Immunocytochernistry was used to show in situ protein 
expression of WT-1, a podocyte specific marker (figure 3.2 A), which is not limited to any 
stage of podocyte development (e. g. not a maturity marker). All cells showed nuclear and 
cytoplasmic positive staining for WT-1 and there was no non-specific staining in the isotype 
controls. Rat glomeruli tissue sections were also incubated with an anti-WT-1 antibody or 
normal mouse IgG (isotype control) at the same concentration as that of the PCPs (figure3.2 B 
and Q. This demonstrated the specificity of the antibody because WT-I staining was seen in 
cells that could only be described micro-anatomically as podocytes (figure 3.2 B), whereas 
there was no staining seen in the isotype control (figure 3.2Q. Immunohistochemistry was 
also used to demonstrate absence of PECAM-I protein in PCPs (figure 33A), a cell surface 
endothelial cell specific marker. No cells were seen to express PECAM-1. Rat glomeruli 
tissue sections were also incubated with an anti-PECAM-1 antibody or normal mouse IgG 
(isotype control) at the same concentration as that of the PCPs (figure3.3 B and Q. This 
demonstrated the specificity of the antibody because PECAM-1 staining was seen in 
endothelial cells throughout the glomerulus (figure 3.2 B), whereas there was no staining seen 
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Figure 3.3. PCPs are negative for PECAM-1 staining 
A. PCPs, incubated with an antibody to the endothelial specific marker, PECAM-1, did not show brown 
staining, indicating that this molecule was not expressed and that endothelial contamination of the cell 
culture was negligible. Cells were counterstained with haematoxylin, which is the blue nuclear stain shown 
by the arrowheads (scalebar = 100pm). The anti-PECAM-1 antibody was optimised using rat glomeruli 
tissue sections. B. An example of brown cytoplasmic and nuclear staining (shown by arrow) of enodthelial 
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cells A ithin the gl(omerulus, dem(onstrating spccificitý (of the antibody. C. An example (of rat gloomeruli 
tissue sections incubated with the normal isotype control (IgG) and counterstained with haematoxylin 
(arrows), which did not show any brown staining (50ýLm scale bar). 
The cells were also characterised using PCR, a more sensitive technique, to test it' the cell 
population was contaminated. Primers were chosen or designed to amplify cl)NA for von 
Willebrand Factor (vWF), a vascular endothelial cell marker and CD45, a cell surtace marker 
of leukocytes- HUVECs and human liver tissue cDNA were used to show that the reaction, 
using the CD45 and vWF primers, was able to result in a product of a length consistent with 
the sequence the primers were designed against. Dep. 1120 was used to show that the cDNA 
samples were not contaminated (Figure 3.4). Primers for GAPDII, a housekeeping gene, 
showed that all of the samples contained mRNA that had been successfully reverse transcribed 
to cDNA. There were no vWF or CD45 bands in the PCIII cDNA samples. Together these 
results support the view that contamination of' the isolated PCPs with endothelial cells or 
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Figure 3.4. PCPs are not contaminated by endothelial cells or leukocytes. 
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PCP, HUVEC and human liver tissue mRNA was probed with primers specifically, designed to amplifýj 
-. WF (2721)p) or CD45 (2331)p) mRNA. VWF and CD45 mRNA Acre amplified in IlUVEC and human 
liver tissue mRNA, but was absent from PCP mRNA. GAPDII (3851)p) was amplified in all mRNA 
samples, and there was no amplification (if either vWF or CD45 in samples "here mRNA was replaced 
with Dep. H20- 
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HUVECs Pcps Liver Dep H, O 
These results demonstrate that the PCP isolation system is suitable to investigate the effects of 
VEGF on podocyte biology. The first stage of this investigation was to test the means by 
which VEGF could have an effect on podocytes. The investigation was, therefore, directed 
towards examining the possible expression of VEGF specific receptors. 
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Figure 3.5. Distribution of VEGF expression by immuno-gold In a normal human glomerulus. 
A. Immuno-gold labelled VEGF distribution was quantified as the percentage of total Immuno-gold 
particles, the distribution was measured within the three components of the glomerular filtration barrier 
(Mean+SEM). The majority of immuno-gold labelled VEGF was found in the podocytes of the filtration 
barrier. EL Immuno-gold labelled VEGF distribution was quantified within podocyte foot processes, and 
distinguished as either membrane (>25nm) associated or intracelfular (<25nm) (mean+SEM). A greater 
proportion of immuno-gold labelled VEGF was podocyte membrane associated. C Immuno-gold labelled 
VEGF distribution was quantified as the percentage of total gold particles, measured at 25nm intervals 




Podocytes GBM Glomerular 
endothelial cells 
declined with distance from the podocyte plasma membrane. Results significantly different using ANOVA 
or impaired t-test *=p<0.05, n--1 1 
The distribution of glomerular VEGF was examined to provide clues as to the site(s) of VEGF 
binding activation. EM sections of human renal cortex tissue, which had been probed with 
immuno-gold labelled anti-VEGF were provided, courtesy of Rachel Hole. The distribution of 
gold particles was measured and categorised according to whether they were podocyte, 
endothelial cell or GBM bound. Podocyte bound gold particles were then identified as either 
membrane associated (within 25nm of the membrane) or intracellular. Podocyte bound gold 
particles were also categorised into distances from the membrane, in groups of 25nm from 0 to 
175nm+ from the plasma membrane. The distribution of immuo-gold labelled anti-VEGF 
particles were significantly higher in podocytes (77.9±1.81% of total gold particles) than in 
the GBM (I 1.9±1.2% of total gold particles) or the glomerular endothelial cells (10.2±1.6% of 
total gold particles, figure 3.5 A, p<0.05, ANOVA). This suggests that although VEGF was 
diffusing to the endothelial cells much of it was retained within the podocytes or at their 
surface. This may be because VEGF was expressed, but had not yet been excreted from the 
podocytes. The majority of immuno-gold labelled anti-VEGF particles, however, were 
membrane associated and of the podocyte foot process membrane bound immuno-gold 
labelled anti-VEGF, 63.15±3.29% of total gold particles were plasma membrane associated, 
whereas only 36.85±3.29% of total gold particles were intracellular (figure 3.5 B, p<0.05, 
unpaired t -test). Immuno-gold labelled VEGF membrane association may have been due to 
glycocalyx bound VEGF, therefore the distribution of VEGF labelled immuno-gold particles 
from the podocyte plasma membrane were examined. Figure 3.5 C shows that the majority of 
VEGF immuno-gold labelled particles were tightly membrane associated (<50nm from the 
membrane) (P<0.0001, ANOVA), and that there was progressively reduced immuno-gold 
labelled VEGF, progressively further from the podocyte plasma membrane. Together, these 
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results show that the majority of podocyte VEGF is tightly membrane bound, suggesting that 
VEGF binds to the podocyte plasma membrane. The next stage therefore was to Investigate it' 
podocytes express any VEGF receptors, other than N p- 1. 
mRNA was extracted from human kidney tissue and WIN and primers were used to amplify 
VEGF-Rl, VEGF-R2, VEGF-R3 and GAIIIDH mRNA expression. PCR products of the size 
predicted for VEGF-R 1, R3 and Np- I were seen after agarose gel clectrophoresis of the PCR 
reaction and ethidium bromide staining (figure 3.6). This technique was used with this 
particular cell line because of its sensitivity and there was no possibility of amplifying 
receptors from small contaminating cell populations because h('11's is a cell line developed 
from one clone. This experiment was performed once. 
hClPs 
A ""VEGFR1 VEGFR2 VEGFR3 NP-1 GAPDHý 
500bp 
300bp 
Kidney Dep H,, O 
B 
VEGFR2 GAPDHý VEGF-Rl VEGFýRý 
500bp 
300pb 
Figure3.6. mRNA expression (PIALGFreceptors in cultured potlov. itcs antl Imman lulnc. ý assuc 
A. PCR products of the predicted size were seen for VEGF-RI (3321)1)), VE(; F-R3 (3581)1)), and Np-I 
(5041)p) hCIP mRNA, whereas a PCR product (of the predicted size A as not seen for VEGF-R2 (332hp) in 
hClPs. A PCR product of the predicted size was seen for CAPD11 (3581)1)), demonstrating that the WIP 
mRNA had been succcssfullý reverse transcribed to cDNA. B. PCR products of the predicted size "ere 
seen for VEGF-R2 and GAPD11 in human kidney tissue, demonstraling, that the VEGF-R2 primers could 
detect VEGF-R2, and that the kidney tissue mRNA had been successfully reverse transcribed. There were 
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no PCR products of predicted size for VEGF-RI and VEGF-R3 in Del). 1120 samples, demonstrating that 
the PCR products, seen in A, were not due to contarnination, n=l. 
There were no PCR products of the predicted size for any of the primers when the mRNA was 
replaced with Dep. H20. This demonstrated that PCR products ot'predicted size were specific 
to the mRNA sample used. There was no PCR product of predicted size in WIP mRNA when 
probed with VEGF-R2 primers (figure 3.6), although there was in human kidney tissue mRNA 
samples when probed with VFGF-R2 primers. This suggests that although hCH's do not 
express VEGF-R2 mRNA, VEGF-R2 primers do amplify PCR products of the predicted 
length in mRNA samples known to express VEGF-R2 mRNA. 
VEGF-Rl protein expression was also examined in P('Ps using Western blotting. This 
technique was used for these cells because it is not as sensitive as PCR, therefore ifthere were 
small populations of contaminating cells the liklihood is that their receptors would not be 
detected because expression levels would be so low. PCPs were serum starved and treated 
with Ink! VEGF or left untreated for 24hrs. Protein was extracted, subjected to SDS PAGE 
and transferred to a PVDF membrane. 'rhe membrane was probed with an anti-VFGFR-1 
antibody 
Serum starved 1 nM VEGF 
199 kDa - VEGF-Rl 
Figure 3.7. Protein expression ol'VEGF-RI in PCPs 
Serum starved PCPs were treated with InM VEGF or left untreated for 24hrs. A PVDF membrane 
containing the protein from these cells was probed with an anti-VEGF-RI antibody. A hand at the 
predicted molecular weight of 200kDa was seen, although it appeared less intense in the VEGF treated 
PCPs that the serum starved PCPs. 
Figure 3.7 clearly demonstrates a band corresponding to the predicted size of VEGF-RI 
protein (200kDa). These results suggest that VEGF-RI protein is expressed by PcPs and it 
appears that treatment with VEGF actually lowered its expression (figure 3.7). These results 
demonstrate that VEGF-R I was transcribed Crom the niRNA in 11CPs. To determine whether 
VEGF-R3 was also transcribed from mRNA in cultured podocytes, a PVDF membrane 
containing protein, this time from hClPs treated with I nM VEGF-C (the figand tor VF GF-R3) 
and probed with anti-VEGFR-3, showed clear expression of VEGF-R3 protein (figure 3.8). 
As observed previously, treatment appeared to lower VEGF-R3 expression. 
D Serum starved lnM VEGFC 
150 kDa -4 VEGF-R3 
Figure 3.8. Protein expression of VEGF-R3 in WIN 
A band at the predicted molecular weight of 150 kDa was seen in protein samples extracted from WIN, 
either serum starved or treated with In M VEGF-C, when probed with anti-VEGF-R3 antibodý. 
These results demonstrate for the first time that cultured podocytes express VEGF-R I and 
VEGF-R3 mRNA and protein as well as Np-1, which has already been demonstrated. 
Surprisingly VEGF-R2 mRNA was not expressed. 
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3.4 Discussion 
PCPs were successfully characterised; glomerular endothelial cell and leukocyte 
contamination was excluded. The cells stained positively for WT-1 mRNA and protein (a 
marker for podocytes), negative for vWF (a vascular endothelial marker), and CD45 (an 
adhesive molecule found on leukocytes). The entire immunocytochernical cell population 
viewed showed positive WT-I staining and this in itself suggests that there was no significant 
contamination of either endothelial cells or mesangial cells. In addition, podocytes have a 
morphology distinct from mesangial cells, which have a rod like or stellate morphology (as 
discussed in (Buniatian et al., 1999)). The cell population, however, was not checked for 
parietal epithelial cell (PEC) contamination from Bowmans' capsule. There is some confusion 
in the literature over PEC specific markers to differentiate PECs from podocytes. Yaoita et al 
used pan cadherin as a specific marker for PECs (Yaoita et al., 2001). P-cadherin, however, is 
found in association with the slit diaphragm in differentiated podocytes and is also expressed 
by de-differentiated podocytes (Reiser et al., 2000a). Pan cadherin, therefore, is not a specific 
marker for parietal cells. PECs also express WT-1 in the mature kidney (<30% expression of 
PECs), a marker that was thought to be specific to podocytes (Kanemoto et al., 2003). The 
immunocytochemistry results in figure 3.2, however, demonstrated a uniform population of 
WT-1 expressing cells. WT-I was chosen as a podocyte specific marker in this investigation, 
instead of a podocyte maturity marker, such as nephrin, which is not expressed by PECs, 
because the PCPs have a mixed population of differentiation. I cannot exclude some minor 
PEC contamination but have done my utmost to minimise this. It is worth noting, however, 
that the PCPs were isolated using the same protocol that was used to isolate and subclone the 
human conditionally immortalised podocytes, which have been fully characterised. PCPs also 
resp9nded in the same way as hCIPs in later functional experiments, which suggests they are 
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of the same origin. Although the PCP isolation technique used in this chapter appears to be 
successful the cells had to be characterised after each isolation, yet the cells only last a few 
passages before they become senescent. These cells were used at the beginning of this 
investigation, mainly because the conditionally immortalised cell line, described in the 
methods, were not yet fully characterised. PCPs and hCIPs were, therefore, used as 
appropriate, and when available. 
I have shown that cultured podocytes express mRNA for VEGF-R1 in hCEPs and protein for 
VEGF-R1 in PCPs and that hCIPs express both mRNA and protein for VEGF-R3, but VEGF- 
R2 was not shown to be expressed in either cell line. In support of VEGF-RI expression Dr S. 
Chen (Renal-Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia) 
demonstrated VEGF-RI mRNA expression in mouse CIPs (Mundelocytes) and had it 
successfully sequenced (unpublished abstract at the 5h International Symposium on Podocyte 
Biology in Seattle). Further on in the thesis evidence on functional effects of VEGF 
(especially those blocked with a class III tyrosine kinase inhibitor) support the evidence for 
VEGF-R1 expression because VEGF has not been shown to be a ligand for VEGF-R3 and it is 
controversial whether Np-1 can signal independently. In support of VEGF-R3 expression in 
cultured podocytes Dr S. Satchell (Academic Renal Unit, Southmead Hospital, Bristol) has 
demonstrated protein expression in hClPs (a different clone to those used in this thesis) at both 
de-differentiation and differentiation (unpublished). This evidence for podocyte VEGF 
receptor expression, other than Np-I opens up a new area of research. It is surprising that 
VEGF-R2 was not expressed, as this is the receptor that is involved in most biological 
functions of VEGF (Zachary and Gliki, 2001). 
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VEGF-RI binds VEGF with a greater affinity then VEGF-R2 (Neufeld et al., 1999), but its 
signalling potential is limited because the tyrosine kinase activity of VEGF-R1 is one order of 
magnitude lower than that of VEGF-R2 (as reviewed in (Shibuya, 2001)). It has been shown 
that VEGF can stimulate the induction of hepatocyte growth factor (HGF) through VEGF-Rl 
activation in sinusoidal endothelial cells (LeCouter et al., 2003). In this manner VEGF-R1 has 
an indirect survival effect due to the nature of HGF. Interestingly, HGF can protect podocytes 
from Cyclosporin A induced apoptosis via regulation of Bcl-2. by the P13-kinase/AKT 
pathway (Fornoni et al., 2001) and it is possible that VEGF-RI can activate a similar pathway 
in podocytes. Monocytes also express VEGF-Rl, but not VEGF-R2 and in these cells VEGF- 
RI is capable of mediating a chemotactic response to VEGF (Barleon et al., 1996). This raises 
possibilities that VEGF-Rl, in response to VEGF, may be involved in development or 
differentiation of podocytes. An important consideration to make is that VEGF-RI is capable 
of binding to, and forming complexes with Np-I (as reviewed in (Neufeld et al., 2002)) and 
Np-2 (Gluzman-Poltorak et al., 2001), which are also expressed on podocytes at least at the 
mRNA level (Harper et al., 2001). VEGF-R3 and its ligand VEGF-C are mainly found in the 
lymphatic system. There is no evidence in the literature to show a direct interaction of VEGF 
with VEGF-R3. Therefore VEGF-C was used as a ligand for VEGF-R3 in the Western blot 
shown in figure 3.7. VEGF-C and VEGF-R3 will be discussed in detail later in the thesis. 
The protein expression of both VEGF-R2 and VEGF-R3 upon activation with their ligands, 
compared to serum starvation (figures 3.6 and 3.7), was reduced. This was not significant 
because there were no replicates, however it was clearly seen in both blots. This may be 
explained by VEGF/VEGF-R2 complex internalisation by endocytosis in bovine adrenal 
cortex endothelial cells (Li and Keller, 2000): VEGF labelled with a fluorescent probe was 
detected in vesicular organelles within three minutes of VEGF treatment lasting for hours. if 
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VEGF/VEGF-RI and VEGF-C/VEGF-R3 complexes were also internalised then this may 
explain the reduction in protein expression seen: vesicular VEGF would be harder to lyse 
during protein extraction, if it had not already been taken into the endosome and lYsed. 
These results suggest that cultured podocytes express VEGF-RI and VEGF-R3 along with 
Np-1, and that VEGF protein is frequently tightly associated with the podocyte plasma 
membrane. VEGF may therefore be capable of acting on podocytes in an autocrine manner. 
Some of the work from this chapter was published in paper I of the list of publications arising 
from this work. 
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Chapter 4 
VEGF can exert a signalling response in cultured podocytes 
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4.1 Introduction 
In the previous chapter I showed that podocytes express VEGF receptors. VEGF has been 
shown to exert its effects through many signalling pathways in endothelial cells. The first 
pathway identified stimulated an increase in [Ca2+]i(Criscuolo et al. ' 1989). In endothelial 
cells, VEGF induces a rapid transient increase in [C2+]i, via a phospholipase Cy (PLC) 
(Brock et al., 1991)-diacylglycerol (DAG) dependent, calcium store-independent transient 
receptor potential (TRP) channel pathway. This allows influx of extracellular calcium 
(Pocock et al., 2004). The increase in [C21i can result in a number of biological actions in 
endothelial cells, such as nitric oxide dependent increased vessel dilatation (Ku et al., 1993), 
vessel permeability (Pocock et al., 2000) and alterations in the actin cytoskeleton (Criscuolo 
and Balledux, 1996). To investigate, therefore, if VEGF can exert an autocrine effect on 
podocytes [Ca2+]i was measured to signify a cellular response to VEGF. 
4.2 Methods 
ICa2+1, nwasurements- VEGF signalling in podocytes 
PCPs and hCfPs were incubated in Hanks' Balanced Salt Solution (HBSS) containing either 
minimal calcium (-200gM) or physiological levels of calcium (1.3mM) (for composition of 
HBSS see p. 75 and p. 76 of methods). Cells were loaded with Fura 2-AM for a minimum of 
I hr and a maximum of 2hrs. They were treated with I nM VEGF (0.4gl of I OOng/gI stock) or 
0.4ptl HBSS containing appropriate levels of calcium. Changes in Fura-2 fluorescence 




4.3.1 The effects of VEGF on [Ca2+Jj in culturedpodocytes 
When PCPs, which had been loaded with Fura-2, were incubated in HBSS containing 
physiological levels of calcium (1.3mM), treatment with VEGF did not cause a change in 
[C21i (Figure 4.1 A). The ratio (R) (treatment [Ca2']i/baseline [C21i) did not significantly 
change (0.98±0.065) (Figure 4.1 E). When incubated in HBSS containing minimal calcium 
([Ca2+],, ), however, there was a reduction in [C2+]i in VEGF treated cells, which was 
significant (0.69±0.07, p<0.05) (figure 4.1 E). The 2 fold reduction in [Ca 2+ 1 was rapid, 
occurring within the first four minutes, then reaching a plateau (figure 4.1 B). VEGF was then 
I 
washed away using BBSS and left for 20 minutes, but it was observed that [Ca2jj levels did 
not return to original baseline levels. This was mirrored in differentiated hClPs: there was no 
21,2 f change in [Ca in hCIPs, treated with VEGF, in the presence of 1.3mM [Ca J,, ( igure 4.1 
Q. There was, however, a reduction in [Ca2']i in minimal [C2']. (figure 4.1 D), which was 
significant (minimal [Ca2+](,: RO. 71±0.03 compared to 1.3mM [Ca 2 1. RI. 03±0.2, p<0.05, 
figure 4.1 F). The 2 fold reduction in [Ca 21, in hCIPs, treated with VEGF and incubated in 
minimal [Ca2+],, was again rapid and reached a plateau within the first five minutes (figure 4.1 
D). Observations revealed that [C21i levels did not return to original baseline levels after 
VEGF had been washed out of these cells either. These results demonstrate that not only did 
VEGF induce a reduction in [C21i in cultured podocytes incubated in minimal [C21., but 
that there was no difference in response to VEGF between the two types of cultured 
podocytes. This reduction in [Ca 2j, ' 
in response to VEGF was the opposite to that seen in 
endothelial cells, and a reduction in [Ca 21, in response to VEGF has not actually been 
documented before in any cell type. 
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Figure 4.1. Effect of VEGF on [Ca2+]i on cultured podocyte. 4. 
PCPs and hCIPs were incubated in HBSS containing either minimal jCa2+jo or 1.3mM ICa2+lo , and 
were either treated with InM VEGF or left untreated. When cells were treated with InM VEGF in the 
presence of 1.3mM [Ca 2+1. , no change was seen for either 
PCPs or hCIPs (A and C). When cells were 
jCa2+l. ' 
2+1i Wa. treated with InM VEGF in minimal however, a significant reduction in [Ca s seen for both 
PCPs and hCIPs (B and D) A. An example of no change in ICa2+li(, f pCpS in response to InM VEGF in 
the presence of 1.3mM [Ca2+1.. B. An example of a reduction in jCa2+Ii of pCpS in response to InM VEGF 
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in minimal [Ca2l, C. An example of no change in [C&211 of WIN in response to lnM VEGF in the 
presence of 1.3mM JCWJ, D. An example of a reduction in [Ca2li of hCfPs in response to InM VEGF in 
the presence of minimal [CWj, The effects of VEGF, in the absence or presence of extracellular calcium 
are summarised and compared in E (PCPs) and F (hCI]Ps). Data were expressed as ratio of VEGF 
treatmentfbaseline [Ca2li. E. VEGF significantly reduced [Ca2l, levels in PCPs that were incubated in 
HBSS containing minimal [CWj, F. VEGF significantly reduced [CWjj levels in hCIPs that were 
incubated In HBSS containing minimal [Ca2j, *=p<0.05 n >7 in each group. 
In each of the experiments lOgM ionomycin was used to induce an influx of calcium from 
intracellular stores and where applicable an extracellular influx of calcium, to demonstrate that 
the system was still responsive to changes in [Ca2']i. This showed for example that the Fura-2 
loaded cells had not quenched during the course of the experiment and that the cells were still 
alive. This was of particular use with cells that did not show a [C2']i response to treatment. 
An example of the magnitude of the response seen to ionomycin is shown in figure 4.2 B and 
summarised in C. There was a 20 fold increase in [Ca2li, which occurred within the first 30 
seconds of exposure to ionomycin (R17.42±1.64, p<0.0001, figure 4.2). After approximately 
I minute the ionomycin began to quench the Fura-2 signal, hence the [C21i signal was 
reduced (not shown). Recordings of changes in [C21i, in response to lonomycin were, 
therefore, restricted to a minute or less. There was the possibility that the act of adding a OAAI 
volume of solution to the cells would introduce an extraneous effect on [C2+]i, for example 
from shear stress. The pressure of ejection of the solution from the pipette onto the cells, and 
the disturbance of the cell surface of the media in which the cells were incubated, by the 
pipette tip could contribute to a change in [Ca2+]i. To test these variables OAAI of HBSS was 
added to the cells incubated in HBSS in the same manner as VEGF. The calcium 
concentration of HBSS used was appropriate to the calcium concentration used in that 
particular experiment. Addition of OAAI HBSS did not stimulate a change in [Ca2li in hCIPs, 
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Figure 4.2. [Ca 2+] i responses to 0.40 HBSS and to 10ýAM ionomycin in PCPs and hClPs. 
hCIPs and PCPs were loaded with Fura-2. The jCa"jj response was measured when 0.4gl HBSS was 
added to hClPs, showing no significant [Ca 2+1 i response (A), and when lOgM ionomycin (10) was added to 
PCPs, showing a massive increase in [Ca 2+]! (B). A: An example of no significant change in [Ca 2+]i in 
response to 0.4ýd HBSS in the presence of 1.3mM [Ca 2+1. in hCIPs. B. An example of a transient increase 
in [Ca 2+1i in PCPs in response to fOgM ionomycin. C. Data were expressed as mean+SEM of the changes 
in ratio of [Ca 2+1i (treatment/baseline). There was no change in [Ca 2+1 iresponse to OAýJ HBSS but there 
was a large increase in jCa2jj in response to 10mM ionomycin in hClPs. (n=6, ***=p<O. OMl, paired t-test). 
These results show that exogenous VEGF can act elicit a reduction in podocytes [Ca 2 j, but 
the actual role of VEGF in podocyte signalling or function has yet to be elucidated. 
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4.4 Discussion 
VEGF induced a reduction in [Caý+]j in PCPs and hCIPs, but only in the presence of minimal 
[Ca 210. If the process by which VEGF induces an increase in [Ca2jj are understood, then it 
may help to explain the reduction in [C21i induced by VEGF in cultured podocytes incubated 
in minimal [Ca2j, Increases in [C21i normally occur when there is either an extracellular 
influx of calcium or a release of calcium from internal stores such as the endoplasmic 
reticulum. (ER) into the cytoplasm. VEGF stimulates a rapid and transient increase in [Ca2']i 
in endothelial cells due to an influx of calcium across the plasma membrane through non- 
specific cation channels, and independently of voltage gated calcium channels (Criscuolo et 
al., 1989). Activation of PLC by VEGF induces the production and release of 1,4,5- 
trisphosphate (IP3) and DAG into the cytoplasm (Brock et al., 1991). The VEGF induced Ca2' 
influx is DAG dependent and independent of capacitative calcium entry, which is the term 
given to the influx of extracellular calcium due to IP3 activated depleted calcium stores 
(Putney and McKay, 1999). The [Ca2jj response of podocytes to VEGF was the opposite of 
that seen in endothelial cells. This may be because VEGF induced [Ca2jj signalling in 
endothelial cells is thought to be VEGF-R2 activation dependent (Brock et al., 1991), and the 
VEGF induced [C2+]i signalling in podocytes would have to be via a different VEGF 
receptor. The VEGF induced reduction in [Ca2+]i in cultured podocytes indicates that calcium 
is either being pumped from the cytosol into intracellular stores by the sarco-endoplasmic 
reticulum calcium ATPase pump (SERCA), that ensures the re-uptake of calcium into the 
sarcoplasm (Lytton et al., 1991), or being pumped from the cytosol out of the cell by plasma 
membrane calcium ATPases (PMCA). It seems unlikely that the Na/Ca 2+ exchange would be 
involved in this process as there is no evidence in the literature to suggest that it is expressed 
pn podocytes and it tends to contribute more to Ca 2+ transport in excitable cells (Sedova and 
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Blatter, 1999). The effects of VEGF on [Ca2+]i in podocytes was masked, when incubated in 
HBSS containing a physiological [C2+]ý,. This may mean that there is normally a small leak 
into the cell down the calcium concentration gradient, or that the cell equilibrates itself if 
[C21i is reduced. It is not understood how VEGF can induce the activation of these pumps 
or what function it has. A series of experiments would be needed in order to elucidate the 
mechanisms behind the [Ca2+]i decline, which could be done in the future, but for the purpose 
of this investigation it has been accepted simply that VEGF can induce a change in [Ca 21i. 
An increase in [C21jis often associated with detrimental effects in cells, such as increased 
necrosis (due to a very high increase in [Ca2']i levels) and apoptosis (due to lower increases in 
[C21j) (as reviewed in (Rizzuto et al., 2003)). An increase in [Ca 2']i has been linked to 
many aspects of apoptosis, such as via release of cytochrome c from the mitochondrial 
membrane: Movement of C2from the EF, and subsequent uptake by the mitochondria (via 
the cytoplasm) can cause mitochondrial C2+ overloading. This induces the opening of the 
permeability transition pore in the mitochondrial membrane, leading to swelling of the 
mitochondria and the release of cytochrome c (as reviewed in (Rizzuto et al., 2003) (Gogvadze 
et al., 2001)). An increase in [Ca 21, can instigate cytotoxicity in many ways in many cell 
types, but increased [Ca 2+], can also induce podocyte specific effects. For example 
Angiotensin-11 stimulates a rapid, transient increase in [Ca 2+]j. in podocytes, which is 
dependent on release from calcium stores and influx of extracellular calcium (Nitschke et al., 
2000), probably via capacitative calcium store release (Putney and McKay, 1999). This 
demonstrates that the effects of angiotensin-II are dependent on an increase in [Ca2li. In 
addition Benigni et al show that the reduction in nephrin expression, seen in rats with severe 
nephrosis, could be fully inhibited by blocking the effects of angiotensin-Il (Benigni et al., 
2001). Nephrin is intricately linked to the actin cytoskeleton, as discussed in the introduction, 
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and any changes in nephrin expression are likely to have a knock-on effect on the actin 
cytoskeleton. The possible effects of the VEGF induced reduction in [Ca2jj therefore may be 
to regulate [C21i homeostasis within the podocyte. This would only regulate changes in 
[Ca2li levels within the same range as VEGF induced [Ca 2+], changes, but may regulate 
podocyte cytoskeletal retraction via nephrin redistribution, or may regulate the other 
consequences of raised [Ca 21, levels, such as apoptosis. 
In summary, these results show that VEGF can induce signalling in podocytes. I have 
therefore attempted to determine the effects of VEGF signalling on podocyte cell function. 
This work was published in paper I of the list of publications arising from this work. 
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Chapter 5 
The effects of VEGF on proliferation and cytotoxicity in cultured podocytes 
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5.1 Introduction 
The results from the previous chapter show that VEGF can induce a reduction in cytosolic 
calcium in podocytes. VEGF is a pluripotent growth factor and many of its functions relate to 
proliferation and survival. The next aim therefore was to decipher the role of VEGF in these 
signalling pathways in podocytes. To understand potential proliferation and survival 
signalling pathways in podocytes these pathways can be examined in endothelial cells in 
which VEGF promotes both proliferation and survival (as reviewed in (Ruhrberg, 2003)). In 
endothelial cells proliferation is regulated by the activation of VEGF-R2 by VEGF, which 
induces the activation of MAPK in a protein kinase C (PKC) dependent manner (Rousseau et 
al., 2000) (Wu et al., 2000). The activation of VEGF-R2 by VEGF in cndothelial cells also 
induces the activation of P13-kinase, which induces the phosphorylation of AKT (Gerber et al., 
1998b). Subsequently, pro-apoptotic Bc1-2 family members are phosphorylated and de- 
activated by phosphorylated AKT (Gerber et al., 1998a). The activation of MAPK p38 by 
auto-phosphorylation of VEGF-R2 regulates migration via actin based motility in endothelial 
cells (Rousseau et al., 2000). Interestingly, the MAPK p38 migration pathway seems to 
negatively regulate the P13-kinase/AKT survival pathway and vice versa in endothelial cells 
(Gratton et al., 200 1) (figure 1.5, chapter 1) suggesting that survival signalling is greater when 
cells are not migrating. When podocytes are mature and terminally differentiated they have 
very limited proliferation, a very low turnover of cells and presumably relatively low 
migration compared to developing podocytes, which are proliferative. VEGF may therefore 
be exerting a proliferative and possibly migratory effect on podocytes during 
glomerulogenesis and may promote survival in podocytes in mature glomeruli. The effect of 
VEGF on PCP proliferation and on hCIP survival was therefore investigated using a3 H- 
thymidine incorporation assay and a lactate dehydrogenase (LDH) assay respectively. The 
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effect of endogenous VEGF was also examined with the use of a neutralising monoclonal 
antibody to VEGF. 
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5.2 Methods 
S. 2.1 3H-thymidine assay-the effects of VEGF on podocyte proliferation 
Serum starved PCPs were treated with InM VEGF (12 wells) in fresh serum free RPMI media 
or in fresh serum free RPMI media alone for 24hrs .3 H-thymidine was added to all of the 
wells for just 4hrs and the cells were then counted, using a Students' haemocytometer and 
assayed for 3 H-thymidine incorporation using a scintillation counter. 
5.22 LDH assay-the effects of VEGF on podocyte cytotaxicity 
Serum starved PCPs and hCIPs were treated with InM VEGF (48 wells) in fresh serum free 
RPMI media or in fresh serum free RPMI media alone for 48 or 24hrs. In order to assess the 
role of endogenous VEGF PCPs were also treated with 0.32ptg/ml mouse monoclonal IgG2A 
neutralising anti-VEGF antibody (VEGF-Mab) in fresh serum free RPMI media by itself or 
with InM VEGF for 24hrs. Serum starved human embryonic kidney (HEK) 293 cells were 
also treated with VEGF and a neutralising monoclonal antibody to VEGF in serum free fresh 
Dulbeccos' Modified Eagles Media (DMEM, containing inorganic salts; 0.265gAL 
CaCL2-2H20,0.0001g/L Fe(N03)3*91-120,0.098g[L MgS04,0.4g/L KCL, 3.7g/L NaHC03, 
6.4g/L NaC1 and 0.109g/L NaH2P04) to demonstrate the effects were podocyte specific. The 
amount of LDH release into the media was quantified using a colourimetric assay for the low, 
experimental and high controls, as described in the methods. The percent of cytotoxicity was 
then calculated from this. 
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5.3 Results 
5.3.1 The effects of VECYF on PCPproliferation 
VEGF plays a role in endothelial organisation in glomerulogenesis, yet the role of VEGF on 
podocytes during glomerulogenes's had never been documented. The reason for this is mal nly 
that VEGF receptor expression on podocytes has not been published. A prime role of VEGF 
during development is mitogenesis, therefore the effects of VEGF on cultured podocyte 
proliferation was examined first. PCPs are proliferative, whereas differentiated hClPs are not, 



















Figure 5.1. The effects of VEGF on PCP proliferation. 
VEGF 
* 
Serum starved PCPs were incubated in 1nM VEGF or left untreated. -, H-thymidine was added and the 
cells were counted, then assayed for 3 H-thymidinc incorporation. A. Data were expressed as mean+SEM 
CPM/3 H-thymidine of serum starved PCPs without (blue) and with (green) InM VEGF .3 H-thymidine 
incorporation was significantly greater in PCPs incubated with VEGF then that (of PCPs. B. Data were 
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Control VEGF Control VEGF 
expressed as mean+SEM cell count (cells/mIXIO without (blue) and with (green) lnM VEGF. PCPS 
incubated with VEGF had a significantly higher cell count than untreated PCPs. C. Data were expressed 
as mean+SEM proliferation rate e1l4hymidine/epin. ceiri) without (blue) and with (green) InM VEGF, 
*=p<0.05 compared to control, unpaired Mest, n= 12. There was no significant difference, however, in 
proliferation rate between PCPs incubated with VEGF or left untreated. 
PCPs were serum starved in a 24 well plate for 16hrs, then were treated with I nM VEGF or 
left untreated for 24 hrs. IýXi 'H-thymidine was added to each of the wells for 4hrs and then 
the cells were trypsinised, counted using a haemocytometer and then the samples were assayed 
for 3 H-thymidine incorporation using a scintillation counter. PCPs incubated with VEGF had 
a significantly greater amount Of3 H-thymidine incorporation compared to serum starved PCPs 
(treated; 3,349±283cpm compared to untreated; 2,364±301cpm, p<0.05, figure 5.1). There 
was also, however, a significant increase in cell count compared to serum starved PCPs 
(treated cells; 4.5±0.7xlO 4 /ml compared to untreated cells; 2.6±0.5xlO4/ml, p<0.05, figure 5.1 
A and B) .3 H-thymidine incorporation gives the number of cells undergoing cell 
division in a 
given time, assuming equal incorporation per cell. Since cell proliferation is a function of cell 
number, the growth rate (the rate at which a population increases) can be calculated from the 
3 H-thymidine incorporation per cell. Figure 5.1 C shows that there was no significant 
difference in the amount of 3 H-thymidine incorporation per cell between groups (VEGF 
treated; 0.125±0.029cpm. cell. " compared to untreated; 0.1±0.015cpm. cell. "). This suggests 
that VEGF did not induce an increase in the rate of proliferation. The increase in 3 H- 
thymidine incorporation in the VEGF treated group was more likely to be due to an overall 
larger population of cells, which may be explained by a reduction in cell loss compared to the 
serum starved control, i. e. a reduction in cell death. 
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5.3.2 The effects of VEGF on cytotoxicity in podocytes 
As there appeared to be an increase in cell survival stimulated by VEGF, the effect of VEGF 
on cytotoxicity of cultured podocytes was primarily tested on PCPs. PCPs were serum starved 
for 16 hrs then treated with I nM VEGF or left untreated for either 24hrs or 48hrs. LDH 
release from the cells was quantified using a colourimetric assay and the percent of 
cytotoxicity was calculated from this. The experiments were carried out at two time points to 
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Figure 5.2. The effects of VEGF on cytotoxicity in PCPs treated for 48 and 24hrs. 
PCPs were serum starved for 24hrs then treated with VEGF or left untreated, under serum free 
conditions, for a further 48hrs (A) or 24hrs (B), before cytotoxicitv was atssaved. A. Data were expressed 
as mean+SEM percent of cytotoxicity after 48hrs without (blue) and with (green) InM VEGF. Incubation 
of cells in VEGF for 48hrs had no significant effect on cytotoxicity compared to serum starved cells. B. 
Data were expressed as mean+SEM percent of cytotoxicity after 24hrs without (blue) and with (green) 
lnM VEGF. Incubation of cells in VEGF for 24hrs induced a reduction in the percentage of cytotoxicity 
compared to that of serum starvation. *=p<0.05 compared to control, unpaired Mest, n= 48. 
There was no significant difference in the percent of cytotoxicity between podocytes treated 
with VEGF for 48hrs and those serum starved for 48hrs (VEGF treated, 47.02±12.7% 
cytotoxicity compared to untreated; 50.55+3.58% cytotoxicity, figure 5.2 A). The percent of 
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cytotoxicity was very high in both cell populations (note the Y axis scale in A compared to B). 
It is possible that the absence of serum over a total of 64hrs induced too much cytotoxicity. 
This would mean that either VEGF could not exert an effect of a significant magnitude, or that 
VEGF did exert an effect at some time point during the course of the experiment but it was 
not sustained over that time period. The serum starved cells were, therefore, incubated with 
VEGF for just 24hrs to examine whether VEGF could induce a significant change in 
cytotoxicity during a shorter time course of serum starvation. The percentage cytotoxicity, 
induced by 24hrs of serum starvation in cells was much lower using this time course (serum 
starvation for a total of 48hrs 12.5±3%, compared to serum starvation for a total of 72hrs 
50.55: 0.58%, figure 5.2 A and B). Using this shorter serum starvation time course VEGF did 
induce a significant reduction in the percent cytotoxicity compared to serum starved cells 
(VEGF treated; 5.9±0.67% cytotoxicity, compared to 12.5±3% cytotoxicity, p<0.05, paired t- 
test figure 5.2 B). This reduction in cytotoxicity induced by VEGF was not limited to PCPs. 
Serum starvation of hCIPs incubated with InM VEGF for 24hrs and assayed for cytotoxicity 
also showed a significant reduction in cytotoxicity compared to serum starvation alone (VEGF 
treated; 10.3±0.96% cytotoxicity compared to untreated: 19.8±1.3% cytotoxicity, p<0.05, 
figure 5.3 A). This provides further support for similarities between PCPs and hCIPs. The 
cytotoxicity induced by a total of 48hrs serum starvation (24hrs VEGF treatment) in KIP 
cytotoxicity experiments was approximately 7% higher than in the PCP cytotoxicity 
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Figure 5.3. Effects of exogenous VEGF on hCIPs and endogenous VEGF on PCPs. 
hCIPs, PCPs and HEK 293 cells were serum starved for 24hrs then treated with either VEGF, a 
neutralising monoclonal antibody to VEGF (VEGF-Mab) or a combination of VEGF with VEGF-Mab, 
then assayed for cytotoxicity. A. Mean+SEM % cytotoxicity after 24hrs without (blue) and with (green) 
InM VEGF in hCIPs. hClPs incubated in VEGF had a significantly reduced percentage of cytotoxicity 
than serum starved cells. B. Mean+SEM % change in cytotoxicity (treatment/control) comparing VEGF 
treated cells with VEGF-Mab, and VEGF combined with VEGF-Mab. PCPS incubated in VEGF-Mab had 
a significantly increased %cytotoxicity compared to both VEGF treated cells, and serum starved cells, as 
did PCPs treated with a combination of VEGF with VEGF-Mab. C. Mean+SEM % change in cytotoxicity 
(treatment/control) after 24hrs with VEGF and VEGF-Mab compared to control in HEK 293 cells. 
Neither VEGF treatment nor VEGF-Mab treatment in HEK 293 cells induced a significant change in the 
percentage of cytotoxicity compared to serum starved cells. *=p<0.05 p< 0.01 compared to control or 
as indicated, n= 48 
Serum starvation of PCPs incubated with a neutralising monoclonal antibody specific to 
VEGF (VEGF-Mab) for 24hrs and assayed for cytotoxicity demonstrated an increase in 
cytotoxicity compared to that of serum starvation (VEGF treatment: 11 7.27±5.46 % change in 
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serum free lnM VEGF 
cytotoxicity, compared to a 100±4.56 % change in cytotoxicity in untreated cells). This 
suggests that endogenous VEGF was required to sustain survival in PCPs. Incubation of PCPs 
with the neutralising monoclonal antibody to VEGF, plus VEGF for 24hrs blocked the 
reduction in cytotoxicity induced by VEGF (109.4±4.7 % change in cytotoxicity in VEGF 
treated cells, compared to 100±4.56 % change in cytotoxicity in untreated cells), which shows 
the effect of was VEGF specific. BEK 293 cells, which do not express VEGF receptors, were 
incubated with VEGF and the neutralising monoclonal antibody to VEGF separately in the 
same manner as the PCPs. These treatments caused no significant changes in cytotoxicity 
(VEGF; 101.1±0.4% change in cytotoxicity and VEGF-Mab; 98.27±1.5 % change in 
cytotoxicity, compared to serum starvation alone; 100±0.46 % change in cytotoxicity). The 
effects of the neutralising monoclonal antibody to VEGF and VEGF were probably, therefore, 
mediated through the receptors expressed on the podocytes. These results support the 3 H- 




VEGF did not stimulate proliferation in PCPs (figure 5.1 Q. This may be because 
proliferation in endothelial cells is mainly mediated through VEGF-R2 whereas VEGF-RI 
signalling in endothelial cells contributes about one tenth of the total tyrosine kinase signal (as 
reviewed in (Shibuya, 2001)). 
VEGF treatment induced a reduction in cytotoxicity in both PCPs and hClPs. There was a 
slight increase in cytotoxicity induced by serum starvation in hCIPs relative to that of PCPs. 
This may be due to variations in seeding densities, which are harder to control for in 
differentiated hCIPs because they go through significant cell death during the process of 
differentiation. A lower confluency of cells would be more exposed. When the effects of 
endogenous VEGF were blocked by a neutralising monoclonal antibody to VEGF, levels of 
cytotoxicity induced by serum starvation were significantly increased (figures 5.1 and 5.3) 
suggesting that endogenous as well as exogenous VEGF promotes survival in cultured 
podocytes. A similar effect was also seen when the effects of endogenous VEGF in 
astrocytes, upregulated in the central nervous system (CNS) after various types of injury, were 
blocked with the use of a neutralising monoclonal antibody to VEGF (Krum and Khaibullina, 
2003). This resulted in astroglial degeneration, due to increased apoptosis as well as a 
reduction in mitogenicity. The authors have pointed out that blocking the effects of 
endogenous VEGF may increase the effects or expression of basic fibroblast growth factor 
because the two have a synergistic relationship in this system (Krum and Khaibullina, 2003). 
This suggests that blocking the effects of endogenous VEGF in podocytes may imbalance the 
system and affect the expression or signalling of other synergistic molecules (discussed later 
in the thesis). Interestingly, astrocytes express VEGF-RI but not VEGF-R2, which indicates 
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that endogenous VEGF induced its effects via VEGF-RI signalling (Krum and Khaibullina, 
2003). 1 made the assumption that the reduction in cytotoxicity induced by VEGF in 
podocytes was mediated through VEGF-RI for reasons mentioned for the proliferation assay. 
VEGF-R2 has again been shown to be the receptor implicated in VEGF mediated survival in 
endothelial cells. VEGF induced AKT signalling in microglial cells, which express VEGF-R1 
but not VEGF-R2, was very limited and if anything, AKT phosphorylation induced by VEGF 
was reduced compared to that of serum starvation (Forstreuter et al., 2002). These results are 
interesting because VEGF is known to signal in these cells (Forstreuter et al., 2002), but 
suggests that survival signalling through VEGF-RI may be limited, or at least survival 
pathways mediated by AKT phosphorylation. It has, however, been shown that VEGF can 
induce the activation of P13-Kinase and AKT phosphorylation via VEGF-R1 signalling in rat 
hepatic stellate cells, which do not express VEGF-R2 (Takahashi et al., 2003). Surprisingly, 
this P13-Kinase/AKT signalling was dependent on MAPK phosphorylation. Together this 
suggests that cell differences determine the signalling effects of VEGF on VEGF-Rl, hence it 
is possible that VEGF activates the P13-Kinase/AKT survival pathway via VEGF-RI in 
podocytes. 
Conclusions drawn from these results suggest that both exogenous and endogenous VEGF 
promote survival in cultured podocytes, via a reduction in cytotoxicity. This will be 
dependent on either inhibition of apoptosis or necrosis, although, due to the nature of VEGF it 
is more likely to be due to a reduction in apoptosis. The work from this chapter was published 
in paper I of the list of papers arising from this work. 
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Chapter 6 




In chapter 5 it was shown that treatment with VEGF resulted in a reduction in cytotoxicity in 
cultured podocytes incubated in VEGF. The mechanism through which VEGF results in this 
reduction in cytotoxicity is not clear. The mechanisms by which cells die, however, have been 
extensively studied. Cytotoxicity can manifest itself in two ways: necrosis or apoptosis. 
Necrosis is accidental or pathological cell death, which results in an inflammatory response. 
The most characteristic features of necrosis are nuclear changes starting with pyknosis; the 
condensation of the chromatin, then karyorrhexis; the uncontrolled fragmentation of nuclear 
material and finally karyolysis; where the nucleus is completely broken down (Burkitt et al., 
1997). The cytoplasm also forms an amorphous mass and the cell membrane integrity is lost 
(cytolysis), due to excess cell swelling (Burkitt et al., 1997). The term apoptosis was first used 
by Kerr et al, "apoptosis" meaning the "dropping of'f' of leaves from trees (Kerr et al., 1972). 
It describes programmed cell death either spontaneously, or in response to physiological 
stimuli. There are two distinct stages of apoptosis; firstly, the formation of apoptotic bodies, 
which are small membrane bound spheres consisting of condensed cytoplasmic and nuclei 
fragments, and secondly, phagocytosis by other cells thus avoiding an inflammatory response 
(Kerr et al., 1972) (Uthaisang et al., 2003). The pathways involved in apoptosis are both 
varied and complex. The pathways can be divided into the death receptor cascade pathway 
and the physiological stimuli induced pathway as shown in figure 6.1, although there is 
interaction between the two. Activation of the death receptors, such as FasL, (Fas ligand), 
TRAEL-RI (TNF-related apoptosis-inducing ligand) and TNF-RI (Tumor necrosis Factor- 
Receptor 1), by their ligands induces receptor clustering. 
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Figure 6.1. Simplified schematic of apoptosis signalling cascades. 
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Apoptosis signalling pathways have been split into death receptor signalling cascades and cascades due to 
physiological stimuli. Death receptors, such as TNF-Rl, Fws and TRAIL-RI are activated by their ligands; 
TNF FasL and TRAIL respectively. Death inducing signalling complexes (DISCs) are formed at each 
death receptor and in the case of Fas it involves FADD (containing a death domain and a death effector 
domain). This complex induces the cleavage, and activation of caspase 8, but its binding can be inhibited 
by FLIP. Activated caspase 8 leads to the cleavage and activation of the effector caspatses, which are either 
inhibited by Ups, or induce the cleavage of CAD from ICAD. Activated CAD then translocates to the 
nucleus and induces DNA fragmentation, which leads to cell death. Physiological stimuli on the other 
hand can induce the activation of pro-apoptotic members of the Bcl-2 family. Homodimers (of these pro- 
apoptotic proteins insert into the mitochondrial membrane, leading to cytochrome c release. The insertion 
of the pro-apoptotic proteins into the mitochondria depends on whether the homodimers are cleaved and 
competitively replaced by anti-apoptotic Bcl-2 family members and retained in the cytoplasm, or if the 
pro-apoptotic proteins are phosphorylated by phosphorylated AKT. The cytochrome c forms a complex in 
the cytoplasm with Apaf-1, a caspase recruiting domain, and caspase 9. This induces the cleavage, and 
activation of caspase 9, which leads to the cleavage and activation of effector caspases resulting in the 
activation of CAD and DNA fragmentation and death. 
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This allows the recruitment of adapter proteins, such as FADD (Fas-associated death domain, 
also known as FLICE), to the cytoplasmic domain of the death receptors (Bortner and 
Cidlowski, 2002). The death receptor complex is termed the death inducing signalling 
complex (DISC). The initiator caspase, caspase 8, is recruited to and activated by this 
complex, as shown in figure 6.1. Caspases are a family of cysteine-activated aspartate- 
specific proteins, which play a role in the initiation (initiator caspases) and execution (effector 
caspases) phases of apoptosis (Bortner and Cidlowski, 2002). The activation of the initiator 
caspase, caspase 8, leads to the cleavage and subsequent activation of the effector caspases, 
caspase 3 and caspase 7. Either of these effector caspases can induce the cleavage of caspase 
activated DNAse (CAD) from its inhibitor, ICAD. The two develop together in ribosome's 
and ICAD ensures that CAD has folded correctly, but blocks its binding to DNA (Nagata et 
al., 2003b). This complex resides in the cytoplasm, but CAD translocates to the nucleus after 
ICAD has been cleaved away by the effector caspases, as shown in figure 6. L CAD is a 
member of the histidine nuclease family, and, within the nucleus, generates DNA fragments 
with blunt ends, carrying a 5' phosphate and a 3' hydroxyl group (Nagata et al., 2003b). DNA 
fragmentation invariably leads to cell death. Various physiological stimuli, summarised in 
figure 6.1, can induce the upregulation of pro-apoptotic proteins, which insert into the 
mitochondrial membrane (Bortner and Cidlowski, 2002). The method by which pro-apoptotic 
proteins can induce activation of apoptosis at the mitochondrial level is controversial, but 
invariably leads to the release of various pro-apoptotic factors, such as cytochrome c (figure 
6.1). Cytochrome c forms a complex (apoptosome) with Apaf-1, a caspase recruitment 
domain, and the initiator caspase, caspase 9, which results in its activation. The activated 
initiator caspase, caspase 9, cleaves and activates the effector caspases, which then cleave 
CAD from ICAD and induce DNA fragmentation and cell death (figure 6.1). The apoptosis 
pathways can be inhibited at a number of levels, in various ways. For example, apoptosis can 
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be inhibited at the level of the DISC by FLICE (FADD)-inhibitory proteins (FLIPs). FLIPs 
are recruited to the DISC due to their death effector domains blocking recruitment of caspase 
8 and its subsequent activation (Bortner and Cidlowski, 2002). Apoptosis can also be 
inhibited at the level of the Bcl-2 family of proteins by heterodimeric binding of anti-apoptotic 
members of the Bcl-2 family to pro-apoptotic members (Gross et al., 1999). Apoptosis can 
also be inhibited at the level of the Bcl-2 pro-apoptotic family of proteins by phosphorylated 
AKT, which phosphorylates and inactivates pro-apoptotic family members (Gross et al., 
1999). The inhibitor of apoptosis proteins (IAPs) can inhibit apoptosis at the caspase level, by 
binding to the activated effector caspases, caspase-3 and caspase-7 (Bortner and Cidlowski, 
2002). The authors of this paper have suggested that the ratio of activated effector caspases to 
IAPs is likely to be a key point in determining whether apoptosis will be inhibited. 
The pathway involved in the VEGF induced reduction in apoptosis in endothelial cells, 
however, is thought to be due to VEGF/VEGF-R2 dependent activation of P13-Kinase leading 
to the phosphorylation of AKT. This results in the phosphorylation and inactivation of 
members of the pro-apoptotic family, thus preventing cytochrome c release from the 
mitochondria. To investigate whether VEGF had an effect on either necrosis or apoptosis, 
cells were assayed using a technique that distinguished between both necrotic and apoptotic 
sub populations using a flow cytometer. An analogy could be made between de-differentiated 
hCIPs in vitro and proliferative immature podocytes in vivo and between differentiated hClPs 
in vitro and non-proliferative, mature podocytes in vivo. The effects of VEGF on hCIPs were 
investigated using both de-differentiated and differentiated cells. This set of experiments were 
carried out to provide clues as to whether VEGF has a different role in podocyte function in 
development and maturity. 
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6.2 Methods 
6.21 Apoptosis assay-the effects of VEGF on podocyte apoptosis 
De-differentiated and differentiated hCIPs were serum starved either for a total of 24hrs 
(acutely) or for a total of 48hrs (chronically). The cells were serum starved for 16hrs then 
incubated in InM VEGF for either 4hrs (acutely) or 8hrs (chronically), or left untreated. 24hrs 
later, the cells in the chronic assay were serum starved for 16hrs then incubated once more 
with VEGF for a further 4hrs, or left untreated. Each sample was incubated with either 
annexin V (AV), propidium iodide (PI), a combination of both AV and PI or left untreated. A 
comparison was made between VEGF treated and untreated de-differentiated hCIPs using the 
24hr serum starvation assay. The induction of apoptosis by a total of 24hrs serum starvation 
and a total of 48hrs serum starvation was compared. A comparison was also made between 
VEGF treated and untreated differentiated hCIPs using the 48hr serum starvation assay. 
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6.3 Results 
6.3.1 The effects of VEGF on apoptosis in hCIPs 
An apoptosis assay was used to differentiate between necrotic and apoptotic sub-populations 
of the total cell population. To investigate whether VEGF had an effect on de-differentiated 
hCIPs they were serum starved for 16hrs, treated with VEGF or left untreated in serum free 
media for 4hrs, then scraped into suspension and rolled for 4hrs, in serum free media (total 
24hrs serum starvation). The cell suspension samples were incubated in AV, PI, AV and PI or 
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Figure 6.2. The effects of VEGF on necrotic and apoptotic cell populations in de-differentiated INCIPs. 
Serum starved, de-differentiated hClPs were either treated with VEGF for 4hrs, or serum starved for 
another 4hrs. Cells in both groups were in serum free media for a total of 24hrs, before being incubated in 
AV, PI, AV and PI or left untreated. Cells were then assayed, using the flow cytometer and sub- 
populations of cells were compared between serum starved and VEGF treated de-diffe rent iated hCIPs. 
Data were expressed as mean+SEM % total population for apoptotic, necrotic, late apoptotic and viable 
sub populations. There was no significant difference between VEGF treated and untreated samples, in any 
of the cell populations. N. s. unpaired AVOVA, n=7. 
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Of the total cell population 70.4±5.45% stained with neither AV nor PI (i. e. met the criteria for 
viable cells), in the serum starved group 20.0±5.17% stained with AV (i. e. met the criteria for 
apoptotic cells), 6.24±1.4% stained with PI (i. e. met the criteria for necrotic cells) and 
6.14±2.25% stained with a combination of both AV and PI (i. e. met the criteria for late 
apoptotic cells) (figure 6.2). There was no significant difference between sub-populations of 
cells in the serum starved group compared to the VEGF treated group. These results show that 
apoptosis was induced under these conditions, although necrotic levels were relatively low. 
These cells do autofluoresce at 525nni (the wavelength at which FITC conjugated AV 
fluoresces) to a certain extent and so there is not a clear distinction between apoptotic and 
viable populations as there is with necrotic and viable populations (figure 2.6 B). I therefore 
analysed the AV positive data from the linear region in histogram C, figure 2.6, which 
describes the percentage of AV fluorescence of the total AV fluorescence that is above 
background. Unfortunately the late apoptotic populations could not be discluded from the 
data. The percentage of AV positive cells above background of cells treated with VEGF were 
normalised to that of serum starved cells; there was no significant difference between AV 
positive cells in VEGF compared to serum starved cells (0.99±0.31 fold change of AV 
positive cells in VEGF treatment compared to serum starvation, p=0.46, n=6, not shown). 
These results compliment results gathered from the gates used in the protocol for this 
experiment. 
To investigate whether 24hrs serum starvation had the same effect on differentiated hCIPs, as 
it did on de-differentiated hCIPs, differentiated hCIPs were serum starved for 16hrs, the media 
replaced with fresh serum free media and left for 4hrs. The cells were then scraped into a cell 
suspension and rolled for a further 4hrs in serum free media, then incubated in AV, PI, AV 
with PI or left untreated and assayed using the flow cytometer. The response of differentiated 
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Figure 6.3. Effect of 24hrs (acute) serum starvation on differentiated hCIPs compared to de-differentiated 
hClPs. 
Differentiated hClPs were serum starved for a total of 24hrs, before being incubated in AV, PI, AV and PI 
or left untreated. Cells were then assayed, using the flow cytometer and sub-populations of cells were 
compared to those of de-differentiated hClPs, serum starved for 24hrs. Data expressed as mean+SEM % 
of total cell population. The viable cell populations were significantly lower in differentiated hCIPs 
compared to de-differentiated hClPs, but necrotic cell populations were significantly greater and apoptotic 
cell populations were significantly lower in differentiated hClPs, compared to de-differentiated hClPs. 
There was no significant difference between late apoptotic cell populations in differentiated, compared to 
de-differentiated hCIPs. *=p<0.05, **=p<0.01, **=P<O. (K)I, unpaired ANOVA, n2A. 
Of the total population of cells, 61.7+4.5% stained with neither AV nor PI (i. e. met the criteria 
for viable cells), which was significantly lower than de-differentlated hCIPsI 70.44±5,45%, of 
the total population of cells stained with neither AV nor PI (figure 6.3, p<0.05, ANOVA). Of 
the total cell population of differentiated hCIPs 2.16±0.4% stained with AV, which was 
significantly lower than with de-differentiated hClPs, of the total cell population 20±5.17% 
stained with AV (i. e. met the criteria for apoptotic cells, p<0.01, ANOVA, figure 6.3). Of the 
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total population in differentiated hCIPs 33.49ýL4.5% stained with PI, which was significantly 
greater than in de-differentiated hCIPs; 6.24±1.4% of the total cell population stained with PI 
(i. e. met the criteria for necrotic cells, p<0.001, ANOVA, figure 6.3). Of the total cell 
population of the differentiated hCIPs 1.5±0.58% stained with both " and PI, which was not 
significantly different to de-differentiated hCIPs: 6.14±2.25% of the total cell population 
stained with both " and PI (i. e. met the criteria for late apoptotic cells, figure 6.3). These 
results demonstrate that serum starvation of differentiated hCEPs for a total of 24hrs was not 
sufficient to induce a significant level of apoptosis. Necrosis however was induced to a 
significant level. This provided the opportunity to investigate whether VEGF could exert an 
effect on levels of necrosis in differentiated hClPs. To investigate whether VEGF had a 
significant effect on necrotic sub-populations the apoptosis assay was repeated as above using 
differentiated hCIPs, which had been serum starved for 16hrs, then incubated in VEGF in 
serum free media for 4hrs, and scraped into suspension and rolled for a further 4hrs. 
There was no significant difference in any of the cell sub-population of differentiated cells, 
incubated in VEGF, compared to untreated differentiated hClPs (figure 6.4). To verify that 
this was not due to a miscalculation of apoptosis due to an overlap of viable and apoptotic 
populations the percentage of AV positive cells of total AV fluorescence minus background 
(autofluorescence) was calculated for each treatment. There was no significant decrease in 
AV positive cells, expressed as a ratio of VEGF treated hCIPs to serum starved hCIPs 
(0.6±0.19, p=0.124, n=3, not shown). This indicates that VEGF does not induce a reduction in 
cytotoxicity in differentiated hCIPs via a reduction in necrosis. 
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Figure 6.4. The effects of VEGF on differentiated hCIPs after a total of 24hrs serum starvation 
Serum starved, differentiated hCIPs were either treated with VEGF for 4hrs, or serum starved for another 
4hrs. Cells in both groups were in serum free media for a total of 24hrs, before being incubated in AV, PI, 
AV and PI or left untreated. Cells were then assayed using the flow cylometer and sub-populations of cells 
were compared between serum starved and VEGF treated differentiated hClPs. Data were expressed as 
mean+SEM % total population for apoptotic, necrotic, late apoptotic and viable sub populations. There 
was no significant difference, in any of the cell sub-populations, between VEGF treated and untreated 
samples. N. s. unpaired AVOVA, n=7. 
These results contradict the results from chapter 5 (figure 5.3), showing that VEGF induced a 
reduction in cytotoxicity in differentiated hCIPs, serum starved for a total of 24hrs. This may 
be because apoptosis was induced in the cytotoxicity assay to a greater extent than necrosis. 
Although the cells were serum starved for the same period of time in the cytotoxicity assay, 
and the apoptosis assay they were treated under different conditions. The cells in the 
cytotoxicity assay were grown in 96 well plates, not In 75 CM2 tissue culture flasks, as in the 
apoptosis assay. This means that the cells were exposed to different amounts of media, and 
possibly different concentrations of oxygen or C02. The cells in the 96 well plate would have 
a greater ratio of media to cells than in the tissue culture flask, therefore C02 levels would not 
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be as affected as in the tissue culture flask and therefore not as toxic. Higher toxicity levels in 
the tissue culture flasks may induce necrosis as opposed to apoptosis. The confluency of cells 
may also be different in the 96 well plate compared to the tissue culture flasks, i. e. cells in the 
96 well plates may be more confluent than within the tissue culture flasks, which may 
decrease the severity of the effect of serum starvation on the cells. The cells would die 
nevertheless, but cell death may be more controlled, i. e. apoptosis. 
To investigate the effects of VEGF on apoptosis in differentiated hCIPs, the apoptosis protocol 
had to be modified so that significant apoptosis was induced. At a total of 24hrs serum 
starvation there was no significant level of apoptosis in differentiated hCIPs, therefore these 
cells either undergo apoptosis over a shorter time course than de-differentiated hCIPs or over a 
longer time course than de-differentiated hCIPs. The latter has been more implied in the 
literature and this theory applies well to immature and mature podocytes in vivo. A serum 
starvation protocol was, therefore, developed over a more chronic time period. Cells were 
serum starved for 16hrs, treated with VEGF or left untreated in serum free media for 8hrs, 'Ieft 
to recover in complete media for 48hrs, serum starved for another 16hrs and treated again with 
VEGF or left untreated in serum free media for 4hrs. Cells were then scraped into suspension 
and rolled in serum free media for a further 4hrs. This protocol was developed by accident, 
but was the only one out of many to induce significant apoptosis. Of the total cell population 
in the group that had been serum starved for a total of 48hrs 33.816.67% stained with neither 
AV nor PI, which was significantly lower than the group that had been serum starved for a 
total of 24hrs; 61.66±4.5% stained with neither AV nor PI (i. e. met the criteria for viable cells, 
p<0.001, AVOVA, figure 6.5). Of the total cell population in the group that had been serum 
starved for a total of 48hrs 37.6±6.08% stained with AV, which was significantly greater than 
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the group that had been serum starved for a total of 24hrs-I 2.16±0.4% of the total cell 
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Figure 6.5. Comparison of induction of apoptosis in differentiated hClPs, serum starved for a total of 
48hrs, compared to a total of 24hrs. 
Differentiated hCIPs were serum starved for 16hrs, the media was replaced with fresh serum free media 
for either 4hrs (acute assay) or 8hrs (chronic assay). Cells in the acute assay were then scraped into 
suspension, rolled for a further 4hrs, then assayed. The cells in the chronic assay were incubated in 
complete media for 48hrs, then serum starved again for 16hrs. The media was replaced with fresh serum 
free media and the cells were incubated for a further 4hrs, before being scraped into suspension and rolled 
for 4hrs, then assayed. Data expressed as mean+SEM % total population for apoptotic, necrotic, late 
apoptotic and viable sub populations. There was a significant reduction in the viable and necrotic cell 
populations, but a significant increase in apoptotic cell populations, as well as a non-significant increase in 
the late apoptotic cell populations in cells starved for a total of 48hn, compared to 24hrs. ***=p<0.001, 
ANOVA, iiýý. 
3.34±7.5% of the total population of cells that had been serum starved for a total of 48hrs 
stained with PI, which was significantly lower than in cells serum starved for 24hrsý 
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33.49+-4.5% of the total cell population (i. e. met the criteria for necrotic cells, p<0.001, 
ANOVA, figure 6.5). There was a small, but not significant, increase in cells staining for both 
PI and AV in cells serum starved for 48hrs compared to cells serum starved for 24hrs (i. e. met 
the criteria for late apoptosis, figure 6.4). The results from the chronically serum starved 
group demonstrated that the levels of apoptosis were significant. Therefore, when treated with 
VEGF a reduction in apoptosis could be measured (i. e. the effects of VEGF could be revealed 
by significant levels of apoptosis). The effects of VEGF on apoptosis in differentiated hCIPs 
could therefore be measured using the chronic serum starvation protocol. Differentiated 
hCIPs were serum starved for 16hrs, treated with VEGF in serum free media for 8hrs, or left 
untreated, then incubated in complete media for 48hrs. The cells were again serum starved for 
16hrs then treated with VEGF in serum free media for 4hrs, or left untreated, scraped into a 
cell suspension and rolled for a further 4hrs and finally assayed using the flow cytometer. The 
results show that there was a significant reduction in cells that stain for AV (i. e. met the 
criteria for apoptotic cells) in chronically serum starved cells incubated in VEGF 
(19.49±5.57% of the total cell population) compared to untreated chronically serum starved 
cells (37.6±6.08%, of the total cell population, p, 0.05, ANOVA, figure 6.6). Of note there 
was also an increase in cells incubated in VEGF that stained for neither AV nor PI (i. e. met the 
criteria for viable cells), although it was not significant. Cells, incubated in VEGF also 
demonstrated a small, but non-significant increase in cells staining with PI (i. e. met the criteria 
for necrosis) compared to untreated cells. There was no difference between cells staining for 
both AV and PI (i. e. met the criteria for late apoptosis), between cells incubated VEGF and 
untreated cells. To confirm there was no miscalculation in AV positive cells due to the 
regions used in the protocol, the percentage of AV positive cells of the total AV fluorescence 
of VEGF treated cells were normalised to that of serum starved cells. There was a 0.5±0.07 
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fold reduction in AV positive cells in VEGF treatment compared to serum starvation (p<0.05, 
one sample I-test, n--3, not shown), which confirms the results in figure 6.6. 
These results show that: 1) VEGF does not have a significant effect on apoptotic or necrotic 
sub-populations in de-differentiated hCIPs; 2) de-differentiated hCIPs are more sensitive to 
apoptosis than differentiated hCIPs; 3) VEGF does not significantly affect necrotic sub- 
populations in differentiated hCIPs; 4) chronic serum starvation induces significant apoptosis 
in differentiated hCIPs; 5) VEGF induces a significant reduction in apoptosis in differentiated 
hCEPs. 
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Figure 6.6. VEGF reduces apoptosis in chronically serum starved, differentiated hClPs. 
Differentiated hCI]Ps were serum starved for 16hrs, cells were then incubated in fresh serum free media, 
either containing VEGF or not for or 8hrs. Cells were then incubated in complete media for 48hrs then 
serum starved again for 16hrs. The media was replaced with fresh serum free media either containing 
VEGF or not and the cells were incubated for a further 4hrs, before being scraped into suspension and 
rolled for 4hrs then assayed. A. Comparison of AV and PI labelling of InM VEGF treated, serum starved 
hCIPs compared to serum starved hCEP's. There is more apoptosis in this example of untreated cells (i) 
compared to cells treated with VEGF (ii), but, what appears to be a smaller necrotic population in serum 
starved (i) compared to cells incubated in VEGF (ii). B. Characteristics of cell populations in chronically 
serum starved InM VEGF treated hCIPs compared to untreated hCIPs. Values are expressed as a 
percentage of the total cell population. There is more apoptosis in the serum starved group (i) whereas 
there is more necrosis and viable cells in the VEGF treated group (ii). C. Mcan+SEM sub-population as a 
percentage of the total cell population. Compared to serum starvation alone, VEGF treatment 
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significantly reduced apoptotic cells. p<0.05, ANOVA, n=3- 
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6.4 Discussion 
VEGF has been implicated in glomerular endothelial cell migration during glomerular 
development (Simon et al., 1995). In the previous chapter it was shown that VEGF could 
exert an autocrine effect on podocytes. It was not established, however, whether the effect of 
VEGF on podocytes could be related to glomerular development glomerular maturity, or 
both. The effects of VEGF on [Ca 2+], were investigated in both PCPs and differentiated 
hCIPs. PCPs contain a population of podocytes at mixed stages of de-differentiation (found 
during development) and differentiation (found at maturity), therefore, the effects of VEGF on 
differentiated podocytes, could not be fully determined in PCPs. The use of WIN, kept at 
33'C, ensured a uniform population of de-differentiated podocytes due to the active SV40 T- 
antigen. hC1Ps were therefore used in apoptosis assays to compare the effects of VEGF on de- 
differentiated (hCfPs kept at 33"C) and differentiated podocytes (hCIPs kept at 37'C). Unlike 
differentiated hCIPs apoptosis was induced in de-differentiated hCIPs using an acute serum 
starvation assay. This suggests that de-differentiated hCIPs are more prone to apoptosis than 
differentiated hCIPs. The de-differentiated hCIPs are still held in the cell cycle because the 
genes that lead'to growth arrest are not transactivated by p53, which has been inactivated. 
This makes de-differentiated hCIPs more vulnerable to cytototoxic processes than terminally 
differentiated podocytes: Exit from the cell cycle in differentiated cells coincides with an 
upregulation in CDK inhibitors, which promote cell survival (Fujio et al., 1999) (as discussed 
in for figure 1.3). There was no significant difference in any of the cell sub-populations of de- 
differentiated hCIPs incubated in VEGF compared to those that were not incubated in VEGF 
(figure 6.2). This was in contrast to the reduction in apoptosis in differentiated hCIPs 
incubated in VEGF compared to serum starved cells (figure 6.4). De-differentiated hC1Ps 
share similar characteristics with immature podocytes in vivo; they are proliferative, do not 
form foot processes and do not express maturity markers whereas differentiated podocytes 
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share characteristics with mature podocytes in vivo; they are non-proliferative, develop 
secondary and tertiary foot processes and express maturity markers associated with 
differentiation. There is the possibility, therefore, that VIEGF acts as a maturity specific 
podocyte survival factor: VEGF induces a reduction in apoptosis in terminally differentiated 
podocytes, in vivo, but not in proliferative, de-differentiated podocytes in vivo, as discussed by 
Saleem et al, 2002 (Saleem et al., 2002). 
Differentiated hCIPs incubated in VEGF demonstrated reduced cytotoxicity due to a reduction 
in apoptosis (figure 6.6). This agrees with known VEGF survival signalling pathways 
mediated through VEGF-R2. Signalling through VEGF-RI though is quite different. VEGF 
can induce the upregulation of the P13-Kinase/AKT signalling pathway in primary rat hepatic 
stellate cells. When these cells are kept in culture for more then 10 days VEGF-R2 expression 
is diminished, but VEGF-RI expression is upregulated (Takahashi et al., 2003). This suggests 
that if VEGF mediates its survival effects through VEGF-RI in podocytes it could induce the 
activation of the P13-Kinase/AKT pathway. VEGF-RI can bind to Np-I and Np-2 as 
discussed earlier, Np-I and Np-2 can form heterodimers (Giger et al., 1998) and it has been 
speculated that VEGF-R3 can bind to Np-2 (Yuan et al., 2002). It is possible, therefore, that 
VEGF-RI and VEGF-R3 form heterodimers in podocytes. VEGF-R3 is involved in similar 
signalling pathways to VEGF-R2 in lymphatic endothelial cells in response to VEGF-C. It 
activates the P13-Kinase/AKT pathway, protects cells from apoptosis and activates the 
PKC/MAPK pathway (Makinen et al., 2001). Interestingly, VEGF-C stimulation induced the 
formation of VEGF-R3/VEGF-R2 heterodimers in lymphatic endothelial cells and it was 
shown that the phosphorylation sites in this signalling complex were distinct from VEGF-R3 
homodimers (Dixelius et al., 2003). VEGF-RI/VEGF-R3 heterodimers on podocytes would 
enable recognition of VEGF by VEGF-RI, although the activation of P13-Kinase by 
155 
phosphorylation sites on both receptors would be hard to predict to due a conformational 
change of the intracellular domain of the receptors on heterodimerisation. There is no 
evidence available from the literature, however, that VEGF-RI and VEGF-R3 can form 
heterodimers. Equally, however, this heterodimerisation has not been shown to be impossible 
or the hypothesis even tested. The reduction in apoptosis in podocytes induced by VEGF may 
stimulate more than one signalling pathway. VEGF protected podocytes from apoptosis 
induced by serum starvation, but it may only be effective in resisting certain apoptotic stimuli. 
From these results we can deduce that VEGF signals in podocytes in an autocrine manner, 
potentially through VEGF-RI/VEGF-R3/Np-I/Np-2 complexes, to promote survival via a 
reduction in apoptosis. The signalling pathways that mediate these effects, though, still have 
to be elucidated in order to fully understand the effects of VEGF on podocyte biology. Much 
of the work from this chapter has been accepted for publication in paper 3 of the list of papers 
arising from this work 
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Chapter 7 
VEGF intracellular signalling pathways in cultured podocytes 
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7.1 Introduction 
The results from the previous chapters showed that VEGF could stimulate an autocrine effect 
on podocytes stimulating an unknown pathway, which ultimately resulted in promoting 
survival via a reduction in apoptosis. To elucidate the effects of VEGF in podocytes the 
survival pathway that VEGF activates was investigated. 
Likely signalling pathways through which VEGF may signal in epithelial cells lacking 
VEGFR-2, but containing VEGFR-I include VEGFR-I tyrosine phosphorylation and 
activation of downstream signalling molecules known to be involved in regulation of 
apoptosis. These include P13 kinase, which has also been shown to be activated after VEGF- 
RI stimulation in activated hepatic stellate cells (Takahashi et al., 2003). It would therefore be 
useful to use inhibitors of these molecules, particularly VEGF-RI and P13 Kinase as a starting 
point for the investigation of the mechanism through which VEGF acts on podocytes. 
1-[4-Chloroanilino]-4-[4-pyridylmethyl]-dihydrochloride (PTK787/ZK222584) is a class III 
tyrosine kinase receptor inhibitor developed by Novards Pharmaceuticals (a kind gift from Dr 
J Wood, Novartis AG, Switzerland), which acts by binding to the ATP-binding sites of these 
types of receptor tyrosine kinases. Class III RTKs include VEGFR-I, VEGF-R2, VEGF-R3, 
placental growth factor receptor (PDGF-R) and c-Kit (a receptor for cell stem factor) with an 
IC5o of less than IgM (Wood et al., 2000). PTK787/ZK222584 can inhibit VEGF-R1 
phosphorylation at an IC50 of 77nM and VEGF-R2 at 130nK whereas PDGF-R and VEGF- 
R3 require higher concentrations with an IC5o of 580nM and 660nM respectively (Wood et al., 
2000). This inhibitor was used at I gM in [Ca 2+ 1 experiments to block the effects of all of the 
above class III tyrosine kinases, and at I OOrM in cytotoxicity experiments to examine whether 
the VEGF effects on cultured podocytes were VEGF-RI dependent. 
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VEGF promotes survival by reducing apoptosis in cultured podocytes, shown in chapter 6. In 
endothelial cells the survival pathway commonly activated by VEGF is the P13-Kinase/AKT 
survival pathway, as discussed in the introduction. Wortmannin is a fungal metabolite, which 
selectively and irreversibly blocks the catalytic activity of P13-Kinase by binding to the ATP 
binding site of the pre-phosphorylated p85/pllO P13-Kinase complex at residue Lys-802 
(Wymann et al., 1996). This inhibitor was used to investigate whether the VEGF induced 
reduction in cytotoxicity was P13-Kinase dependent in podocytes. VEGF has been shown to 
be able to exert its effects both externally, via VEGF receptors expressed at the plasma 
membrane, and internally, via in-side-out VEGF receptor expression on the membrane of 
caveolae within the cytosol (Labrecque et al., 2003) (Feng et al., 1999). Wortmannin is cell 
permeant (Wymann et al., 1996) and therefore can inhibit VEGF signalling both externally 
and internally. 
A neutralising monoclonal antibody to VEGF was also used in these experiments. It binds to 
an epitope of VEGF on the receptor-binding site and therefore VEGF cannot recognise and 
bind to its receptors (MAB393, R&D Systems, Abingdon, UK). The neutralising monoclonal 
antibody to VEGF is not cell permeant and can only neutralise exogenous or endogenous 
VEGF externally to the cell plasma membrane, therefore it has no neutralising effect on 
internal VEGF signalling. The neutralising monoclonal antibody to VEGF was used to ensure 
that the effects of exogenous VEGF were VEGF specific, and was also used to block the 
external effects of endogenous VEGF. 
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7.2 Methods 
ZZI JCa2+jj nwasurenwnts- VEGF-R signalling 
hCIPs and PCPs were incubated in HBSS containing minimal calcium (minimal [Ca2+],, ) so 
that the reduction in [Ca2']i in hCIPs induced by VEGF could be detected. Cells were pre- 
incubated for 10 minutes with IgM of the class III tyrosine kinase inhibitor, 
PTK787/ZK222584, then treated with lnM VEGF as described in the methods. The cells 
were washed three times with HBSS containing minimal calcium, then left for 20 minutes to 
wash out the inhibitor before being treated once more with I nM VEGF. Cells were not treated 
with VEGF before incubation with PTK787/ZK222584 because the VEGF-induced reduction 
in [C21i did not reverse during the experiment which may affect the magnitude of the [Ca2jj 
response. Cells were also treated with 0.32gg/ml of a neutralising monoclonal antibody to 
VEGF (R&D Systems, Abingdon, UK) and 0.32gg/ml of normal mouse IgG in the same 
manner as with treatment of VEGF. The analysis of these experiments was carried out in two 
ways; the measurement of the mean [C2+]i values at the peak of the response or the mean 
[Ca2jj values taken at the end of the experiment, once a plateaux had been reached. This 
enabled both increases and reductions in [Ca2jj to be measured in response to a stimulus. 
Z22 Cytotoxicity assay-VEGF-R signalling 
Serum starved PCPs were incubated for 24hrs in fresh RPMI media containing IOOnM 
PTK787/ZK222584, not IgM, so that the effects of VEGF-RI could be distinguished from 
VEGF-R3 or PDGF-R signalling. Serum starved PCPs were also incubated in InM VEGF, 
VEGF with PTK787/ZK222584, or left untreated for 24hrs. The percentage of cytotoxicity 
was quantified in low, experimental and high controls, and compared between treatments, as 
described in the methods. 
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7 Z3 Cytotoxicity assay-PI3-Kinase signalling 
Serum starved hCIPs and PCPs were incubated in fresh RPMI media containing a range of 
Wortmannin concentrations, a P13-Kinase inhibitor) including 0,50,100,200 and 400nM, 
either alone, to assess endogenous levels of P13-Kinase activity, or with I nM VEGF for 24hrs. 
% cytotoxicity was quantified in low, experimental and high controls, and compared between 
treatments, as described in the methods. 
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7.3 Results 
7 3.1 Signalling through VEGF-Rs 
Incubation of hClPs with VEGF loaded with Fura-2 and pre-incubated with the class III 
tyrosine kinase inhibitor, PTK787/ZK222584, induced a2 fold transient increase in [Ca'+]i. It 
peaked approximately 2 minutes after the addition of VEGF and reached a plateaux 
approximately 4 minutes from the addition of VEGF (figure 7.1 A). This increase in [C2+]i 
in response to VEGF in the presence of PTK787/ZK222584 was significantly greater than 
baseline recordings over the course of 5 experiments (a ratio (treatment/baseline [C2']i) of 
1.48±0.25) compared to baseline (a ratio (baseline/average baseline [Ca 2+ 1) of 1±0.16, figure 
7.1 B, p<0.01). The recovering [Ca 2+]i baseline (at the end of the experiment) in cells pre- 
incubated in PTK787/ZK222584, then treated with VEGF was if anything slightly higher than 
the original baseline and was significantly higher than the recovering [Ca2+]i baseline in cells 
treated with VEGF alone (a ratio (baseline/average baseline [C2+]i) of 1.23±0.13 compared to 
that of 0.72±0.09, figure 7.1 C, p<0.05). The data were analysed in this manner so that these 
experiments could be compared to similarly analysed historical experiments and also 
demonstrated that there was no decrease in [Ca? jj from original baseline recordings in the 
presence of VEGF. This suggests that pre-incubation of hCIPs with PTK787/ZK222584 
blocked the VEGF induced reduction in [Ca 2+], shown previously in figure 4.117 and it also 
induced an increase in [Ca2li. The phosphorylation of all class III tyrosine kinases in 
question was blocked, in principle, because the concentration of inhibitor used was at an IC50 
much greater then was required. These results indicate that VEGF induces its effects on 
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Figure 7.1. PTK787/ZK222584 blocks the reduction in [Ca 2+1i induced by VEGF in hClPs. 
Serum starved hCIPs, loaded with Fura-2, were pre-incubated with PTK787/ZK222584 for 10 minutes 
2+ before the addition of 1nM VEGF in the presence of minimal [Ca I .. Fluorescent inensity changes were 
recorded and used to calculate [Ca 2+]i concentrations and then the ratio (treatment/baseline [Ca 2+ ji) was 
used for comparisons between experiments in WIN. A. An example of the peak [Ca 2+ ]i response to InM 
VEGF in cells pre-incubated with PTK787/ZK222584 (incubated in minimal jCa2ý], ). VEGF induced an 
increase in lCa 21i in WIN pre-incubated in PTK787/ZK222584. B. The peak jCa'+jj response in hCIPs 
pre-incubated in PTK787/ZK222584 after the addition of InM VEGF (pale blue) was significantly higher 
compared to baseline in the presence of PTK787/ZK222584 (dark blue) (p<0.05; two-tailed t-test). C. 
Comparison of [Ca 21i following recovery of the response to the addition of InM VEGF in hCIPs pre- 
incubated in PTK787/ZK222584 (pale blue) to that of hCIPs treated with VEGF alone (dark blue, 
historical data as shown in figure 4. IF). The change in jCa2+jj, expressed as the ratio (of treatment/control, 
following recovery was significantly higher compared to those of historical VEGF experiments, but was 
not significantly different from one (ie not different from baseline; one tailed 1-test). The I Ca2ý following 
recovery in the PTK787/ZK222584 and VEGF experiments was significantly lower than the peak JCa2+jj 
resonse (p>0.05, paired t-test, not shown). *=p<0.05, **=p<0.01 compared to baseline or as indicated, 
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Pre-incubation of PCPs with PTK787/ZK222584 induced an increase in [Ca 21 ]i when treated 
with VEGF compared to baseline in the same manner as with hClPs-, a ratio 
(treatment/baseline [Ca 2f]i) of 1.21±0.07 in cells treated with VEGF in the presence of 
PTK787/ZK222584; compared to a ratio (baseline/mean baseline [Ca 2, ]i) of 1±0 . 
12 in cells 
treated with PTK787/ZK222584 alone p<0.05, figure 7.2A). After PTK787/ZK222584 was 
washed out three times with HBSS and left for 20 minutes the [Ca 24 ]i response on re-addition 
of VEGF to PCPs was not different to the effects of VEGF on [Ca 241i in the presence of 
PTK787/ZK222584 (a ratio (treatment/baseline [Ca 2f], ) of 1.21+0.07 in cells treated with 
VEGF plus PTK787/ZK222584 compared to a ratio (treatment/baseline [Ca 21 Ii) of 1.3+0.2 of 
cells incubated in VEGF for the second time, figure 7.2A). This indicates that the effects of 
PTK787/ZK222584 did not reverse. 
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Figure 7.2. PTK787/ZK222584 blocks the VEGF induced reduction in [Ca 2+1i in PCPs. 
Serum starved PCPs, were loaded with Fura-2 and pre-incubated with PTK787/ZK222584 for 10 minutes 
before the addition of InM VEGF. Fluorescent intensity changes were recorded and used to calculate 
[Ca 2+] i and were compared to baseline [Ca 
2+1 
i recordings in the presence of PTK787/ZK222584 in PCPs. 
Data were expressed as mean+SEM ratio (treatment/baseline ICa 2+] j). A. The jCa2+jj response of PCPs to 
InM VEGF in the presence (blue) of PTK787/ZK222584 and a second treatment with VEGF in the 
absence (green) of PTK787/ZK222584. VEGF induced a significant increase in jCa 2+]i in PCPs, pre- 
incubated in PTK787/ZK222584 compared to baseline recordings. The re-addition of VEGF after the 
PTK787/ZK222584 had been washed from the cells for 20 minutes did not significantly change the [Ca 2+ Ii 
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levels compared to in the presence of FITK787/ZK222584. B. A comparison of the recovering [Ca2li 
baseline recordings following treatment of VIEGF In cells either pre-incubated in PTK787/ZK222584 (blue) 
or not (green). *=p<0.05, ***=p<0.001, paired Mest compred to baseline or as Indicated. 
Not only did VEGF stimulate an increase in [Ca2jj in cells pre-incubated in 
P'IK787/ZK222584 in PCPs but the recovering baseline in these experiments was also slightly 
higher than the original baseline and significantly higher than the recovering baseline in 
historical responses to VEGF alone; a ratio (treatment/baseline [C21) of 1.13±0.07 compared 
to that of 0.7±0.07 (figure 7.2 B, p<0.001). This suggests that, as with hCIPs, pre-incubation 
with PTK787/ZK222584 blocks the reduction in [Ca? ']i seen in response to VEGF alone. 
Observations of baseline recordings in hClPs in the presence of PTK787/ZK222584 were 
made to test that PTK787/ZK222584 itself was not having an effect other than blocking class 
III tyrosine kinase receptors. These observations revealed that there was no elevation of 
baseline [C21i in experiments such as that shown in figure 7. IA. The addition of 
PTK787/ZK222584 alone to hC1Ps did not induce a change in [Ca2+]i levels as shown in 
figure 7.3 (baseline; 47.8±5.57nm compared to PTK787/ZK222584; 49.24±3.6nm). This 
demonstrates that the effects of PTK787/ZK222584 were specific to VEGF treatment. It also 
implies that there was either no endogenous effect of VEGF on [Ca2+]i, or that there was an 














-50 0 50 100 150 200 250 300 350 400 baseline Inhibitor 
Time after addition of inhibitor (secs) 
Figure 7.3. Effect of PTK787/ZK222584 on changes in JCa2+]j in hCIPs. 
Serum starved hCIPs, loaded with Fura-2 were incubated with PTK787/ZK222584. Changes in 
fluorescent intensitY were recorded, and used to calculate [Ca 2+]i and then compared to baseline recordings 
of changes in [Ca2+Jj in hCIPs. A. An example of an [Ca 2+1i measurement in response to treatment with 
PTK787/ZK222584 alone showed no change in [Ca2+1j. B. Mean+SEM of [Ca2*]i in cells before (blue) and 
after vellow) pre-incubation with PTK787/ZK222584 shows no significant difference in lCa 2 +]i 
concentration. N. s. n=6. 
Surprisingly, the inhibition of endogenous VEGF (in the absence of exogenous VEGF), by a 
neutralising monoclonal antibody to VEGF, reduced [Ca 21 ], in hClPs to the same extent as 
VEGF (a ratio (treatment/baseline [Ca 24 ]i) of 0.64±0.06 in cells treated with a neutralising 
monoclonal antibody to VEGF, compared to a ratio (treatment/baseline [Ca 2f ]i) of 0.72±0.13 
in cells treated with VEGF, figure 7.4, p<0.05, ANOVA). The effects of a neutralising 
monoclonal antibody to VEGF, combined with VEGF, not only blocked the effects of VEGF 
on [Ca 24 ]i, in hCIPs but also significantly increased [Ca 21ji from baseline recordings (a ratio 
(treatmentibaseline [Ca 2+]i) of 1.38±0.29 in cells treated with VEGF plus a neutralising 
monoclonal antibody to VEGF, p<0.01, figure 7.4). These results were similar to the effects 








Figure 7.4. The effect of VEGF-Mab on the reduction in [Ca 2+li induced by VEGF in hClPs. 
Serum starved WIN, loaded with Fura-2, were incubated in VEGF, VEGF-Mab, VEGF plus VEGF-Mab 
or normal mouse IgG. Changes in fluorescent intensity were recorded, and used to calculate lCa 2+1i, Data 
were expressed as mean+SEM ratio (treatment/baseline [Ca 2+1j). There was a significant reduction in 
JCa 2+1i in cells treated with both VEGF (green) and VEGF-Mab (yellow) to cells treated with a 
combination of VEGF plus VEGF-Mab (light blue). There was no significant effect on ICa 2+1i in cells 
treated with normal mouse IgG. Student-Newmann-Keuls Test, *=p<0.05, n->O. 
Treatment of hCIPs with normal mouse IgG did not induce a significant change in [Ca 2 
compared to baseline [Ca 2+]i (a 0.97±0.07 fold change in ratio of (treatment/baseline [Ca 2f ]i) in 
cells treated with mouse IgG, figure 7.4). This shows that the effect of the neutralising 
monoclonal antibody to VEGF was not due to a non-specific mouse IgG effect (the species in 
which the neutralising monoclonal antibody to VEGF was raised). Together, these results 
demonstrate that exogenous VEGF induced a class III tyrosine kinase dependent reduction in 
[Ca 21]i in cultured podocytes. To investigate whether VEGF survival signalling was also 
dependent on class III tyrosine kinases, the effect of PTK787/ZK222584 on the VEGF 
induced reduction in cytotoxicity was assayed. 
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To investigate whether the reduction in cytotoxicity induced by VEGF was dependent on 
VEGF-Rs in cultured podocytes PCPs were incubated in media containing VEGF, 
PTK787/ZK222584, or VEGF with PTK787/ZK222584 for 24hrs. The media was assayed for 
LDH as described in the methods and the percentage cytotoxicity calculated from this. The 
concentration of PTK787/ZK222584 used was 10 fold less than that used in the [Ca 21]i 
experiments. This was to specifically target VEGF-Rl, which has a much lower IC50 to 
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Figure 7.5. The effects of PTK787/ZK22258-1 on the reduction in cytotoxicity induced by VEGF in PCPs. 
Serum starved PCIP's were incubated in VEGF, PTK787/ZK222584, VEGF plus PTK787/ZK222584 or left 
untreated for 24hrs. The percentage (if cytotoxicity was then assayed and compared between treatments. 
The bar graph shows mean+SEM ratio of (percentage cytotoxicity treatment/baseline). There was no 
significant difference in ratio between cells treated with PTK787/ZK222584 or cells treated with 
PTK787/ZK222584 plus VEGF, with either cells that were serum starved or cells that were treated with 
VEGF. * =p<0.05, Bonferroni test, n=18. 
There was a small, but not significant reduction in cytotoxicity in PCPs treated with a 
combination of the inhibitor and VEGF compared to that of serum starved cells (a 0.87+0.43 
fold reduction of ratio (treatment/serum starvation) in cells treated with VEGF plus 
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PTK787/ZK222584, figure 7.5). These results imply that either PTK787/ZK222584 did not 
fully block the effects of VEGF and that the effects of VEGF on cytotoxicity are only partially 
dependent on VEGF-R1, or that PTK787/ZK222584 did not have an effect on the VEGF 
induced reduction in cytotoxicty. Figure 53B shows that treatment of cultured podocytes with 
a neutralising monoclonal antibody to VEGF increased cytotoxicity compared to control. This 
indicates that the endogenous effects of VEGF on cytotoxicity act via an external autocrine 
loop because the neutralising monoclonal antibody to VEGF acts externally. It was predicted, 
therefore, that treatment of PCPs with PTK787/ZK222584 alone would block the endogenous 
effects of VEGF on cytotoxicity, which was not the case. I can not conclude either way from 
these results whether the effects of VEGF on cytotoxicity were mediated via VEGF-RI. The 
VEGF specific survival pathway was next investigated, focusing on the P13-Kinase survival 
pathway using Wortmannin, a P13-Kinase inhibitor. 
7 3.2 VEGF survivalpathway in culturedpodocytes 
Both hCIPs and PCPs were incubated with a range of concentrations of the PD-Kinase 
inhibitor Wortmannin for 24hrs before LDH was quantified in cell media and cytotoxicity 
calculated to assess how Wortmannin effected cytotoxicity levels. Wortmannin induced a 
dose dependent increase in cytotoxicity in PCPs, becoming significant at a concentration of 
200nM Wortmannin (p<0.01, ANOVA, figure 7.6 A). Wortmannin also induced a dose 
dependent increase in cytotoxicity in hCIPs, becoming significant at a lower concentration 
than with PCPs, at 50nM Wortmannin (p<0.01, ANOVA, figure 7.6 B). The increase in 
cytotoxicity, induced by Wortmannin in cultured podocytes could be either due to an 
inhibition of baseline levels of PD-Kinase in serum starved cells, resulting in increased 















Figure 7.6. Cytotoxicity dose response of PCPs and hClPs to Wortmannin. 
Serum starved PCPs and hCIPs were incubated in increasing doses of Wortmannin for 24 hrs. 
Cytotoxicity was then assayed and compared between treatments. Data were expressed as mean+SEM 
ratio of (percentage of cytotoxicity of treatment/serum-starvation). Wortmannin dose dependently 
increased cytotoxicity in PCPs (A) and hClPs (B). Wortmannin caused a significant increase in 
cytotoxicity in PCPs from 200nM upwards whilst in hClPs it was active at lower concentrations; from 
5OnM upwards. *=p<0.05 **=p<0.01, ***p<0.001 compared to serum starvation, one wav ANOVA, 
Student-Newmann Keuls posthoc test 
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To investigate whether the VEGF induced reduction in cytotoxicity (shown in figures 5.2 and 
5.3) was dependent on P13-Kinase activation, the effects of Wortmannin on VEGF induced 
reduction in cytotoxicity were investigated. Since the data shown in Figure 7.6 indicates that 
concentrations of Wortmannin greater than 25nM had a cytotoxic effect, 25nM Wortmannin 
was used for this objective. Therefore, PCPs and hClPs were serum starved and incubated in 
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Figure 7.7. The effects of Wortmannin on the VEGF mediated reduction in cytotoxicity. 
Ai. Data from figure 5.213 re-expressed as change in cytotoxicity (treatment/serum starvation). Aii. The 
effect of VEGF on cytotoxicity in PCPs in the presence of 25nM Wortmannin. Bi. Data from figure 5.3A 
re-expressed as change in cytotoxicity (treatment/baseline). Bii. The effect of VEGF (on cytotoxicit,, - in 
hCIPs in the presence of 25nM Wortmannin. *=p<0.05, paired týtest. 
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As expected, this concentration of Wortmannin did not have a cytotoxic effect on serum- 
starved PCPs (108.4±2% cytotoxicity compared to 94.63±5.63%, unpaired 1-test, figure 7.7 
Aii). On the other hand, in the presence of just 25nM Wortmannin the reduction in 
cytotoxicity induced by VEGF (45.5±5.76% of cytotoxicity induced by serum starvation, 
paired t-test, figure 7.7 Ai) was blocked (94.63±5.63% of cytotoxicity induced by serum 
starvation, paired t-test, figure 7.7 Aii). In hCIPs, conversely, there was still a significant 
reduction in cytotoxicity induced by VEGF in the presence of 25nM Wortmannin 
(83.4.7±2.56% of cytotoxicity induced by serum starvation, paired Mest, figure 7.7 Bii). The 
effects of Wortmannin on the VEGF induced reduction in cytotoxicity in hCIPs were not 
investigated futher because concentrations of Wortmannin above 25nM proved to be 
cytotoxic. 
It was surprising that Wortmannin blocked the anti-cytotoxic effects of VEGF in PCPs but not 
in hCIPs. This may have been because VEGF was more cytotoxic in hCIPs than in PCPs (as 
shown in figures 7.7 Ai and Bi). These results suggest that in PCPs VEGF reduces 
cytotoxicity in a P13-Kinase dependent manner, yet are inconclusive in so far as the effects of 
VEGF on P13-Kinase in hClPs. 
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7.4 Discussion 
Pre-incubation of PCPs and hCIPs with the class III tyrosine kinase receptor inhibitor, 
PTK787/ZK222584, blocked the VEGF induced reduction in [Ca2jj when incubated in 
minimal [Ca2+].. This suggests the effects of VEGF on [Caýjj in hCIPs were class III tyrosine 
kinase receptor dependent. The receptors that could be inhibited at the concentration of 
inhibitor used were VEGF-RI, VEGF-R2, VEGF-R3 and PDGF-R. Differentiated, cultured 
podocytes express PDGF-RP protein (Nakagawa et al., 2000) and mRNA (Asanuma et al., 
2002). They also express PDGF-B protein (Nakagawa et al., 2000) and mRNA (Floege et al., 
1993). There is no evidence in the literature to suggest that VEGF can bind directly to PDGF- 
Rs. It is possible, however, that incubation of cultured podocytes with PTK787/ZK222584 
could block an autocrine loop effect of PDGF-B. Yet changes in [C2']i were in response to 
VEGF (figure 7.1 A), not to the inhibitor (figure 7.3). Hence, it is most likely that the effects 
of PTK787/ZK222584 on [C21j are VEGF-R1 and/or VEGF-R3 dependent in podocytes. 
The effects of VEGF on PCPs and hCIPs pre-incubated with PTK787/ZK222584 were very 
similar (figure 7.1 and 7.2). This supports the hypothesis that the two cell types express 
similar receptors and act in a similar manner in culture. 
Surprisingly, VEGF stimulated an increase in [Ca2li in cultured podocytes pre-incubated with 
PTK787/ZK222584. This rapid transient response was similar to the in vivo response of 
endothelial cells to VEGF (Pocock et al., 2000). If activation of VEGF-RI and/or VEGF-R3 
by VEGF activates either the SERCA or PMCA (as discussed in chapter 3) then the inhibitor 
may act by blocking the active pumping of calcium from the cytosol. Thus, it would be 
predicted that cells would no longer respond to VEGF, not respond in an opposite manner. it 
may be possible that VEGF can act through another receptor in podocytes, which is not a class 
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III tyrosine kinase receptor. For example, if VEGF was capable of signalling independently 
through Np-I or Np-2, as suggested by Wang et at 2003 this may induce an increase in [Ca 2+ ]i 
via a different signalling pathway than when VEGF-RI and VEGF-R3 are activated by VEGF. 
Blocking the effects of exogenous VEGF, using a neutralising monoclonal antibody to VEGF 
also resulted in a significant increase in [Ca 21, compared to untreated cells (figure 7.4). This 
suggests that because the neutralising monoclonal antibody to VEGF binds directly to VEGF 
and thus prevents it from binding to its receptors this increase in [Ca2jj was not dependent on 
VEGF receptor activation by VEGF. Yet the reduced [Ca2jj response was mediated by the 
addition of VEGF. Interestingly, inhibition of endogenous VEGF by a neutralising 
monoclonal antibody to VEGF induced a significant reduction in [Ca2']i similar to that of 
VEGF. This will be discussed further in more detail later in the thesis, as will the implications 
of natural VEGF inhibitors within the glomerulus. 
The VEGF induced reduction in cytotoxicity in cultured podocytes was not significantly 
blocked by PTK787/ZK222584, which was used at a concentration too low to affect VEGF- 
R3, but able to inhibit VEGF-Rl (figure 7.5). This indicated that either the effects of 
exogenous VEGF on cytotoxicity were only partially dependent on VEGF-RI and that they 
were also dependent on another receptor, most likely VEGF-R3 or that the effects of VEGF on 
cytotoxicity were not VEGF-R1 dependent. A similar response was also seen when the cells 
were incubated in PTK787/ZK222584 alone at the same concentration; it did not significantly 
block the effects of endogenous VEGF. It has been suggested that PTK787/ZK222584 
inhibits VEGF mediated VEGF-R signalling at different concentrations depending on the 
signalling pathway, for example in HUVECs VEGF mediated proliferation is blocked at an 
IC5o of l6nM, whereas cell survival and migration are blocked at an ICso of 58nM (Traxler et 
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al., 2001). When PTK787/ZK222584 was used to block the auto-phosphorylation of VEGF- 
R1 by VEGF in Multiple Myeloma cells, which do not express VEGF-R2 or VEGF-R3, the 
proliferative effects of VEGF were significantly blocked at 5OOnM PTK787/ZK222584 (a 
lower concentration was not used) (Lin et al., 2002). The effects of PTK787/ZK222584 on 
VEGF-Rl auto-phosphorylation mediated by VEGF have not yet been examined with respect 
to survival signalling. The IC5o of PTK787/ZK222584 needed to block this signalling 
pathway may therefore be higher than the concentration of PTK787/ZK222584 used 
podocytes in this chapter. If a higher concentration of PTK787/ZK222584 was needed to 
block the reduced cytotoxicity induced by VEGF activation of VEGF-RI in podocytes then 
this may explain why the use of PTK787/ZK222584 did not significantly block the survival 
effect of exogenous and endogenous VEGF (figure 7.5). PTK787/ZK222584 does not appear 
to have been used experimentally in the literature to block the effects of VEGF-R3 auto- 
phosphorylation by VEGF. These results demonstrate that external VEGF mediated [Ca2']i 
effects are at least partially VEGF-RI dependent and are possibly also VEGF-R3 dependent. I 
can not draw any conclusions on VEGF-RI mediated VEGF survival signalling in cultured 
podocytes. 
Wortmannin, a PD-Kinase inhibitor, dose dependently increased cytotoxicity in PCPs within 
the range whereby Wortmannin had no non-specific toxic effects (figure 7.6), although in 
hCIPs the concentration at which Wortmannin blocked the reduction in cytotoxicity induced 
by VEGF was beyond the range whereby Wortmannin only had an effect on PD-Kinase. This 
suggests Wortmannin had non-specific cytotoxic effects past a given concentration, as 
discussed by Wyman et al, 1996 (Wymann et al., 1996), particularly in hCIPs. This may be 
due to a number of factors, for example hCIPs may have had lower serum starved induced 
levels of P13-Kinase, or they may have been seeded at a lower density, as discussed for figure 
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3.1 IB in chapter 3. In PCPs Wortmannin is most likely to be acting on P13-kinase activated 
by VEGF-R1 auto-phosphorylation. VEGF-R2 is not expressed and VEGF cannot interact 
directly with VEGF-R3. VEGF-R1 auto-phosphorylation can induce the activation of P13- 
Kinase in VEGF-R1 -expressing insect cells (Yu et al., 2001b), but the effects of Wortmannin 
on the activity of VEGF-R1 induced P13-Kinase activity have not yet been assessed. It is 
therefore not known if Wortmannin can block the activation of P13-Kinase, by VEGF-RI 
autophosphorylation at the same concentration as it is effective against VEGF-R2 and VEGF- 
R3. It is possible that P13-Kinase can also be activated by the indirect auto-phosphorylation of 
VEGF-R3. 
These results demonstrate that the VEGF induced reduction in [Ca 2 Ji in cultured podocytes 
was class III tyrosine kinase dependent. Although the receptor and the mechanism by which 
VEGF induced a reduction in cytotoxicity in cultured podocytes are as yet undefined, the data 
are consistent with the involvement of VEGF-R1 and P13-Kinase. To investigate this survival 
pathway further the direct effects of VEGF on AKT phosphorylation will be determined. 
Reduced cytotoxicity in cultured podocytes has also been associated with nephrin 
phosphorylation (reduced apoptosis) in a P13-Kinase/AKT phosphorylation dependent 
manner, as discussed in the introduction. This is another potential mechanism to investigate 
the role of VEGF in podocyte survival. Much of the work from this chapter was published in 
paper I of the list of publications arising from this work. 
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Chapter 8 
VEGF mediated induction of nephrin phosphorylation and survival 
signalling in cultured podocytes 
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8.1 Introduction 
The results of the previous chapter were consistent with the hypothesis that VEGF reduced 
cytotoxicity in cultured podocytes by activating PD-Kinase. I therefore continued to persue 
this line of investigation. There is some evidence in the literature to show that the 
phosphorylation of nephrin at the podocyte slit diaphragm induces the activation of P13- 
Kinase, which induces the phosphorylation of AKT (Huber et al., 2003c). Phosphorylated 
AKT is known to induce the phosphorylation and inactivation of the pro-apoptotic family 
member, Bad, resulting in inhibition of apoptosis (Gerber et al., 1998a). Nephrin and VEGF 
have therefore both been linked to survival signalling in podocytes. Nephrin can be 
phosphorylated by various members of the Src family kinases including Fyn, Lyn and Yes 
(Lahdenpera et al., 2003) (Verma et al., 2003). In vascular endothelial cells VEGF can 
activate members of the Src family kinases (Chou et al., 2002). Interestingly, in these cells 
Fyn and Lyn show preferential binding to VEGF-R1 whereas Src preferentially binds to 
VEGF-R2 (Chou et al., 2002). It is possible, therefore, that VEGF can activate members of 
Src family kinases in podocytes and induce the phosphorylation of nephrin via VEGF-Rl, 
which may allow activation of PD-Kinase and result in reduced apoptosis. I therefore 
investigated whether VEGF could induce the phosphorylation of nephrin. Various parameters 
of the P13-Kinase/AKT pathway were then studied in relation to VEGF-nephrin signalling 
such as AKT phosphorylation and apoptosis to verify that VEGF did activate the P13- 
Kinase/AKT phosphorylation survival pathway in cultured podocytes. The human 
conditionally immortalised nepluin mutated (NMhCIP) and nephrin deficient (NDhCIP) cell 




&ZI Immunoprecipitation (IP)-VEGF inducedphosphorylation of nephrin 
Serum starved, differentiated hCIPs were treated with I nM recombinant VEGF protein for 20 
minutes, a neutralising monoclonal antibody to VEGF for 24hrs, or left untreated for an 
appropriate length of time. Protein was extracted and quantified. Cell lysates were incubated 
with a total of I gg of mouse monoclonal IgG2b anti-phospho-tyrosine primary antibody (P-Y) 
overnight then incubated for 2hrs with protein A/G slurry, as described in the methods. The 
pellet and supernatant were subjected to SDS PAGE and transferred to a PVDF membrane. 
The membrane was probed with 1: 300 rabbit polyclonal IgG anti-nephrin primary antibody (a 
kind gift from Karl Tryggvasson) in 5% non-fat milk blocking solution and 0.03gg/ml FIRP 
conjugated goat polyclonal anti-mouse IgG secondary antibody in 5% non-fat milk blocking 
solution. The membranes were stripped and re-probed with O. OSAglml anti-p-Y primary 
antibody in 1.5% BSA blocking solution and 0.003gg/ml of HRP conjugated anti-mouse 
secondary antibody. The p-Y probe was used to show that tyrosine phosphorylated proteins 
had been immunoprecipitated and also showed other bands of unidentified proteins that had 
also been tyrosine phosphorylated by treatment with VEGF or serum starvation. 
&22Apoptosis assay-VEGF induced nephrin signalling 
Nephrin mutated and nephrin deficient podocyte cell lines (NMhCIPs and NDhCIPs) were 
serum starved for either 16hrs or 4hrs then treated with InM VEGF in serum free media for 
4hrs or left untreated. Cells were scraped into suspension in serum free media and rolled for a 
further 4hrs. Each treatment group was then incubated with either AV, PI AV with PI or left 
untreated. Samples were assayed using the flow cytometer and necrotic and apoptotic sub- 
populations were quantified, as a percentage of the total cell population. 
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8.23 Western blotting- VEGF-induced AKT signalling 
Serum starved hCIPs and NDhClPs were either treated with InM VEGF for 20 minutes, a 
neutralising monoclonal antibody to VEGF for 24hrs or left untreated for the appropriate 
amount of time. Serum starved HUVECs were either left untreated or treated with IOOmM 
ethanol for 30 minutes to act as a positive control for AKT phosphorylation (Liu et al., 2002). 
Membranes were probed with Igg/ml mouse monoclonal anti-phospho-AKT (p-ser 472/473) 
primary antibody (BD Bioscience, Oxford, UK) in 5% non-fat milk blocking solution and 
O. Olgg/ml IIRP conjugated anti-mouse secondary antibody in 5% non-fat milk blocking 
solution. Membranes were then stripped and re-probed with Igg/ml. mouse monoclonal anti- 
AKF antibody (20OAg/ml) and O. Olgg/ml HRP conjugated anti-mouse secondary antibody. 
Densitometry analysis of the appropriate bands (at 6OkDa) was carried out using NIH ftnage 
software, and then phospho-AKT was normalised to total AKT. 
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8.3 Results 
8.3.1 VEGF inducedphosphorylation of nephrin. 
hCIPs were incubated with VEGF, a neutralising monoclonal antibody to VEGF, or left 
untreated. Tyrosine phosphorylated proteins were immunoprecipitated and then PVDF 
membranes, containing protein from immunoprecipitate and supernatant were probed with an 
anti-nephrin antibody to assess whether nephrin had been tyrosine phosphorylated in any of 
the treatments. There was a greater intensity of a band corresponding to nephrin (180kDa) 
when hCIPs were incubated in VEGF in the phospho-tyrosine precipitate compared to the 
supernatant (figure 8.1 A, lanes 2 and 3). The intensity of the band corresponding to nephrin 
was of a similar intensity in the phospho-tyrosine precipitate compared to the supernatant of 
serum starved hCIPs with no VEGF treatment (figure 8.1 A, lanes 4 and 5). Nephrin 
phosphorylation, normalised to total nephrin (the sum of the supernatant and precipitate 
bands) in cells treated with VEGF was 3.36: 0.21 fold greater than that in serum starved cells 
(p<0.05, figure 8.1 B). Nephrin appeared to be constitutively phosphorylated in serum starved 
hCIPs (figure 8.1 A, lanes 4 and 5) and approximately 50% of total nephrin expression was in 
the precipitate. To investigate if this constitutive phosphorylation was induced by endogenous 
VEGF cells were incubated with a neutralising monoclonal antibody to VEGF. The intensity 
of the band corresponding to nephrin in cells incubated with the neutralising monoclonal 
antibody to VEGF was barely detectable in the phospho-tyrosine precipitate compared to the 
supernatant. Nephrin phosphorylation normalised to total nephrin in hClPs incubated in a 
neutralising monoclonal antibody to VEGF was 0.21±0.09 fold lower than that in serum 
starved cells (Figure 8.1 B). The reduction in nephrin phosphorylation induced by the 
neutralising monoclonal antibody to VEGF suggested that the majority of constitutive nephrin 
phosphorylation was due to endogenous VEGF. 
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Figure 8.1. Exogenous and endogenous VEGF induces nephrin phosphorylation in hClPs. 
Serum starved hCIPs were treated with VEGF, VEGF-Mab, or left untreated. Protein was 
immunoprecipitated using an anti-p-V antibody. Both the lysate and precipitate were subjected to SDS 
PAGE, transferred to a PVDF membrane and probed with an anti-nephrin antibody. A. An example of 
immunodetection with an anti-nephrin antibody for lysate and precipitate is shown for each treatment 
group. VEGF treatment resulted in increased nephrin phosphorylation compared to that of serum starved 
cells (2 vs 4), whereas there was attenuated constitutive nephrin phosphorýlation in cells that were pre- 
incubated with VEGF-Mab compared to that of serum starved cells (6 vs 4). Protein extracted from renal 
cortex demonstrated the correct molecular weight for nephrin (180kDa) (1). B. Data were expressed as 
mean+SEM of densitometry ratios: (treated ppt/serum starved ppt)/(treated s-n/serum starved s-n). 
VEGF treatment resulted in an increase in nephrin phosphorylation compared to that of serum starved 
cells whereas VEGF-Mab treatment resulted in a decrease in nephrin phosphorylation compared to that of 
serum starved cells. *=p<0.05 unpaired f-test, n=6 and 4 respectively. Ppt = precipitate, s-n = supernatant. 
These results show that both exogenous and endogenous VEGF induce the phosphorylation of 
nephrin. It is known that VEGF reduces cytotoxicity in cultured podocytes and that VEGF 
induces phosphorylation of nephrin. The next stage of the investigation was to assess the 
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VEGF VEGF-Mab 
consequences of this. My hypothesis was that VEGF promoted survival in podocytes through 
the phosphorylation of nephrin and the subsequent reduction in apoptosis. The effect of 
nephrin on the VEGF mediated reduction in apoptosis was, therefore, investigated. 
8.3.2 VEGF- nephrin apoptosis signalling 
NMhClPs and NDhCIPs were serum starved for 16hrs, the media replaced with fresh serum 
free media and left for 4hrs, then the cells were scraped into a cell suspension and rolled for a 
further 4 hrs a total of 24hrs serum starvation. Samples were then incubated in AV, PI, AV 
with PI or left untreated. They were then assayed using a flow cytometer and compared to 
previous results with hCIPs serum starved for the same time period. These results showed that 
there were significant differences in levels of induction of apoptosis between normal and 
nephrin-mutated podocytes. Of the total cell population 4.43±0.52% of NMhClPs stained 
with PI alone (i. e. met the criteria for necrotic cells), which was significantly lower than hClPs 
(33.5±4.65) and NDhCIPs (29.1±4.23%, p<0.01, AVOVA, figure 8.2). There was only a 
significant induction of cells staining with just AV (i. e. met the criteria for apoptotic cells) in 
NMhClPs; 25.3±2.1% of the total cell population compared to 2.17±0.4% in hClPs and 
9.12±2.7% in NDhCIPs (p<0.01, ANOVA figure 8.2). The induction of a significant AV 
stained population in NMhCIPs indicated that these cells were more sensitive to apoptosis, 
presumably due to the mutation in the Ig5 domain of the extracellular domain in nephrin, 
which may interfere with nephrin-nephrin interaction. This may make the cells less stable in 
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Figure 8.2. The induction of apoptosis in nephrin mutated/deficient hCIPs compared to normal hCIP. s for 
a total of 24hrs. 
Cells were serum starved for 16hrs, the media replaced and left for 4hrs, then the cells were scraped into 
suspension and rolled for a further 4hrs. Cells were then assayed using a flow cYtometer. A. Comparison 
of AV and PI labelling of hCIPs, NMhCIPs and NDhCtPs, serum starved for a total of 24hrs. NMhClPs 
and NDhCIPs show a greater apoptotic cell population than hClPs. B. Characteristics of cell populations 
in serum starved hCIPs compared to NMhCIPs and NDhCIPs. Necrotic hCIPs account for a significant 
proportion of the total population, whereas in NMhCIPs apoptotic cells account for a significant 
proportion of the cell population. With NDhCtPs necrotic cells accounted for a greater proportion of the 
cell population than apoptotic cells. Data were expressed as mean+SEM percentage of total population. 
Serum starvation in NMhCIPs significantly increased apoptosis and significantly decreased necrosis 
compared to hCIPs and NDhCIPs. p<0.05 unpaired ANOVA., **= p<0.01 Bonferroni test. 
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8.3.3 Effect of VEGF on apoptosis in Nephrin nwtated cellk 
To determine the effects of VEGF on apoptosis in these three cell types assays were developed 
that resulted in approximately equal levels of apoptosis by serum starvation. The increased 
sensitivity to apoptosis in NMhCIPs, due to the nephrin mutation, provoked some surprise in 
that levels of apoptosis were relatively low in the NDhCIPs. There was some apoptosis and it 
may have been that the cells had already undergone apoptosis. If this were the case then a 
larger population of late apoptotic cells would be seen and was not. It is possible that the 
apoptotic bodies were formed well before the cells were assayed, this would mean that they 
would be under the size limit picked up by the discriminator on the flow cytometer and would 
not be included in the experiment. This was also suggested by the reduction in cell number in 
this assay (there are fewer events described in figure 8.2 Aiii, than in all the other protocols). 
A protocol on a much shorter timescale would therefore be needed to assess apoptosis in 
NDhCIPs, and was thus developed. 
Even though the 24hr time course protocol was based on that used for the cytotoxicity assay, it 
did not induce apoptosis in normal podocytes (hCIPs). There was, however, a lot of necrosis 
induced in hCIPs, but this was not significantly reduced with VEGF treatment, as discussed 
for figure 6.4. Due to the robust nature of normal differentiated podocytes it was assumed that 
the hCIPs had not yet undergone apoptosis at this time in this specific assay. An assay over a 
longer time period was therefore developed, which induced significant apoptosis and was 
significantly reduced by VEGF (as discussed for figure 6.6). The NDhCIPs were serum 
starved forjust 4hrs, scraped into a cell suspension and rolled for a further 4hrs, then assayed 
by flow cytometry. The results of this are compared, in figure 8.3, to the NMhCIPs, serum 
starved for a total of 24hrs, as described for figure 8.2, and WIN serum starved for a total of 
72hrs, as described for figure 6.6. 
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Figure 8.3. Time courses used to induce apoptosis in hCIPs, NMhClPs and NDhClPs- 
hCIPs were serum starved for a total of 48hrs, NMhCIPs were serum starved for a total of 24hrs and 
NDhCIPs for a total of 8hrs. Cells were then assayed using a flow cytometer. A. A comparison of AV and 
PI labelling of hCIPs, NMhCl[Ps and NDhCIPs that had been serum starved. A Substantial apoptotic 
population was seen for all cell types. B. Characteristics of cell populations in serum starved hCtPs 
compared to NMhCIPs and NDhCtPs. A significant proportion of the total population was apoptotic in all 
cell types, although the greatest induction of apoptosis was seen in hCIPs, under the serum starvation time 
course used. C. Data were expressed as mean+SEM percentage of total population. Chronic serum 
starvation in hClPs resulted in a significant reduction in viable cells and a significant increase in apoptosis 
compared to NMhCIPs and NDhClPi. **=p<0.01 unpaired ANOVA. SS = serum starvation. 
A significant level of AV staining (i. e. met the criteria for apoptotic cells) was induced in each 
of the cell types under the time period of serum starvation chosen. 37.6±6.1 % of the total cell 
population of hClPs serum starved for a total of 48 hrs, which was significantly greater than 
both NMhC[Ps (25.32±2% of the total cell population, when serum starved for a total of 
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24hrs) and NDhCIPs (22.1±4.7% of the total population, when serum starved for a total of 
8hrs, p<0.001, ANOVA, figure 8.3). There was also a significantly lower percentage of hClPs 
staining with neither AV nor PI (i. e. met the criteria for viable cells) (33.8±6.7% of the total 
cell population) compared with NMhCIPs (58.1±2.3% of the total cell population) and 
NDhClPs (66±2.5% of the total population, p<0.01, ANOVA, figure 8.3). These results 
suggest that sensitivity of podocytes to apoptosis is nephrin dependent. Using these optimised 
time courses, the effects of VEGF on apoptosis could be investigated on nephrin mutated 
podocytes. 
NMhCIPs were serum starved for 16hrs, incubated in VEGF, or left untreated for 4hrs, then 
scraped into a cell suspension and rolled for a further 4hrs. Cells were then assayed using the 
flow cytometer, and sub-populations of cells were compared between treatments. There was a 
significant reduction in NMhCIPs stained with AV (i. e. met the criteria for apoptotic cells) in 
those cells incubated in VEGF (15.1±1.53% of the total cell population) compared to 
untreated cells (25.3±2.01% of the total cell population, p<0.05, ANOVA, figure 8.4). The 
population stained with neither PI nor AV (i. e. met the criteria for viable cells) was slightly 
although not significantly larger in NMhCIPs incubated in VEGF (62.6±2.40% of the total cell 
population) compared to untreated (58.1±2.25% of the total population). This was probably 
because there was also a similar small, but not significant, increase in NMhCIPs stained only 
with PI (i. e. met the criteria for necrosis), incubated in VEGF (8.7: LO. 93% of the total cell 
population) compared to untreated (4.43±0.52% of the total cell population). 
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Figure 8.4. VEGF reduces apoptosis in podocytes with a missense in the Ig5 motif of nephrin. 
NNIhCIPs were serum starved for 16hrs, incubated in VEGF for 4hrs or left untreated, then scraped into 
suspension and rolled for 4hrs. Cells were then assayed by a flow cytometer. A. Comparison (of AV and PI 
labelling of InM VEGF treated NMhCIPs compared to serum starved NMhClPs. There in-as a reduction of 
cells in the apoptotic population of NMhClPs, treated with VEGF, compared to untreated. B. 
Characteristics of cell populations in InM VEGF treated NMhClPs compared toserum starved NMhCIPs. 
There was a reduction in apoptosis as a proportion of the total cell population in cells treated with VEGF 
compared to untreated. C. Data were expressed as mean+SEM of the total cell population. Compared to 
serum starvation alone, VEGF treatment significantly reduced apoptotic cells. *=p<0.05. Bonferroni n=4 
in all. 
The percentage of AV positive cells of the total fluorescence picked up at 525nm (minus the 
background) in the VEGF treatment were normalised to that of cells that had been serum 
starved. There was no significant reduction in AV positive cells when treated with VEGF 
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compared to serum starvation (1.32±0.23 fold change, p=0.249, one sample Mest, n--4, not 
shown). This contradicts the results shown in figure 8.4, but this is likely due to the inclusion 
of the late apoptotic data (AV and PI) in the AV positive cells, which overwrites moderate 
changes in the apoptotic population. From figure 8.4 and previous figures it seems that there 
is a necrotic/apoptotic balance that is affected by VEGF. These results demonstrate that there 
was no significant difference in effects of VEGF on apoptosis between normal podocytes 
(hCIP) and podocytes with a mutation in the Ig5 extracellular domain of nephrin. This 
suggests that VIEGF does not interact with the Ig5 motif of nephrin. 
To ascertain whether nephrin is involved in the VEGF induced reduction in apoptosis at all I 
measured the effects of VEGF on nephrin deficient cells (NDhClPs). NDhCEPs were serum 
starved for 16hrs, treated with VEGF for 4hrs, or left untreated, then scraped into suspension 
and rolled for a further 4hrs. Cells were then assayed using a flow cytometer. This time 
course of serum starvation was chosen over a total of 8hrs because a significant amount of 
both apoptotic and necrotic populations were seen in figure 8.3 Biii, which allows the effects 
of VEGF on necrosis and apoptosis to be measured simultaneously. There was no significant 
difference seen in any of the cell sub-Oopulations between VEGF treated and untreated 
NDhCIPs (figure 8.5). There was also no significant change in AV positive cells (expressed 
as a percentage of total fluorescence picked up at 525nm) in VEGF treated cells when 
normalised to serum starved cells (1.03±0.11 fold change, p=0.78, n=3, not shown). 
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Figure 8.5. The effects of VEGF on serum starved nephrin deficient podocytes (NDhCIPs) 
NDhCIPs were serum starved for 16hrs, then treated with VEGF for 4hrs, or left untreated. Cells were 
then scraped into suspension and rolled for a further 4hrs then assayed using a flow cytometer. A. A 
Comparison of AV and PI labelling of InM VEGF treated NDhCIPs compared to serum starved 
NDhCEPs. There was no difference seen between cell sub-populations of cells treated with VEGF 
compared to those left untreated. B. Characteristics of cell populations in chronically serum starved InM 
VEGF treated NDhCIPs compared to untreated NDhCIPs. The cell Sub-populations, expressed as a 
percentage of the total cell population were the same in both VEGF treated and untreated cells. C. Data 
were expressed as mean+SEM percentage of the total cell population. Compared to serum starvation 
alone VEGF treatment had no significant effect on any of the cell populations (n. s. ANOVA, n=5). 
These results demonstrate that VEGF had no significant effect on apoptosis induced by serum 
starvation in podocytes deficient in nephrin. The reduction in apoptosis in cultured podocytes 
induced by VEGF may, therefore, be nephrin dependent. Since nephrin phosphorylation leads 
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to the activation of P13-Kinase and P13-Kinase is known to phosphorylate AKT it is 
reasonable to predict (since we have not yet ruled it out) that VEGF-nephrin signalling is also 
dependent on AKT phosphorylation by PB-Kinase activation. 
8 3.4 VEGF inducedphosphorylation qfAKT 
To investigate whether the effects of VEGF on AKT phosphorylation were dependent on 
nephrin in cultured podocytes hCIPs and NDhCIPs were treated with VEGF or left untreated. 
To determine whether AKT phosphorylation could be effectively measured and to facilitate 
quantitation HUVECs were treated with ethanol or left untreated as a positive control for 
induction of AKT phosphorylation. Protein was extracted, run on a gel and transferred to a 
PVDF membrane. Membranes were probed with anti-phospho-AKT and anti-AKT antibodies 
and the intensity of the phospho-AKT bands was normalised to that of the total AKT bands. 
The comparison between AKT phosphorylation in hClPs and NDhCIPs is shown in figure 8.6. 
I predicted that there would be an increase in AKT phosphorylation in hCIPs treated with 
VEGF, but a decrease in AKT phosphorylation in NDhClPs treated with VEGF was seen 
when compared to untreated cells. An example of membranes from the experiments described 
are shown in figure 8.6 A. Membranes containing protein of both hCIPs and NDhCIPs treated 
with VEGF or left untreated showed a band that corresponded to total AKT (60kDa) of similar 
intensities. The membrane containing hCIP protein was stripped and re-probed with an anti- 
phospho-AKT antibody and surprisingly demonstrated a lower intensity of band 
corresponding to phospho-AKT in VEGF treated cells compared to untreated cells. The 
membrane containing NDhCIP protein was also stripped and re-probed with an anti phospho- 
AKT antibody and surprisingly demonstrated a greater intensity of band corresponding to 
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Figure 8.6. The effects of InM VEGF on AKT phosphorylation in hClPs compared to that of NDhClPs. 
PVDF membranes containing protein extracted from hCIPs and NDhCIPs, which were treated with InM 
VEGF, or left untreated, were probed with an anti phospho-AKT antibody, stripped and re-probed with 
an anti-AKT antibody. A. An example of membranes probed with anti-AKT and anti-phospho-AKT 
antibodies from each experiment. Bands corresponding to phospho-AKT (60kDa) were less intense in 
VEGF treated hCEPs, compared to untreated hCIPs and were more intense in NDhClPs treated with 
VEGF compared to untreated. B. Data were expressed as mean+SEM ratios: phospho-AKT 
(treatment/control)/total AKT (treatment/control). AKT phosphorylation induced by InM VEGF was 
significantly lower in hCEPs then in NDhCIPs. AKT phosphorylation induced by VEGF in NDhClPs was 
not significantly different to serum starvation. *= p<0.05, ***= p<0.001 unpaired Mest compared to serum 
starved cells or as indicated, n=5. Treated =I nM VEGF, SS = serum starved. 
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The reduction in normalised AKT phosphorylation in hC1Ps treated with VEGF was 
significantly lower than untreated hC1Ps (0.35±0.06 fold reduction in AKT phosphorylation, 
compared to untreated cells, p<0.05, one sample Mest, figure 8.6). Increases in normalised 
AKT phosphorylation in NDhCEPs treated with VEGF were not significant compared to 
untreated NDhC1Ps (1.73±0.29 fold increase in phosphorylated AKT, compared to untreated 
cells, figure 8.6). Normalised AKT phosphorylation though was significantly higher in 
NDhCIPs, treated with VEGF compared to hCIPs treated with VEGF (p<0.001, unpaired I- 
test, figure 8.6). An observation was made of a difference between levels of AKT 
phosphorylation in serum starved cells in hC1Ps and NDhCIPs, as shown in figure 8.7. AKT 
phosphorylation induced by serum starvation expressed as a fold increase of ethanol induced 
AKT phosphorylation was significantly higher in hCIPs than in NDhC1Ps (hClPs 2.91±0.93 
fold increase and NDhCIPs (0.70±0.29 fold increase compared to ethanol induced AKT 
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Figure 8.7. Basal AK-T phosphorylation in hCIPs compared to NDhCIPs. 
A comparison was made between levels of AKT phosphorylation in serum-starved hClPs and NDhClPs. 
The data were re-analysed from the experiments shown in figure 8.6. Data were expressed as mean+SEM 
ratios: phospho-AKT (serum starvation/positive control)/total AKT (serum starvation/positive control). 
Basal AKT phosphorylation was significantly higher in hCIPs then it was in NDhClPs. *= p<0.05 unpaired 
t-test, n=3 and 5 respectively). Ethanol = ethanol treated HUVECs, SS = serum starved 
If endogenous V-EGF could also induce an effect on AKT phosphorylation in hClPs then it 
might be predicted that treatment of hCIPs with a neutrallsing monoclonal antibody to VEGF 
would significantly increase phosphorylated AKT compared to serum starvation. This was not 
the case as shown in figure 8.8. Treatment of hCIPs with a neutralising monoclonal antibody 
to VEGF had no significant effect on normalised AKT phosphorylation compared to serum 
starved cells. AKT-phosphorylation was significantly increased however compared to cells 
treated with VEGF (VEGF-Mab 1.02±0.19 fold increase compared to serum starved cells, 
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Figure 8.8. Effects of VEGF-Mab compared to VEGF treatment on AKT phosphorylation in hCIPM. 
Serum starved hCIPs were either treated with VEGF, VEGF-Mab or left untreated. Protein was 
extracted, subjected to SDS PAGE, transferred to a PVDF membrane and probed with an anti-phospho- 
AKT antibody, stripped and re-probed with an anti-AKT antibody. Data were expressed as mean+SEM 
ratio: phospho-AKT (treatment/control)/total AKT (treatment/control). VEGF-Mab did not significantly 
effect phospho-AKT levels compared to control but was significantly different to the VEGF induced 
reduction in AKT phosphorylation. *= p<0.05 unpaired I-test, n=5. SS = serum starved. 
These results suggest that endogenous VEGF does not have an effect on AKT phosphorylation 
in hClPs, or at least not external effects of endogenous VEGF, if endogenous VEGF acted 
externally, then the neutralising monoclonal antibody to VEGF would be able to block the 
effects of endogenous VEGF. 
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Together, these results show that VEGF can induce nephrin phosphorylation and that the 
reduction in apoptosis induced by VEGF in cultured podocytes is dependent on normal 




VEGF has been shown to induce nephrin phosphorylation, as shown in figure 8.1. This figure 
also shows that endogenous VEGF stimulated the constitutive phosphorylation of nephrin in 
serum starved podocytes, which was inhibited by a neutralising monoclonal antibody to 
VEGF. A proportion of cell survival was hypothesised to be a consequence of VEGF- 
mediated nephrin signalling in cultured podocytes. This was investigated using nephrin 
mutant and nephrin deficient podocyte cell lines in apoptosis assays. 
The first observation made was that podocytes are more susceptible to apoptosis if they 
express a nephrin mutant and even more so if they are nephrin deficient (figure 8.2 and 8.3). 
This was identified by the time taken for a similar level of apoptosis to be achieved in each of 
the podocyte cell lines (between 2040% of the total cell population). The nephrin mutant 
cells (NMhClPs) have a mutation in the Ig5 motif of the extracellular domain of nephrin. This 
should not directly influence nephrin survival signalling because survival signalling is 
postulated to occur at the tyrosine residues of the intracellular domains. It is possible that 
head to head nephrin-nephrin interactions may be disrupted as is postulated to occur using the 
first 6 Ig motifs (figure 1.9, chapter 1). This may have a number of effects. For example it 
may make the cultured podocytes less stable due to the disruption of cell-cell interactions 
(Khoshnoodi et al., 2003). Isolation of podocytes from each other in culture may increase 
their vulnerability, just as lower confluency would. Nephrin-nephrin interactions may result 
in constitutive nephrin phosphorylation in the same way that overexpression of nephrin on 
HEK 293 cells causes clustering and phosphorylation of nephrin (Lahdenpera et al., 2003). A 
mutation in the part of the nephrin extracellular domain that mediates homophilic binding, 
therefore, may indirectly affect nephrin phosphorylation and P13-Kinase activation. This 
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would ultimately result in increased susceptibility to apoptosis induced by serum starvation. 
Using this reasoning I predicted that nephrin deficient podocytes would have lower 
constitutive P13-Kinase activity and would be susceptible to apoptosis to an even greater 
degree. It became clear when comparing these different serum starvation time course 
apoptosis assays between the different cell types that necrotic and apoptotic sub-populations 
were mutually exclusive. When apoptosis levels were high necrotic levels were low and vice 
versa. Looking at figures 8.2 to 8.4 it seems that necrotic and apoptotic subpopulations in 
each cell population always equates to approximately 40% of the total population. It may be 
that there is cross talk between the apoptotic and necrotic pathways in podocytes. 
VEGF reduced apoptosis induced by serum starvation in NMhCIPs (figure 8.4). This is not 
surprising as it was thought that VEGF could induce nephrin phosphorylation indirectly via 
activation of Src family kinases. A mutation limited to the extracellular domain should not in 
theory therefore affect the intracellular tyrosine kinase activation of nephrin by cytosolic Src 
family kinases. The extracellular domain of nephrin is thought to be predominantly involved 
in integrin interaction. Therefore, it is unlikely that VEGF would be able to bind to the 
extracellular domain to induce intracellular signalling. VEGF had no significant effect on 
NDhCIPs (figure 8.5). This demonstrates that the VEGF mediated reduction in apoptosis is 
nephrin dependent. 
It has been shown that VEGF mediated survival signalling is dependent on nephrin signalling 
in podocytes and that VEGF can induce the phosphorylation of nephrin. it is also known that 
the phosphorylation of nephrin can induce the activation of P13-Kinase, therefore it is 
reasonable to assume that AKT phosphorylation was also implicated (Gerber et al., 1998a). 
The effects of VEGF on AKT phosphorylation were therefore investigated in hC1Ps and 
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NDhCIPs. Surprisingly, VEGF induced a reduction in serum starvation induced AKT 
phosphorylation (figure 8.6). The effects of VEGF on AKT phosphorylation in NDhCIPs 
were assessed to see if nephrin was mediated in the VEGF intracellular apoptosis-signal ling 
pathway. This also provided unexpected results: VEGF increased AKT-phosphorylation, 
induced by serum-starvation in NDhC1Ps (figure 8.6). The evidence in chapter 7 suggesting 
that VEGF reduced cytotoxicity by activating P13-Kinase was inconclusive, but it may be that 
VEGF-nephrin mediated survival signalling is independent of AKT phosphorylation. It is 
worth noting that normal podocytes (hCIPs) have elevated levels of AKT phosphorylation 
when serum starved compared to that of nephrin deficient podocytes (NDhCIPs) and hCIPs 
enter apoptosis after a longer time period compared to NDhCIPs. This suggests that levels of 
AKT phosphorylation in podocytes are dependent on normal nephrin expression and play a 
role in cytoprotection, independent to that of VEGF. This was supported by figure 8.8 where 
the external effects of endogenous VEGF were blocked using a neutralising monoclonal 
antibody to VEGF. When endogenous VEGF was blocked there was no significant change in 
AKT phosphorylation compared to serum starvation. 
These results suggest that the VEGF induced reduction in apoptosis in cultured podocytes is 
dependent on nephrin phosphorylation. VEGF does not appear to signal through AKT 
phosphorylation. Much of the work from this chapter has been accepted for publication in 
paper 3 of the list of publications arising from this work. 
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Chapter 9 
The effects of VEGF-C on cultured podocytes 
200 
9.1 Introduction 
It is intriguing that podocytes express VEGF-R3, a receptor activated by members of the 
VEGF family VEGF-C and VEGF D. VEGF-R3 is expressed on various tissues such as the 
spleen, brain, and epithelial cells of fetal lung (Pajusola et al., 1992), although it is 
predominantly expressed on lymphatic endothelial cells (as reviewed in (Jussila and Alitalo, 
2002)). There is no evidence to date to suggest that VEGF can activate VEGF-R3, however it 
has been suggested that VEGF-R3 can negatively modulate VEGF-R2 (Matsumura et al., 
2003). This would suggest that VEGF-R2 and VEGF-R3 can interact and VEGF may then be 
able to modulate VEGF-R3 via VEGF-R2. Podocytes do not express VEGF-R2 however and 
there is no evidence as yet to indicate that VEGF-R1 and VEGF-R3 can interact. The question 
therefore remains; is VEGF-R3 functional in podocytes? 
Recent unpublished results from this laboratory show in situ VEGF-C protein expression in 
human kidney tissue sections (figure 9.1 A and B). These sections demonstrate that although 
VEGF-C protein is expressed by podocytes it is not expressed by every podocyte and it is 
possible that other glomerular cells also express VEGF-C. If podocytes do produce VEGF-C 
protein then it is possible that it may also be involved in an autocrine loop binding and 
activating VEGF-R3 (as reviewed in (Jussila and Alitalo, 2002)). VEGF-C promotes similar 
survival pathways via VEGF-R3 (Makinen et al., 2001) as VEGF does via VEGF-R2. This 
VEGF-R3 activation by VEGF-C leads to phosphorylation of AKT and reduced apoptosis as 
well as PKC dependent activation of p42/p44 MAPK, which has also been linked to survival 
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Figure 9.1. In sitw VEGF-C protein expression by podocytes (courtesy of Miss YL Joory)- 
Immunohistochemistry was carried out on sections of human renal cortex using an antibody specific to 
VEGF-C. A-C show sections through a glomerular tuft surrounded by Bowmans' space (BS) and 
encapsulated by parietal epithelial cells (PECs). An example of a capillary is shown in each section (Cap) 
and the scale bar for each section is 20gM. A and B show examples of brown positive VEGF-C staining in 
podocytes (arrows) situated on the periphery of the glomerular tuft indicating that this protein is 
expressed. It is possible that other glomerular cells, such as mesangial cells, also express VEGF-C, because 
not all of the brown staining can be defined micrco-anatomically as podocytes. C. Cells incubated with 
just the normal IgG were counterstained with haematoxylin (top RH corner), which is the blue nuclear 
stain (shown by the arrowheads) and did not show any brown staining. 
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The VEGF/VEGF-C survival pathways are very similar, but follow different time courses. For 
example in HMVECs AKT phosphorylation by VEGF peaked between 20 and 30 minutes 
after initial exposure whereas AKT phosphorylation by VEGF-C peaked at 10 minutes and 
VEGF-C induced a more prolonged upregulation of phosphorylated MAPK (Makinen et al., 
2001). Interestingly, AKT phosphorylation induced by VEGF-C is independent of P13-Kinase 
activation in these cells. To investigate whether VEGF-C plays a signalling role in podocytes 
a similar approach was used to that of investigating VEGF signalling in podocytes. The 
effects of VEGF-C on [Ca? ji, cytotoxicity and apoptosis was investigated in cultured 
podocytes to assess if VEGF-C could exert an effect in podocytes and whether it promoted 
survival in a similar manner to VEGF. AKT/N4APK signalling pathways were studied to 
investigate similarities between VEGF and VEGF-C signalling. 
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9.2 Methods 
9.21 [Ca2'jj nwasurenwnts- VEGF-C signalling 
hC1Ps were incubated in H13SS containing minimal [Ca2+],,. If the effects of VEGF-C were 
similar to that of VEGF then a reduction in [Ca2jj would not be detected in the presence of 
1.3mM [Ca 21". Cells were treated with InM human recombinant VEGF-C protein (a kind gift 
from Kari Alitalo) as described for InM VEGF. Ionomycin was used towards the end of each 
experiment to ensure that the system was still measuring changes in [Ca2jj i. e. the Fura-2 had 
not quenched and the cells were still alive. Manganese was used at the end of each experiment 
to quench the Fura-2 signal, to achieve an Rin measurement. 
9.2 2 Cytotoxicity assay- VEGF- C signalling 
Serum starved hCIPs were treated with InM VEGF-C in fresh serum free RPMI media or with 
fresh serum free RPMI media for 24hrs. Low, experimental and high LDH controls were 
assayed using a colourimetric assay, and cytotoxicity was calculated as described in the 
methods. 
9.23 Apoptosis assay-VEGF-C signalling 
hCIPs were chronically serum starved for 16hrs, treated with fresh serum free RPMI media 
containing InM VEGF-C, or not for 8hrs. Cells were left for 48hrs in complete RPMI media, 
serum starved for 16hrs, then treated with fresh RPMI media containing InM VEGF-C or not 
for 4hrs, scraped into suspension and rolled for a further 4hrs. Cells were then incubated with 
AV, PI, AV and PI or left untreated and then assayed by a flow cytometer. 
204 
9. Z4 Western Blotting- VEGF- C survival signalling 
Serum starved hCIPs were treated with InM VEGF for 20 minutes, InM VEGF-C for 10 
minutes, a neutralising monoclonal antibody to VEGF for 24hrs or left untreated for the 
appropriate amounts of time. Protein was extracted, quantified and subjected to SDS PAGE. 
Protein was transferred to a PVDF membrane, which was then probed with an anti-phospho- 
AKT and anti-AKT antibody as described previously. Membranes were also probed with 
0.4gg/ml rabbit polyclonal IgG anti-p44/42 MAPK primary antibody (Cell signalling, 
Beverly, USA) and 0.005ptg/ml IIRP conjugated goat anti-rabbit IgG secondary antibody 
(Pierce, Cheshire, UK). Membranes were stripped and re-probed with 0.5gg/ml mouse 
monoclonal anti-phospho p44/42 MAPK (T202/Y204) (Cell Signalling, Beverly, USA) and 
0.005ptg/ml IIRP conjugated goat anti-mouse IgG secondary antibody (Pierce, Cheshire, UK). 
Data were expressed as ratio of treatment/control to total amount of protein. 
9.25 Imnwnoprecipitation- VEGF-C-VEGF-R31nephrin signalling 
Serum starved hClPs were either treated with IW VEGF for 20 minutes, InM VEGF-C for 
10 minutes or left untreated for the appropriate amount of time. Protein was extracted and 
quantified. Tyrosine phosphorylated proteins were immunoprecipitated from the lysate, and 
both pellet and supernatant were subjected to SDS PAGE and transferred to PVDF membrane. 
The membrane was probed with anti-p-Y, and mouse anti-nephrin as previously described. 
Membranes were also probed with 0.5ýig/ml rabbit polyclonal IgG anti-Flt4 (C-20) (VEGF- 




9.3.1 VEGF-C intracelfular signalling in culturedpoilocytes 
To investigate whether VEGF-C exerted a response in hC1Ps the [Ca2+]i response of hCIPs to 
VEGF C was measured. [Ca? +]i measurements were chosen as a method for studying the 
response of hCIPs to VEGF-C for the same reason that it was chosen to investigate whether 
VEGF exerted an effect in cultured podocytes; because [Ca 2+ ]i is a general secondary 
messenger that is involved in many cell signalling pathways. This technique was also chosen 
to compare the [Caýjj signalling effects of VEGF-C with those of VEGF. hC1Ps were 
incubated in HBSS containing minimal [Ca 2+]. and were treated with InM VEGF-C as 
described previously. Changes in [Ca2+]i were measured and compared to the effects of 
VEGF on [Ca 21, in hC1Ps. Interestingly, VEGF-C also reduced [Ca 2+], in hCIPs compared to 
baseline [Ca2jj recordings (figure 9.2 B). The reduction in [C2']i in response to VEGF-C 
was immediate and rapid and approximately 2 fold lower than baseline [Ca 2+ ]j. After 
approximately 2 minutes the [Ca2jj response levelled off and remained a constant 
concentration until the end of the experiment. VEGF-C significantly reduced [C21i by 
0.74±0.09 fold of baseline [Ca 21, (figure 9.2 C, p<0.05, one sample t-test), similarly VEGF 
induced a significant reduction in [Ca2+]i by 0.7±0.1 fold of baseline [C21i (figure 9.2C, 
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Figure 9.2. The effects of VEGF and VEGF-C on the change in lCa 2+]i in hClPs incubated in HBSS 
containing lCa 
2+]ý. 
hCIPs were serum stamed and loaded with Fura-2. VEGF-C was then added to the cells in the presence of 
HBSS containing minimal [Ca 2'],. Fluorescence intensity changes were recorded and used to calculate 
[Ca 2+]i.. Changes in [Ca2-]i in WIN treated with VEGF-C were compared to previous effects of VEGF on 
changes in [Ca 2+1i in hCIPs. A. An example of the effect of VEGF on the change in [Ca 2 +] 1 on hClPs 
showing a reduction in [Ca 21i B. An example of the effect of VEGF-C on the change in ICH 2+1i on hClPs, 
showing a reduction in [Ca 2+]i. C. Data expressed as mean+SEM ratio of treatment/ba. 4eline Ca2+li. 
[Ca 2+1i levels were reduced in hCIPs when treated with both InM VEGF and InM VEGF-C. One sample 
t-test compared to baseline. *= p<0.05, n=5 and 8 respectively. 
These results suggest that VEGF-C may activate a similar [Ca 
21]i 
signalling pathway to VEGF 
2f in hCIPs. The function of reduced [Ca ]i in hCIPs is debatable, yet these results clearly show 
that VEGF-C can stimulate an effect in cultured podocytes. The similar effects of' VEGF-C 
and VEGF on [Ca 2,1 suggests that the function of VEGF-C is also similar. The effects of 
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VEGF VEGFC 
InM VEGF-C were therefore investigated on cytotoxicity induced by seruni starvation in 
hCIPs. In addition, the effects of VEGF-C on cytotoxicity induced bv serum starvation in 
HEK293 cells were also determined to ensure that the effects of VEGF-C on hCIPs were 
VEGF receptor specific. hCIPs and HEK 293 cells were serum starved for 16hrs then the 
media was replaced with fresh serum free media with InM VEGF-C or without. The amount 
of LDH released from the cells into the media was quantified for the low, experimental and 
high controls, using a colourimetric assay, as described in the methods. The percentage 
cytotoxicity was calculated from the densitometry readings of the LDH release. 
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Figure 9.3. A comparison between the effects of InM VEGF and InM VEGF-C (on c-vtotoxicitN in WIPS 
and between the effects of VEGF-C and serum starvation in HEK293 cells. 
hCIPs and HEK293 cells were serum starved then treated with InM VEGF-C, or left untreated for 24hrs. 
LDH release from the cells was quantified and the percentage (of cytotoxicity was then calculated. Data 
were expressed as mean+SEM the ratio of the percentage of cytotoxicity (treatment/serum starvation). A. 
The effects (of VEGF-C on the percentage of cytotoxicity were compared to previous results showing the 
effects of VEGF on the percentage of cytotoxicity in hCIPs. Both VECF-C and VEGF significantly 
reduced the percent of cytotoxicity (treatment/serum starvation), induced by serum starvation. B. There 
was no significant difference in the effects of VEGF-C compared to serum starvation in IIEK293 cells. 
Unpaired t-test, *=p<0.05, ***=p<0.001, n=16. 
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VEGF-C reduced serum starved induced cytotoxicity in hCIPs as predicted (figure 9.3). 
VEGF-C appeared to reduce cytotoxicity to a greater extent than VEGF. There was a 
reduction in the ratio of cytotoxicity by VEGF-C of 70.8±3.8% of cells that had been serum 
starved (p<0.001, figure 9.3 A) compared to a reduction in the ratio of cytotoxicity by VEGF 
of 77.3±4. % (p<0.04, figure 9.3 A). In contrast, VEGF-C had no significant effect on 
cytotoxicity in HEK 293 cells, which had been serum starved (figure 9.3 B). HEK 293 cells 
do not express any VEGF receptors therefore these results demonstrate that the reduction in 
cytotoxicity in hCIPs, induced by VEGF-C was cell specific. Presumably, the reduction in 
cytotoxicity in hCIPs incubated in VEGF-C was due to either reduced necrosis or apoptosis. 
VEGF-C and VEGF regulate similar survival pathways in endothelial cells (lymphatic and 
vascular respectively), therefore I predicted that VEGF-C would also reduce apoptosis in 
hCIPs as was seen for VEGF (chapter 6). 
9.3.2 The effects of VEGF-C on apoptosis 
The chronic serum starvation assay, developed to investigate the effects of VEGF on apoptosis 
in hCIPs was also used to investigate the effects of VEGF-C on apoptosis in hClPs. This was 
so that a significant level of apoptosis was achieved by serum starvation in differentiated 
hCIPs, as discussed in chapter 6. hCIPs were serum starved for l6hrs then the media was 
replaced with fresh serum free media either with VEGF-C or without, for 8hrs and then the 
media was replaced again with complete media, which was left for 48hrs. The cells were 
serum starved again for 16hrs, the media was replaced with fresh serum free media either with 
VEGF-C or without for 4hrs and the cells were then scraped into suspension and rolled for a 
further 4hrs. Surprisingly, VEGF-C did not have a significant effect on AV stained cell sub- 
populations even though a significant proportion of serum starved cells stained for AV 
(17.4±3.2% of the total cell population, figure 9.4 Q. VEGF-C did not have a significant 
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effect on any of the other cell sub-populations either (figure 9.4 Q. To verify that a change in 
apoptosis was not lost due to the definitions of the regions in the flow cytometry protocol, the 
percentage of AV positive cells (expressed as a percentage of total fluorescence picked up at 
525nm) in VEGF treated cells was normalised to that of serum starved cells. There was, 
however, no significant difference in AV positive cells between treatments (1.29±0.32 fold 
change, p=0.46 one sample Mest, n=3, not shown). 
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Figure 9.4. The effects of VEGF-C on aimptosis and necrosis in hCIPs. 
hCUPs were chronically serum starved and treated with VEGF-C or left untreated. Cells were assaved bv 
flow cYtometry. A. A comparison of AV and PI labelling of InM VEGF-C treated hClPs compared to 
untreated hC[Ps, showing no visual difference in cell sub-populations. B. Characteristics of cell sub- 
populations in chronically serum starved InM VEGF-C treated hCIPs compared to untreated WIN. 
There was no significant difference in cell sub-populations treated with VEGF-C and left untreated. C. 
Data were expressed as mean+SEM percentage of total cell population. Compared to serum starvation 
alone, VEGF-C had no significant effect on any of the cell sub-populations (n. s. &)nferroni, n=3). 
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VEGF-C does however reduce cytotoxicity (figure 9.3 A) so it is reasonable to assume that it 
does affect either necrotic or apoptotic sub-populations. It is possible that VEGF-C works 
over a different time course to VEGF. Thus, it is difficult to investigate the effect of VEGF-C 
on apoptosis, using this assay, because apoptosis in hCIPs can only be induced under 
chronically serum starved conditions. It may be that VEGF-C acts to reduce necrosis, not 
apoptosis. Necrotic sub populations can be induced in hCIPs using a much shorter time course 
(figures 6.10 Ai and Q. This assay needs further optimisation to assess the effects of VEGF- 
C on necrosis and apoptosis. 
A VEGF-C cell-signalling pathway linked with reduced apoptosis is the P13- 
Kinase/phosphorylated AKT pathway. To further investigate potential survival pathways 
induced by VEGF-C in hCIPs the effects of VEGF-C on AKT phosphorylation in hClPs was 
examined. hCIPs were serum starved and treated with InM VEGF-C for 10 minutes and then 
protein was extracted. The cell lysate was subjected to SDS PAGE and transferred to a PVDF 
membrane, which was probed with an anti-phospho-AKT antibody. It was then stripped and 
re-probed with an anti-AKT antibody and the intensity of the bands corresponding to phospho- 
AKT were normalised to the intensity of the bands corresponding to AKT. These results were 
compared to previous results showing the effects of VEGF on AKT phosphorylation. It was 
previously shown in chapter 8, that VEGF reduced AKT phosphorylation in hCIPs that had 
been serum starved. I predicted that VEGF-C would have the same effect on phosphorylated 
AKT as VEGF in hCIPs. This however was not the case. There was no significant effect on 
AKT phosphorylation induced by serum starvation in cells that were treated with VEGF-C 
(0.87±0.12 fold lower than that in cells that had been serum starved, figure 9.5). The 
phosphorylated AKT levels in hC1Ps treated with VEGF, however, were significantly lower 
than that in hClPs treated with VEGF-C; in VEGF treated cells AKT phosphorylation was 
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0.37±0.08 fold lower and in VEGF-C treated cells it was 0.87±0.12 fold lower than serum 
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Figure 9.5. Effects of I nM VEGFC on AKT phosphorývlation compared to VEGF in hClPs. 
hCIPs were serum starved and treated with VEGF for 20 minutes, VEGF-C for 10 minutes. (or the cells 
were left untreated for the appropriate amount of time. PVDF membranes containing this protein were 
probed with an anti-phospho-AKT antibody then stripped and re-probed with an anti-AKT antibotiv. 
Data were expressed as mean+SEM ratios: phospho-AKT (treatment/serum starvation)/total AKT 
(treatment/serum starvation). AKT phosphorylation induced by InM VEGFC was not significantlý 
different to serum starved levels, but it was significantly greater than in InM VEGF treated. Unpaired I- 
test. *=p<0.05, n=3 and 5 respectively. SS = serum starved cells. 
These results indicate that VEGF-C does not activate the AKT survival pathway in hClPs. 
VEGF-C survival signalling has also been associated with elevated levels of phosphorylated 
MAPK in HMVECs. Hence, the effect of VEGF-C on MAPK phosphorylation in hCIPs was 
investigated. hCIPs were serum starved, then treated with VEGF for 20 minutes, VEGF-C for 
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10 minutes, a neutralising monoclonal antibody to VEGF for 24hrs or left untreated for the 
appropriate amount of time. Protein was extracted and subjected to SDS PAGE, then 
transferred to a PVDF membrane and probed with an anti-phospho-MAPK antibody, then 
stripped and re-probed with an anti-MAPK antibody. Compared to VEGF treated cells 
(1.25±0.12 fold greater than serum starved phospho-MAPK) and cells treated with a 
neutrallsing monoclonal antibody to VEGF (0.94±0.17 fold lower than serum starved 
phospho-MAPK). 
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Figure 9.6. Effects of exogenous and endogenous VEGF and VEGF-C on MAPK phosphorylation in 
hClPs. 
hCIPs were serum starved and incubated in VEGF, VEGF-Mab, VEGF-C or left untreated for the 
appropriate amount of time. PVDF membranes containing this protein were probed with an anti- 
phospho-1%1[APK antibody and then stripped and re-probed with an anti-MAPK antibOdl. DHta were 
expressed as mean+SEM ratios: phospho- MAPK (treatment/control)/total MAPK (treatment/control). 
InM VEGF-C significantly reduced p-NtAPK compared to VEGF treatment in hCIPS. *=p<0.05, ANOVA, 
Bonferroni post hoc test n=4. 
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The intensity of the band corresponding to phospho-MAPK was normalised to the intensity of 
the band corresponding to MAPK. Surprisingly, VEGF-C induced a significant reduction in 
phosphorylated MAPK levels (0.5±0.13 fold lower in than serum starved phospho-MAPK, 
p<0.05, ANOVA, figure 9.6). The increase in phosphorylated MAPK levels in cells treated 
with VEGF compared to that of serum starved cells was not significant (one sample Mest, 
n=4, not shown). It was interesting to note that neither VEGF nor the neutralising monoclonal 
antibody to VEGF significantly increased phospho-MAPK in cells that were serum starved 
(figure 9.6). This suggests that neither exogenous nor endogenous VEGF signal through 
MAPK phosphorylation in hCIPs, which is compatible with the absence of VEGF-R2. It may 
be that phosphorylated MAPK levels are constitutively high in serum starved KIN, as are 
phosphorylated AKT levels. These results suggest, therefore, that VEGF and VEGF-C 
activate different signalling pathways in hC1Ps to promote survival, although the pathways 
involved may still overlap. For example, VEGF-C may promote survival in hClPs via nephrin 
signalling. 
According to results from chapter 8, VEGF survival signalling in hCIPs is nephrin mediated. 
If VEGF-C does promote survival in hCIPs then it is possible that it also mediates survival 
through nephrin. signalling. This hypothesis was tested using the same method as the effects 
of VEGF on nephrin phosphorylation. hCIPs were serum starved and then incubated in I nM 
VEGF-C for 10 minutes, or left untreated for the appropriate amount of time. Protein was 
extracted and the cell lysate was subjected to immunoprecipitation, using an anti-p-Y 
antibody. The supernatant and precipitate were then subjected to SDS PAGE, transferred to a 
PVDF membrane and then probed with an anti-nephrin antibody. The mean intensity of the 
band corresponding to nephrin in the precipitate of each sample, measured by N111 image, was 
divided by the mean intensity of the band corresponding to nephrin in the supernatant of each 
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sample. This experiment was only repeated twice, so the results could not be tested for 
significance. Clearly though, there was a band of greater intensity corresponding to nephrin in 
the precipitate of VEGF-C treated cells compared to the intensity of the band corresponding to 
nephrin in the precipitate of the serum starved cells (figure 9.7 A). The intensity of the band 
corresponding to nephrin in the precipitate of each of the samples normalised to that in the 
supernatant is summarised in figure 9.7 B, which demonstrates graphically the greater 
intensity of the band corresponding to nephrin in the precipitate of VEGF-C treated cells. This 
suggests that VEGF-C can induce the phosphorylation of nephrin in WIN. 
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Figure 9.7. The effect. % of VEGF-C on nephrin phosphorylation in WIN. 
hCIPs were serum starved and treated with VEGF-C, or left untreated. Protein was immunoprecipitated 
using an anti-p-V antibody. Both the lysate and precipitate were subJected to SDS PAGE, transferred to a 
PVDF membrane and probed with an anti-nephrin antibody. A. An example of a PVDF membrane 
probed with an anti-nephrin antibody. InM VEGF-C treatment induced a more intense nephrin band in 
the precipitate compared to that of the band in the serum starved hClPs. B Data expressed as mean+SEM 
ratio of treatment/control: InM VEGF-C treatment resulted in a two fold increase in nephrin 
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phosphorylation compared to serum starvation whereas non-phosphorýlatcd nephrin was less in VECF-C 
treated cells, n=2. 
In HMVECs VEGF-C can mediate its effects through VFGF-R2 and VF. (; F-R3. Podocytes do 
not express VEGF-R2, therefore the phosphorylation ofnephrin by VF. GF-C was predicted to 
be VEGF-R3 dependent. To confirm that VEGF-C signalling in h(Al's was Vl: (11-' R3, 
dependent an immunoprecipitation was carried out to assess tile el , fects ol'VF(iF-(' on VI-'(1F- 
R3 tyrosine phosphorylation. hCIPs were serum starved and treated with or left 
untreated for 10 minutes. The protein was extracted and IMMUnoprecipitated using in anti- p- 
Y antibody and the precipitate and supernatant were subjected to SDS PAGF, 11ansterred to a 
PVDF membrane which was then probed with an anti-VFGF-R3 antibody. The membrane 
shown in figure 9.8, demonstrates that the intensity of the band corresponding to VF(IF-R. 3) 
was greater in the precipitate of the VEGF-C treated hCIPs compared to that In the precipitate 
of the untreated hClPs, which was negligible. 
I nM VEGF C Scrum starvation 
I pp, S/11 ppt S/1) 
VEGF-R3 
150kDa 
Figure 9.8. The effects of VEGF-C on VEGF-R3 tYrosine phosphorýlation in h('111's. 
hCIPs were serum starved and treated with VEGF-C or left untreated. Protein A as iminunoprecipitaled 
using an anti-p-V antibody. Both the lysate and precipitate were subJected to SDS PACE. transferred to a 
PVDF membrane and probed with an anti-VEGF-R3 antibody, sho"n in the figure. The infensilY of file 
hand corresponding to VEGF-R3 was greater in the precipitate (ppt) of the VEGF-C treatcd cells 
compared to that (of the serum star% ed cells. s/n =supernatant, n= 1. 
The intensity of the band corresponding to VEGF-R3 in the supernatant ofboth the 
treated cells and the untreated cells was very faint. This preliminary data (n I) sl, ý-Ivests that 
VEGF-C can induce the auto-phosphorylation of VEGF-R3 in IWII's Some interestiny 
preliminary results were observed during the optimisation ofthe anti-VI: GF-R ', MItIbOLk 011 
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old PVDF membranes containing precipitate and supernatant of h('11's treated with Vl'. (Il- 
The intensity of the band corresponding to VEGF-R3 was more intense in the precipitatc of 
VEGF treated hClPs compared to that of serum starved cells as shown in figure 9')A 
A 
I nM VEGF scruill stal-val, 101) 














VEGF ppt VEGF s/n SS PPI SS shl 
Figure 9.9. The effects of VEGF on the tyrosine phosphorflation (of VE(; F-R3 in WIN. 
hCIPs were serum starved and treated with VEGF or left untreated. Protein was immunoprecipilated 
using an anti-p-Y antibody. Both the lysate and precipitate "ere subjected too SDS PAGE, transferred to a 
PVDF membrane and probed with an anti-VEGF-R3 antibody. A. An example of a PVDF membrane 
containing, hCIP protein treated with VEGF and probed with an anti-VEGF-113 ikntibod. ý. There was a 
more intense hand corresponding to VEGF-R3 in the immunoprecipitate of cells treated "ith VTCF than 
that of serum starved cells. B. Data are expressed as mean+SEM ratio of band intensity background 
intensity. Ppt = precipitate, s/n = supernatant, n=2. 
The results from two expenments were summarised graphically in figure 1) 1) B, but dUC to thC 
small n value they were not analysed statistically. These results suggest that VFGI: can also 
induce the auto-phosphorylation of VEGF-R3 in hClPs directly or indirectIN, Flus \ýils 
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unexpected, but indicates that VEGF may signal through VEGF-RI and VEGF-R3 in cultured 
podocytes. These results demonstrate that VEGF-C can promote survival in cultured 
podocytes, probably through VEGF-R3 signalling, but through a different signalling pathway 
to that of VEGF. 
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9.4 Discussion 
There has been very little research to date concerning VEGF-C expression or function in 
podocytes. This is because until now it was not known that podocytes express VEGF-R3, a 
receptor for VEGF-C. This allows the possiblility that VEGF-C is functional in podocytes. 
VEGF-C is predominantly expressed in the lymphatics and promotes survival, growth and 
migration of lymphatic endothelial cells (Makinen et al., 2001). Yet during an 
immunohistochemical human tissue screen for VEGF-C protein recently in this laboratory, 
results were presented showing in situ VEGF-C protein expression in human renal cortex 
tissue sections (figure 9.1). VEGF-C protein was expressed in glomeruli in some cells that 
could only be described micro-anatomically as podocytes. This does not necessarily mean that 
VEGF-C is produced by podocytes-only mRNA expression can determine that definitively. 
Therefore, this study was to determine if VEGF-C could promote survival in podocytes, but it 
was not assumed that VEGF-C served an autocrine role. 
VEGF-C induced a reduction in [Ca2']i in hCIPs, which was proportionally similar to the 
reduction seen with VEGF. The baseline [Ca2jj levels in the VEGF-C set of experiments 
were much lower than those in the VEGF set of experiments. This may be due to a number of 
experimental variables such as the cells may have been less confluent in the VEGF-C 
experiments than the VEGF [C21i experiments, so that no matter how well the cells had 
loaded, if [C21i changes were measured in fewer cells then overall fluorescence levels would 
be lower. The lower the fluorescent signal the higher the background, which is demonstrated 
by a higher noise ratio on figure 9.2 B compared to figure 9.2 A. The possibility that VEGF-C 
does not have as much physiological significance as VEGF cannot be ruled out: if VEGF-C 
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reduces [Ca2+]i by' the same amount in cells with a higher baseline [Caýjj then the 
proportional effect of VEGF-C on podocyte[Caý+]j homeostasis, as discussed for VEGF, 
would be negligible. This is unlikely, however, as VEGF-C has quite obvious effects on 
podocytes as discussed below. 
VEGF-C induced a reduction in cytotoxicity in hCIPs that had been serum starved to an even 
greater extent than VEGF in cultured podocytes (figure 9.3). These results, together with the 
[Caýjj results indicate that VEGF-C activates a signalling cascade, which results in similar 
affects to VEGF, governed by VEGF-R3 and VEGF-RI respectively. In HMVECs VEGF-C 
has a more pronounced effect on signalling than VEGF, even though HMVECs express both 
VEGF-R2 and VEGF-R3 (Makinen et al., 2001). It was suggested that this was due to 
activation of both VEGF-R2 and VEGF-R3 by VEGF-C, unlike VEGF. The signalling 
pathways of both receptors were therefore suggested to be cumulative. This explanation 
cannot be applied to podocytes, which do not express VEGF-R2 unless VEGF-R3 can interact 
with, or modulate VEGF-R1. 
It is not known whether VEGF-C reduces cytotoxicity through the same means as VEGF, 
because the VEGF-C apoptosis assays were inconclusive and need to be optimised futher. 
Another approach was taken to investigate if VEGF-C induced survival, through AKT 
phosphorylation. The results showed that VEGF-C did not significantly affect AKT 
phosphorylation (figure 9.5), in contrast to VEGF. This was surprising, yet it narrows down 
the possibilities for VEGF-C survival signalling. 
MAPK phosphorylation, usually associated with mitogenesis in VEGF signalling, has been 
implicated in VEGF-C survival signalling in HMVECs (Makinen et al., 2001); MAPK 
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activates a signalling cascade, which increases transcription of pro-survival genes such as Bcl- 
2 and has also been shown to result in the phosphorylation of BAD at serine 112, a different 
serine residue to the one phosphorylated by activated AKT (Bonni et al., 1999). 1 therefore 
predicted that VEGF-C would increase MAPK phosphorylation in podocytes, but the results 
showed the opposite (figure 9.6). It is interesting that a similar effect was seen with VEGF on 
AKT phosphorylation. The results remain inconclusive as to how VEGF-C promotes survival, 
but they do show that VEGF-C signals through a separate pathway to VEGF in podocytes. 
If it was known that VEGF-C could signal through nephrin this would support the hypothesis 
that VEGF-C reduces apoptosis, because nephrin phosphorylation induced by VEGF is 
associated with reduced apoptosis. Immunoprecipitation studies demonstrated that VEGF-C 
could induce the phosphorylation of nephrin to a greater extent than in serum starved cells 
(figure 9.7). These results do provide huge potential for VEGF-C signalling and imply that 
VEGF-C promotes survival in podocytes by inhibiting apoptosis pathways. The means by 
which VEGF-C/VEGF-R3 signalling induces nephrin phosphorylation are as yet unclear as is 
the VEGF-C survival signalling pathway in podocytes and therefore should be investigated 
further and clarified. 
I assumed that VEGF-C signalling in podocytes was VEGF-R3 dependent. Preliminary data 
confirmed this, shown in figure 9.8, which demonstrated that VEGF-C could induce the 
phosphorylation of VEGF-R3. Surprisingly, VEGF could also induce the phosphorylation of 
VEGF-R3 (figure 9.9). Due to the inability of VEGF to bind directly to VEGF-R3 it is more 
likely that activation of VEGF-R3 by VEGF is via heterodimerisation of the VEGF receptors. 
Heterodimerisation has previously been shown between VEGF-R2 and VEGF-R3 by VEGF-C 
in lymphatic endothelial cells (Dixelius et al., 2003). This provides potential for VEGF-R3 
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and VEGF-RI heterodimerisation. This hypothesis may explain results seen in figure 6A a 
neutralising monoclonal antibody to VEGF induced a reduction in [C21i. I had predicted that 
when endogenous VEGF was blocked the VEGF induced reduction in [Caýjj would also be 
blocked. Blocking endogenous VEGF ensured that it could not bind to the receptor complex, 
yet a reduction in [C2+]i was still seen. VEGF-C, however, would still be able to bind to the 
putative VEGF-I/VEGF-R3 complexes, if indeed podocytes do produce VEGF-C. Inhibition 
of endogenous VEGF would therefore allow an increased effect of VEGF-C, which may 
account for the reduction in [C21i in cultured podocytes treated with a neutralising 
monoclonal antibody to VEGF. 
These results demonstrate that VEGF-C promotes survival in cultured podocytes through a 
separate signalling pathway to that of VEGF, via activation of VEGF-R3 and possibly a 
VEGF-R3/VEGF-RI complex. The signalling pathway includes nephrin phosphorylation, and 
effects MAPK phosphorylation. It is postulated that the end result is inhibition of apoptosis. 
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Chapter 10 
The effects of VEGF, 6. sb on cultured podocytes 
223 
10.1 Introduction 
The recent discovery of a new VEGF isoform in this laboratory (Bates et al., 2002) has 
complicated the potential interpretation of experiments investigating the effects of VEGF165 on 
podocytes. The new isoform is identical to VEGF165 except for the last six amino acids (figure 
10.1). The first 18 nucleotides of exon 8 of the VEGF gene are encoded in VEGF165, but this 
encoded region is replaced by a more distal splice site selection within exon 8, termed exon 8b 
(figure 10.1 A). The distal exon 8b is translated to the same number of amino acids as exon 8 
in the VIEGF165 protein (figure 10.1 Q. This new isoforin has been termed VEGF165b (Bates 
et al., 2002), (Cui et al., 2003). The consequence of the homology between these isoforms is 
that detection of what was previously thought to be VEGF165,, using antibodies or primers, 
could be VEGF165, VEGF165b or both. This is interesting since the function of VEGF165b is 
different 
to that of VEGF165 in endothelial cells. VEGF165b does not stimulate proliferation or 
migration of endothelial cells as VEGF165 does (Bates et al., 2002). VEGF165b actually 
competitively binds to VEGF-R2 on endothelial cells, thus blocking VEGF165 binding to 
VEGF-R2. When bound to VEGF-R2, VEGF165b does not seem to activate any signalling 
pathways, hence it blocks the proliferation and migration induced by VEGF165 in endothelial 
cells (Bates et al., 2002). VEGF165b is expressed endogenously in human tissue, including the 
kidney, but is downregulated in renal and prostate carcinomas (Bates et al., 2002). The major 
implications of VEGF165b to this project are outlined by Cui et al. Primers designed to 
distinguish VEGF165b from VEGF165, and short interference RNA (siRNA) designed to 
degrade VEGF165b specifically, showed that VEGF165b is primarily expressed by non- 
proliferative, differentiated hCIPs, rather than by de-differentiated, proliferative PCPs (Cui et 
al., 2003). 
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a Exon 7/8 boundary 
nt 518 608 
VEGF 165 AAGGCGAGGCAGCTTGAGTFAAACGAACGTACTrGCAGATGTGACAAGCCGAGGCGGTGAGCCGGGCAGGAGGAAGGAGCCTCCCTCAGGGT 
VEGF 165b AAGGCGAGGCAGCTTrAGTrAAACGAACGTACrTGCAG ------------------------------------------------------ 
nt 609 666 
VEGF 165 T-rCGGGAACCAGATCTCrCACCAGGAAAGACTGA, I'ACAý', AACGATCGATACACAAA(7. CAC 
VEGF 165b ------------ ATCTCTCACCAGGAAAGACTGA ! AACGATCGA, rACA, ýAAACI'Al' 
b 
aa 146 Exon 7 158 
Thr Asp Ser Arg Cys Lys Ala Arg Gin Leu Glu Leu Asn Glu Arg Thr Cys Ar Intron 
ACA GAC TCG CGT TGC I GCG AGG CAG CTr GAG TrA AAC GAA CGT ACT TGC AG gttggttcccagaggca.. -.. 
Amino acid no 160 165 1 
Intron g Cys Asp Lys Pro Arg Arg 
....... ttttccatttccctcag A TGT GAC AAG CCG AGG CGG TGA gccgggcaggaggaaggagcctcc 
aa no Exon 9 165 1g 
Ser Leu Thr Arg Lys Asp TUTR 




VEGF,. Thr Asp Ser Arg Cys Lys_Ala Ara Gln Leu Glu Leu Asn Glu &MThr Cys 8MCys Asp LY. LPro Ara Ara 
IIIIIIIIIIIIIIIIII 
VEGF,. b Thr Asp Ser Arg Cvs Lys Ala LkEIGIn Leu Glu Leu Asn Glu Arg Thr CVs IýUSer Leu Thr Arg Lys 
Figure 10.1. Sequence and putative structure and amino acid differences between VEGFI. Ah and VE(; F,.,. 
A. A comparison of the nucleotide sequences of VEGF165 and VEGF165b, the 66bp downstream of exon 7 
are missing from VEGF165b. B. The exon structure of the COOH-terminal end of VEGFI,,.,, and VE(; F,.. tl). 
The YUTR sequence of exon 8 contains a consensus intronic sequence for exon 9, a C`l'-rich region and a 
CAG immediately prior to the splice site. The nucleotide sequence results in an alternate 6-amino acid 
COOH terminus. Capital letters are open reading frames; lowercase letters are either infrons or YUTR 
(italics, VEGF16r,; bold VEGF165b). C. The predicted amino acid sequence of VE(; F,,!; comapred 14) 
VEGF165b. The six alternative amino acids result in a different COOH-terminal structure of the VEGF 
likely to affect receptor activation but not receptor binding or dimerization. The Cý -4 is replaced with a 
Ser, and the COOH-terminal amino acids are a basic (underlined) and an acidic (italics) moieft instead of 
two basic ones. Therefore, the net charge on this end of the molecule in-ill be altered (Genhank ref. No. 
AF430806). Taken from figure 5, (Bates et al., 2002). 
It has been hypothesised that VEGF165b expression in non-proliferative, differentiated 
podocytes reflects the VEGF isoform. expression in podocytes in the normal, mature kidney 
Furthermore, VEGF165b expression is downrcgulated in proliferative, de-differentlated 
podocytes, as it is in proliferative renal carcinomas compared to normal renal tissue (Bates et 
al., 2002). Therefore, VEGF expression by podocytes, shown by in sau hybridisation in figure 
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1.5, is likely to be a combination of VEGF165 and VEGF165b expression. Of the two isoforms 
the majority of expression in healthy, mature podocytes is probably VEGF165b because siRNA 
knockdown of VEGF165b in differentiated, cultured podocytes reduced the overall VEGF 
expression to less than a third of what it was in missense siRNA transfected cells. siRNA 
techniques though are not 100% effective. In addition podocytes are known to produce many 
VEGF isoforms (Simon et al., 1995) (Whittle et al., 1999), therefore the remaining VEGF 
expression may or may not include VEGF165 (Cui et al., 2003). Hence, the functional effects 
of VEGF165 in experiments described here do not fully cover the effects of VEGF on podocyte 
biology. If VEGF165b has the same function in podocytes as it has in endothelial cells then 
these two isoforms may actively oppose each other in podocytes. Therefore, the function of 
both isoforrns will be considered separately. 
At the time of the cytotoxicity experiments in this chapter there was no source of recombinant 
purified VEGF165b protein. VEGF165b protein was therefore produced in house by Dr J. 
Woolard: A pcDNA3 vector containing VEGF165b cDNA was transfected into non-VEGF 
expressing cells (CHO cells). These cells then expressed VEGF165b protein into the tissue 
culture media, which was quantified and used neat or diluted on cells. 
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10.2 Methods 
10.21 Condidonedinediafrom Chinese Hainster Ovary (CHO) cells 
CHO cells were transfected using the LipofectAmine Plus method (Invitrogen) with a pcDNA3 
vector containing either 2gg VEGF165b cDNA or left empty. Cells were grown to conflucncy 
with the aid of 0.1% Geneticin (Gibco), to select for transfected cells. The F-12 CHO cell 
media was removed, the cells washed once with IXPBS and serum free RPMI media was 
added to the cells. CHO cells do not grow well in RPMI media so the incubation time was 
limited to a period of 48hrs. After this time the serum free RPMI media, conditioned by CHO 
cells that had been transfected with VEGF165b or an empty pcDNA3 vector, was removed 
(10ml) and kept separately at -200C until ready for use. The CHO cells were allowed to 
recover in complete F-12 media for at least 48hrs and then the process was repeated. 
IO. Z2 Enzyine linked inwtunoahsorbancy assay (ELISA)- quantification VEGF163b protein 
in conditioned inedia (CM. 
A 500gl sample was taken from each lot of CM before it was frozen down. The amount of 
VEGF165b protein was quantified using a commercially available pan-VEGF ELISA (R&, D, 
Systems, Abingdon, UK) according to manufacturers instructions. CHO cells do not producc 
VEGF normally (and cells transfected with empty vector produced no VEGF), so the VEGF 
protein quantified was known to be VEGF16sb produced by the transfected cells. 
10 Z3 VEGF, 65b antibody 
An antibody specific to the last nine amino acids of VEGF165b (see figure 10.1 A) was raised 
in mice in this laboratory. The antibody was cloned, purified and the specificity against 
VEGF165 was confirmed by Western Blotting. 
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10.24 Western blotting-expression of VEGFi65b in hCIPs 
Protein was extracted from serum starved hCIPs and quantified. A total of 20ng recombinant 
VEGF165 and VEGF165b protein (R&D, Systems, Abingdon, UK, developed after the 
cytotoxicity and apoptosis assays were carried out) plus the hCIP protein were subjected to 
SDS PAGE. Protein was transferred to a PVDF membrane and was then probed with 
OAAg/ml anti mouse monoclonal IgG anfl-VEGF165b primary antibody and 0.006Ag/ml IIRP 
conjugated goat anti-mouse IgG secondary antibody (Pierce, Cheshire, UK). The membrane 
w as stripped and re-probed with lAg/ml mouse monoclonal IgG2. anti-VEGF (C-1) primary 
antibody (Santa Cruz, Heidelberg, Germany) and 0.006Ag/ml HRP conjugated goat anfi- 
mouse IgG secondary antibody (Pierce, Cheshire, UK). 
IO. Z5 Cytotoxicity assay- effects of VEGF, 65b alone or in coinhinationwith VEGFi6s 
hCIPs were serum starved overnight using pcDNA3 CM- Cells were then treated with a range 
of concentrations of VEGF165b CM, a range of concentrations of VEGF165b CM combincd 
with InM VEGF, or left untreated in pcDNA3 CM for 24hrs. Low, experimental and high 
controls were assayed and quantified as described previously. 
]OZ6Apoptosisassay-effects of VEGFi65b alone or in combination )*, ith VECIF165. 
hCIPs were serum starved for 16hrs using pcDNA3 CM- Cells were then treated with 298pNI 
VEGF165b CM, InM VEGF165b in pcDNA3 CM, 298pM VEGF165b and I nNI VEGF165 or lcft 
untreated in pcDNA3 CM for 4hrs. Cells were then scraped into suspension and rolled for a 
further 4hrs. Cells were then assayed using the flow cytometer as previously described. 
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10.3 Results 
10.3.1 The expression of VEGF, 65b protein in differentiatedpodocytes 
To confirm that differentiated podocytes express VEGF165b protein a PVDF membranc 
containing protein from serum starved hCIPs and recombinant VEGFi65 and VEGF16sb protein 
was probed with anti-VEGF, stripped and re-probed with and-VEGF165b. The results wcre 
intriguing: A ladder of bands were seen in both blots and were reproducible (figure 10.2 A). 
These bands correspond to a number of VEGF isoforms that are summarised in table 10.1. 
The bands are split into three groups; VEGF monomers, VEGF dimers and large 
VEGFs. Larger molecular weight VEGFs are generated by an alternate translation initiation 
process at the CUG start codon in the 5'UTR region, upstream from the normal ATG start 
codon (Huez et al., 2001). Lower molecular weight VEGF fragments are produced by the 
cleavage of the carboxy-terminal domain by plasmin (c-terminal fragments) (Keyt et al., 
1996). 
The VEGF165b antibody was raised to the terminal 9 amino acids encoded for by the last three 
codons of exon 7 and the whole of exon 8b (see figure 10.1 A), yet the same bands wcre 
detected with the anti-VEGF165b antibody as with the and-VEGF165 antibody. This indicatcs 
that other common VEGF isoforms also have sister splice variants. These results confirin that 
differentiated podocytes express various VEGF isoforms, but that at least some of those 
isoforms are VEGF=b. These isoforms are also expressed in different proportions to cach 
other in differentiated hCIPs. 
The intensity of each band, from both cell lysates, was expressed as a percentage of the 
intensity of band e (figure 10.2 B-D). Anything over 100% was above saturation levcls and 
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could not be measured relative to the intensity of band e. The intensity of bands, a, b and c of 
the putative isoform monomers were lower than that of band e in the anti pan-VEGF blot (data 
expressed as a percentage of the intensity of band e: band a. 2.3-+1.8%, band b. 3.7±2.8% and 
band c. 4.1±3.3%, figure 10.2 B), yet only the intensifies of bands a appeared lower in the 
anti-VEGF.. b blot (band a. 73.5±10.2% of the intensity of band e, figure 10.2 B). Of the 
bands corresponding to VEGF dimers, bands f and g appeared to have a lower intensity than 
that of band e in the anti-pan VEGF blot (data expressed as a percentage of the intensity of 
band e: band f. 64±7.2 %, band g. 70.3±5.4%, figure 10.2 Q. The same was seen in the anti- 
VEGF.., b blot; of the VEGF dimers bands f and g appeared to have a lower intensity than that 
of band e (data expressed as a percentage of the intensity of band e: band f. 85.9±3%, band g. 
77±9%, figure 10.2 Q. Of the large VEGFs, neither the intensity of the bands in the pan-anfl- 
VEGF blot, nor the intensity of the bands on the anti-VEGF,,, b blot were lower than that of 
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Figure 10.2. hClPs express VEGF, 65b protein and other VEGF ... b isoforms 
A. Multiple bands were seen when a PVDF membrane, containing hCIP protein, recombinant VEGFIg 
., 
I) antibodý. Similar bands and VEGF165b protein was probed with an anti pan-VEGF and an anti-VEGFI, I, 
were seen with both probes; the multiple bands corresponded to postulated sister splice %ariants of the 
, b, VEGF 
b, VEGF121b etc. Human recombinant VE(; F,,,, and common isoforms VEGFIs9b, VEGF16r 14c 
VEGF, 6sb protein was used to demonstrate the specificity of the antibodies. The inlen., lit, # (of each hand 
was expressed as mean+SEM percentage of intensity of band c (B-D). Bands %ere defined liý "hether theý 
Dimers 
Anti-VEGF16, b antibody 
hum rec human 
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Anti-pan VEGF Anti-VEGF.., b 
were monomers (B), dimers (C), or large VEGFs according to their corresponding estimated molecular 
weights as idicated in table 10.1. 
Table 10.1. The various calculated molecular weights (NM of VEGF and VEGF.. b Isoforms. 
Polypeptide species 
II aa C terminal fragment of VEGF121 
35 aa C terminal fragment of VEGFI 45 
55 aa C terminal fragment of VEGF, 65 
73 aa, C terminal fragment of VEGF, &3 
79 aa C terminal fragment of VEGF, gg 













VEGF. b antibody Pan-VEGF antibody 
MW (kDa) MW (kDa) 






96 11.1 110 12.7 25.3 
121 13.9 (a) 27.9 (d) 121 13.9(s) 27.9 (d) 
145 16.7 (b) 33.4 (c) 145 16.7 (b) 33.4 (c) 
165 19.0 (c) A0 (f) 165 19.0 (C) 3&0 (f) 
183 21.1 42.1 183 21.1 42.1 
189 21.8 43.5 189 21.8 43.5 
206 23.7 47.4 (g) 206 23.7 47.4 (g) 
314 36.2 72.3 314 36.2 72.3 
338 38.9 77.8 338 38.9 77.8 
358 41.2 82.4 358 41.2 82.4 
376 43.3 86.6 376 43.3 86.6 
382 44.0 88.0 (h) 382 44.0 88.0 (h) 
399 45.9 91.9 (1) 399 45.9 91.9(l) 
The molecular weights of various VEGFs have been calculated according to whether they have been 
cleaved by plasmin, were the predicted molecular weight, or were larger than that predicted due to a 
different translation initiation process. The molecular weights for both monomers and dimers were also 
calculated and the corresponding number of amino acids was shown (courtesy of Dr D. Bates). Note; these 
putative bands do not include heterodimers. The estimated band sizes corresponding to bands &-I 
labelled 
on rigurel. 0-1A and their corresponding VEGF isoforms have been Indicated in brackets (bold). 
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10-3.2 The effects Of VEGF165b alone and in conjunction with VF, (; IV165 on c3lotoxicio, in 
h CIPY. 
As differentiated hClPs do express VEGF165b I proceeded to compare the effects ot'Vl-'. GFI,,,. b 
on survival with that of VEGF165 in hClPs. The function of VEGF165b in podocytes may be 
completely different to its function in endothelial cells. In order to comprehend the 
implications of possible expression of both VEGF isoforms in podocytes the function of' 
VEGF165b in podocytes was investigated. In endothelial cells VEGF, 65b does not seem to 
induce functional effects on its own. The effects of VEGF165b on cytotoxicity in hCH's were 







- 100 0 
CD 







Concentration VEGF165b (pM) 
Figure 10.3. The effects of VEGF, 65b on cytotoxicity in differentiated hClPs- 
Serum starved hCIPs were incubated in conditioned media containing increasing concentrations (if 
VEGF, 6sb for 24hrs and then the amount of LDH release from the cells was quantified. The percentalte (if 
cytotoxicity was calculated from this. Data were expressed as mean+SEM percentage change in 
cytotoxicity, normalised to serum free peDNA3 CM values. VEGFI&J) dose-dependentl% reduced 
Cytotoxicity compared to treatment with pcDNA3 CM in hCH's. **=p<O. f)l. n= !5N. ANOVA nIIh 
Bartletts post Hoc test- 
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pcDNA3 8.125 16.25 32.5 65 130 179 
hCIPs were serum starved for 16hrs and the media was replaced with a mixture of serum free 
CM from CHO cells that were transfected with a pcDNA3 vector containing VEGF165b protein 
or left empty, mixed to give an increasing concentration of VEGF165b and left for 24hrs. The 
amount of LDH released into the media for the low, experimental and high controls was 
quantified using a colourimetric assay and these values were then used to calculate the 
percentage of cytotoxicity, as described in the methods. Unexpectedly, VEGF165b dose 
dependently decreased cytotoxicity in hCIPs (p. 0.01, ANOVA, figure 10.3). The maximum 
concentration of VEGF165b used was limited by the efficiency of the transfected C110 cells to 
produce the VEGF165b protein. Therefore, the VEGF165b concentrations were very low 
compared to those used for VEGF165. Nevertheless, VEGF165b was effective at significantly 
reducing cytotoxicity from a concentration as low as 8.125pM VEGF163b (88.013.2 percentage 
change in cytotoxicity of serum free pcDNA3 CM treated cells, p<0.01, figure 10.3). 
It is possible that both VEGF165 and VEGF165b are expressed simultaneously undcr 
physiological conditions in podocytes. Th e effects of VEGF165b on cytotoxicity werc 
therefore investigated in the presence of VEGF165. hCIPs were serum starved for 16hrs thcn 
incubated in serum free CM from CHO cells expressing VEGF165b. The CNI containing 
VEGF165b protein was used in increasing concentrations, from 8.125pM to 179pNI in the 
presence of InM VEGF165- The amount of LDH released into the media was quanfiricd using 
a colourimetric assay and the percentage of cytotoxicity was calculated from this. 
Surprisingly, in the presence of InM VEGF165 VEGF165b dose dependcntly incrcascd 
cytotoxicity (figure 10.4). At a concentration of 32.5pM, VEGF165b blocked the reduction in 
cytotoxicity induced by InM VEGF165 to the same cytotoxicity levels as cells incubatcd in 
serum free CM (IML9 percentage increase in cytotoxicity of that in serum free pcDNAj C&I 
treated cells, figure 10.4). At a concentration of 65pM of VEGF165b protein, thcrc was a 
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significant increase in cytotoxicity compared to the other concentrations of VI-GF,,, 5b protein 
(151±9.4 percentage increase in cytotoxicity of that in serum free pcDNA., CM treated cells, 
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Figure 10.4. The effects of VEGF, 65b on the reduction in cytotoxicity induced by. VEGFIs. 
Serum starved hCIPs were incubated in CM containing an increasing dose of VEGF, 6gb protein in the 
presence of InM recombinant VEGF16s protein, or left untreated in CM for 24hrs. The amount of LDII 
release from cells was quantified and the percentage of cytotoxicity was calculated. Data inerr expressed am 
mean+SEM percentage change in cytotoxicity, normalised to serum free CM. In the presence of InM 
VEGF165 VEGF165b dose dependently blocked the reduction in cytotoxicity induced hý VEGFI. & and also 
significantly increased the percentage of cytotoxicity compared to cells incubated in serum free pcDNAj 
CM. *=P<0.0.5, **=p<0.01, ***=p<0.001, ANOVA with Bartletts post I-loc test. 
These results indicate that VEGF165b has a more potent beneficial effect than vI-"(, I,,, (it, 
cytotoxicity in podocytes because the concentration required for VEGI-',,, 5b (I OOpM) to teduce 
cytotoxicity to the same extent as that of VEGF165 (InM) was significantly lower. Vl-. '(iF,,,.. b 
reduced cytotoxicity to 39.2±1.03 percent of that in serum free CM treated cells (p- 001. 
ANOVA, figure 10.3) at a concentration of 179pM. This demonstrated that %, vas 
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also more efficacious than VEGF165, since a concentration as high as InM VEGF16s did not 
reduce cytotoxicity to the same extent (52.1±4.9 percent of that in serum free pcDNA3 Chi 
treated cells, p<0.05, ANOVA, figure 10.4). These results suggest that VEGF165b antagoniscs 
the survival effects of VEGF165. It also suggests that VEGF165b is more potent than VE-GFi6s. 
Since VEGF165b in conjunction with VEGF165 can result in an increase in cytotoxicity then it 
would be interesting to know if it did this via an increase in apoptosis or necrosis. Thcrcforc, 
preliminary apoptosis assays were conducted to study the effects of VEGF165b in conjunction 
with VEGF165 on hCEPs. 
hC1Ps were serum starved for 16hrs and were then incubated in serum free media containing 
20% CM or serum free media containing 20% VEGF165b CM (300pM). Cells were also 
incubated in 20% CM containing InM recombinant VEGF or both InM VEGF and 300pN1 
VEGF165b protein. The amount of CM media used in each experiment was limited to 20% 
because CM was limited. Samples were treated for 4hrs then scraped into suspension within 
the same media and rolled for a further 4hrs and then assayed by the flow cytomctcr. The 
Samples were run through a different protocol on the flow cytometer compared to that used in 
chapters 6 and 9 because these experiments were actually carried out first. The discriminator 
settings on the flow cytometer were changed after these experiments because the 
autofluorescence values were too high demonstrated by the "tails" in the AV regions (figure 
10.5 A). The percentage of cells of the entire population stained with AV (i. e. met the criteria 
for apoptosis) may therefore have been overestimated in the scattergrams. These preliminary 
results however clearly demonstrated a difference in sub-populations between hClPs serum 
starved in 20% CM and those treated with VEGF165b, VEGF165, and a combination of both at 
least in this one experiment. Interestingly, cells incubated with both VEGF165/CNI and 
VEGF165b/CM appeared to have a lower percentage of cells that stained with AV alone (i. e. 
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met the criteria for apoptosis) than those incubated in serum free CM: Of the total cell 
population, 51.7% of cells stained with AV alone when treated with serum free CNI, 0.4% 
stained with AV alone when treated with serum free CM containing VEGF165, and 0% stained 
with AV alone when cells were incubated with serum free CM containing 300pN1 VEGF165b 
(figure 10.5, Q. A combination of both isoforms resulted in a greater amount of cells staining 
for AV alone than either isoform by itself. Of the total cell population 10.8% of cells stained 
with AV alone when treated with serum free CM containing InM VEGF, 65 plus 300pN1 
VEGF165b. In all treatments with VEGF isoforms there was an increase in the cell populations 
that picked up neither stain (i. e. met the criteria for viable cells) compared to cells that had 
been serum starved: Of the total cell population 36.5% of cells picked up neither stain when 
treated with serum free CM, 93.2% of cells picked up neither stain when treated with serum 
free CM containing VEGF165,84.9% of cells picked up neither stain when treated with serum 
free CM containing 300pM VEGF165b and 81.9% of cells picked up neither stain when treated 
with serum free CM containing InM VEGF165 plus 300pM VEGF165b. There was no obvious 
difference between the populations stained with PI alone or both PI and AV. These results 
suggest that VEGF165 and VEGF165b can individually reduce apoptosis, although together act 
to reduce apoptosis to a lesser extent than individually. 
I- 
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FigurelO. S. The effects of VEGF165b on apoptosis compared to and in combination "ith VEGFI. A. 
Differentiated WIN were serum starved for 16hrs and incubated in CM containing VE(; F, Mb p"14ein. 
CM containing recombinant VEGFI(,, protein or CM with an empty peDNA., sector for 4hr. 1. Cells were 
then scraped into suspension and rolled for a further 4 hrs before being assayed. A. Comparison tof 
differences in sub-populations in hCIPs incubated in of InM VEGF (A-111). 3(K)pM VFGF166b (A. 11). IMM 
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VEGF16, b and VEGF,,,, 
VEGF16sf3OOpM VEGF165b (A. M and untreated cells (A. 1) in serum free 20% CM. B. Characteristics of 
cell populations in hCIPs, which have been serum starved In 20% CM and treated with InSl VEGF 
(B. IH), 300pM VEGF16sb (B. H) and InM VEGF,, 5/300pM VEGF165b (B. IV) or left untreated (B. 1) as a 
proportion of the total cell population. C. Data were expressed as mean+SEM percentage of total 
population. VEGF16s and VEGF165b both reduce apoptosis to a negligible amount compared to serum free 
20% conditioned media control. In combination apoptosis was reduced compared to that of the control, 
but by a lesser amount than either treatment alone, n--1). 
Of note apoptosis was induced much more readily using serum free CM rather than serum free 
RPML This was probably due to various cytokines released by the CHO cells into the RPNII 
media. From these results it appears that VEGF165b on its own has similar effects on podocytc 
survival to those of VEGF165 on its own. Together, these isoforms may antagonise each other 
and induce an opposite or lesser effect. There is of course a huge amount of further research 
that could be done in this area, but these results are loaded with implications of the effects of 
V"ýG]7165b on podocyte biology. 
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10.4 Discussion 
The effects of VEGF165 on podocyte biology were previously studied in this thesis because 
podocytes express high levels of VEGF under physiological conditions (figure 1.5) despite 
little overt angiogenesis in the mature glomerulus. It had previously been thought that this 
VEGF expression was conventional VEGF121, VEGF165 and VEGF189. The discovery that 
podocytes expressed a potentially anti-angiogenic isoform of VEGF - VEGF1r, 5b (Bates et al., 
2002) possibly more abundantly than VEGF165 has significant potential in so far as podocyte 
biology and function were concerned. Hence, the basic effects of VEGF165b on podocyte 
survival were determined and, more importantly, the effects of the two isoforms combined, in 
an attempt to decipher the role of VEGF production on podocyte biology. 
VEGF165b protein production by podocytes had previously been shown by quantification using 
a pan-VEGF ELISA on media from differentiated podocytes that had been transfected with a 
VEGF165b siRNA match or mismatch siRNA (Cui et al., 2003). The expression of total VEGF 
was visualised compared to VEGF165b expression using western blotting with an anti-pan 
VEGF and an anti-VEGF165b specific antibody (figure 10.2). The VEGF165b blot shows bands 
of greater intensity than the VEGF165 blot despite the fact that the and-VEGF165b antibody 
was used at a lower concentration (0.4Aglml) compared to the anti pan-VEGF antibody 
(lAg/ml). This indicates that the anti-VEGF165b antibody has a greater binding affinity, 
therefore unfortunately VEGF165b cannot be expressed as a proportion of total VEGF. 
Multiple bands were seen in serum starved cell lysate isolated from two separate tissue culture 
flasks. This suggests the possibility that apart from glycosylated products, monomers and 
dimers, the extra bands correspond to different length isoforms from full length VEGF206 to 
VEGF121- Bands of the same molecular weight were seen in the blots probed with anti- 
VEGF165b antibody, which, because the anti-VEGF165b antibody is specific to any VEGF 
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isoform with an amino acid sequence corresponding to exon 8b, suggests that for each VEGF 
isoform there is a sister VEGF.. b isoform. This hypothesis was first postulated by Cui et al 
(Cui et al., 2003), but this is the first time it has been supported by experimental evidence. 
Densitometry analysis was carried out on these Western blots and was expressed as a 
percentage of intensity of band e in each lysate as an internal control. Interestingly, some 
bands had proportionately different intensifies in the anti VEGF ... b blot compared to the anti 
pan-VEGF blot. For example the intensity of bands a, b and c were much lower in the pan 
anti-VEGF blot whereas in the anti-VEGF ... b blot the intensity of these bands were similar to 
that of band e. By corresponding the molecular weight of these bands to those in table 10.1, it 
appears that bands a, b and c are the VEGF monomers-VEGF121 and VEGF121b, VEGF145 and 
VEGF145b, and VEGF165 and VEGF165b. This suggests that VEGF121b, VEGF145b and 
VEGF165b monomers are present in greater proportions compared to band e in cultured 
podocytes than their sister isoforms. The scope of VEGF research in podocytes is therefore 
far greater than just VEGF165 and VEGF165b and these implications may stretch beyond 
podocytes to the rest of the VEGF expressing tissues in the human body. 
Published work shows that VEGF165b inhibits the effects of VEGF165 induced proliferation, 
migration and vasodilatation in endothelial cells, yet by itself induces no significant effect 
from serum starved cells (Bates et al., 2002). It was therefore surprising to see that VEGF165b 
could induce a dose dependent reduction in cytotoxicity in cultured podocytes. Firstly, 
because it was not known that VEGF165b was able to induce its own signalling effects and 
secondly because, if anything, it was expected that VEGF165b would have the opposite effect 
to that of VEGF165. The effects of VEGF165b were surprisingly potent for the low 
concentrations used. It was yet more surprising to see that VEGF165b dose dependently 
inhibited the InM VEGF165 induced reduction in cytotoxicity and, from a concentration ofjust 
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65pM, actually increased cytotoxicity in cultured podocytes (figure 10.4). When VEGF165b 
and VEGF165 were used in combination in experiments, they were mixed prior to adding to the 
cells to avoid one isoform binding to the receptors more dominantly than the other. In 
endothelial cells VEGF165b competitively binds VEGF-R2, yet it does not initiate the normal 
signalling pathways that VEGF165 does (Woolard et al, Cancer Research, in press). The 
effects of VEGF165b on VEGF-RI and VEGF-R3 signalling have not yet been studied in 
endothelial cells, but the effects may well be different to VEGF-R2. It is not surprising then, 
that VEGF165b had a different effect on signalling in podocytes than on endothelial cells. It is 
not known whether VEGF165b binds VEGF-RI homodimers, or VEGF-RINEGF-R3 
heterodimers in podocytes. In theory, VEGF165b signalling should be enhanced by Np-I in 
podocytes, because VEGF isoforms that contain an amino acid sequence corresponding to 
exon 7, including VEGF165b, are able to bind Np-I (Soker et al., 1997). The dynamics of 
VEGF-R3 and Np-2 on functional VEGF165b signalling cannot be predicted at this point but 
may be involved in podocyte signalling. In endothelial cells VEGF165b homodimers 
competitively bind to VEGF-R2 (Woolard et al, Cancer Research, submitted). They may also 
competitively bind to VEGF-RI or VEGF-RI/VEGF-R3 complexes in podocytes, which 
would inhibit the effects of VEGF165- VEGF165b, however, induces a reduction in cytotoxicity 
in podocytes, which suggests that it may be the receptor to which VEGF165b binds that 
determines whether VEGF165b has any signalling effects and not the protein itself. Indeed 
VEGF165b may be the ligand for VEGF-RI. It is interesting to note that VEGF-RI binds 
VEGF165 with a much greater binding affinity than VEGF-R2 (Neufeld et al., 1999) and if 
VEGF165b is signalling mainly through VEGF-RI in podocytes then this may explain the 
differences seen in response to VEGF165b in endothelial cells. In general VEGF biology it 
could be postulated that VEGF165b binds VEGF-RI, but that VEGF165 competes for the same 
receptorjust as VEGF165 binds VEGF-R2, but VEGF165b also competes for the same receptor. 
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The amino acid sequence corresponding to exon 8 has a proline bond, resulting in a putative 
kink, which the amino acid sequence corresponding to exon 8b lacks and this may effect 
protein stability and also conformation of the VEGF165b protein (Bates et al., 2002) (see figure 
10.113). This amino acid "kink" may be utilised in different ways in differerit receptor 
binding. The antagonistic effect of VEGF165b on VEGF165 in podocytes cannot be due to 
competitive inhibition as in endothelial cells, otherwise the same effects would be seen as 
VEGF165b binding alone. The results point to an interaction between the two proteins. In 
future the purified protein of the two isoforms should be used at the same concentrations to 
compare the binding affinities. The comparison of effects of VEGF165b protein in CM with 
purified human recombinant VEGF165 protein on podocytes is not ideal. The source of 
VEGF165 protein should have been the same as for VEGF165b, and many extraneous variables 
were probably introduced as a consequence. These experiments should therefore be repeated 
with purified, recombinant VEGF165b, which has become available within the last few weeks, 
to confirm that the results are the same. 
Preliminary apoptosis assay data shows a similar trend of effects of VEGF165b on apoptosis. 
VEGF165b massively reduced the serum free CM induced apoptosis in hCIPs as did VEGF165, 
together however, although apoptosis was still reduced compared to control it was increased 
compared to VEGF165b alone (figure 10.5). These results demonstrate that on its own 
VEGF165b has a similar effect to VEGF165 on survival in podocytes, but together VEGF165b 
may antagonise the effects of VEGF165 on apoptosis. The likelihood is that, in vivo both 
isoforms are expressed simultaneously but not in equal proportions. The effects of the 
isoforms may well depend on the balance between the two. It would be interesting to see the 
effect of purified human recombinant VEGF165b protein in the same assay, but in RPMI media 
not CM, which contains many extraneous variables that cannot be controlled. VEGF165 
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protein was used at a higher concentration than VEGF165b protein because VEGF165b appears 
to be more potent than VEGF165 protein, and VEGF165b protein could not be produced at a 
concentration of InM. 
It is hard to draw conclusions from these results to reflect physiological effects because there 
is not yet enough known about VEGF165 or VEGF165b protein production in differentiated 
podocytes. This data is vital as the ratio of the two isoforms will probably determine the 
actual effect. These results do give a glimpse of the complexity of interactions involved in 
VEGF signalling in podocytes and opens up a new area of research. The Results shown in 






The purpose of this investigation was to test the hypothesis that VEGF can act in an autocrine 
manner in cultured podocytes promoting survival through phosphorylation of nephrin and a 
reduction in apoptosis. The interaction of VEGF and nephrin could have been bypothesised 
because, even though nephrin expression is limited outside of the kidney, it is co-localised 
with VEGF in more than one organ. For example; VEGF is expressed by the endocrine cells 
of the Islets of Langerhans, within the pancreas, and VEGF-RI and VEGF-R2 are expressed 
by the endothelial-like P-cells (Christofori et al., 1995). Nephrin is also expressed by the P- 
cells of the Islets of Langerhans, on which VEGF is known to act (Palmen et al., 2001). The 
role of nephrin in the pancreas is not yet known, although it has been speculated that it is 
involved in P-cell-cell junctions (Palmen et al., 2001), hence it is not known if VEGF induces 
nephrin mediated signalling in the pancreas. VEGF, VEGF-RI and VEGF-R2 are expressed 
in Leydig cell and Sertoli cells in the testis (Ergun et al., 1997). Nephrin is also expressed by 
the Sertoli cells, which form a parallel array of tight junctions, of which nephrin is thought to 
form a part and constitute the blood-testis barrier (Liu et al., 2001). It is unknown whether 
VEGF can induce nephrin mediated signalling in these cells either, but VEGF induced nephrin 
mediated signalling in podocytes outlines a role for VEGF-nephrin interactions in other 
organs. 
The evidence from this investigation suggests that VEGF16s and VEGF-C promote the survival 
of cultured podocytes. VEGF165 (and presumably VEGF165b) are likely to interact with 
VIEGF-Rl. There is also the possibly that VEGF receptor complexes form at the plasma 
membrane of cultured podocytes involving VEGF-R3 and/or Np-I and/or Np-2. VEGF-C is 
thought to interact with VEGF-R3, again possibly complexed with Np-2 and/or VEGF-RI 
and/or Np-1. VEGF receptor auto-phosphorylation by VEGF165 induced the phosphorylation 
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of nephrin either directly or indirectly. The extent of involvement of P13-Kinase in VEGF 
mediated survival signalling is not yet known, although the evidence is contrary to the 
involvement of AKT phosphorylation. It is possible that the time course chosen for VEGF 
treatment in the AKT phosphorylation assay was not optimal and that an increase in AKT 
phosphorylation may have been missed. It would be interesting to investigate levels of basal 
AKT phosphorylation in unstarved cultured podocytes because these may be significantly 
greater than those seen in serum starved cultured podocytes. These experiments will be 
carried out at a future date. The signalling cascade induced by VEGF16s resulted in a 
reduction in cytotoxicity due to a reduction in apoptosis. The auto-phosphorylation of VEGF 
receptors by VEGF-C (most likely VEGF-R3) stimulated a signalling cascade, which induced 
a reduction in MAPK phosphorylation and the phosphorylation of nephrin. VEGF-C 
treatment also resulted in a reduction in cytotoxicity. It would also be interesting to 
investigate levels of basal MAPK phosphorylation in unstarved cultured podocytes because 
these may be significantly greater than those seen in serum starved cultured podocytes and 
may explain the unpredicted response to VEGF-C. In summary VEGF165 and VEGF-C 
therefore seem to promote survival via different signalling pathways in podocytes. 
There is still a large amount of research though that could be done to clarify the precise 
signalling pathways involved. The concept of VEGF signalling in podocytes is very complex, 
especially when all isoforms of VEGF, VEGF receptors and VEGF-C function are considered. 
It is important to form a concept that considers all of these components, and apply it to the 
entire glomerulus. 
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11.1.1 Physiological Relevance 
Terminally differentiated podocytes in healthy, mature glomeruli must be maintained because 
their turnover is so low and risk factors associated with podocyte loss are so high. The 
findings of this investigation suggest the possibility, in vivo, for VEGF to promote podocyte 
survival. VEGF is expressed throughout glomerulogenesis and in the mature glomerulus by 
podocytes (Simon et al., 1995). It is generally accepted that VEGF plays a paracrine role in 
vascularisation during glomerulogenesis (Simon et al., 1995) (Saxen and Sariola, 1987) and is 
also known that VEGF plays a paracrine role in the mature glomerulus (Eremina et al., 2003). 
The role of VEGF though is different during development than in maturity in vivo. During 
development (glomerulogenesis) VEGF effects follow an established route for VEGF 
signalling, such as inducing proliferation, migration and angiogenesis of endothelial cells (Wu 
et al., 2000), (Ilan et al., 1998). At maturity, however, VEGF is thought to maintain the entire 
filtration barrier (Simon et al., 1995), (Eremina et al., 2003) including, as suggested by 
evidence from work in this investigation, podocytes. The change in the role of VEGF in vivo 
appears to be clarified by the discovery that differentiated, cultured podocytes express 
VEGF165b (Cui et al., 2003)- an anti-angiogenic isoform of VEGF in endothelial cells (Bates 
et al., 2002) and de-differentiated cultured podocytes do not (Cui et al., 2003). It is possible 
that there is a splicing switch between VEGF165, the isoform that is able to mediate all of the 
VEGF induced events observed during glomerulogenesis, and VEGF165b, the isoform 
expressed in differentiated cultured podocytes, at podocyte differentiation in maturing 
glomeruli (in vivo). The results from chapter 10 showing the effects of VEGF165b on cultured 
podocytes (figures 10.3-10.5) supported this hypothesis. On its own VEGF165b appeared to 
have the same effects as VEGF165 on podocyte survival. Assuming that VEGF165b has the 
same effect on glomerular endothelial cells, in vivo as it does on other vascular endothelial 
cells (Bates et al., 2002) this would have no significant consequence on signalling in 
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glomerular endothelial cells. If VEGF165b were not expressed during glomerulogenesis then 
the effects of VEGF165 would not be hindered. Complications arise, however, with the 
simultaneous expression of VEGF165 and VEGF165b in vivo. According to Cui et al, VEGF165b 
mRNA is not expressed by proliferating, de-differentiated PCPs (with characteristics relating 
to immature podocytes in vivo), but it is possible that VEGF165 is expressed in low levels by 
differentiated podocytes (with characteristics relating to mature podocytes in vivo) (Cui et al., 
2003). According to the results describing the effects of VEGF165b with VEGF165 on 
podocytes (chapter 10, figures 10.3-10.4) this would induce an increase in cytotoxicity due to 
an unknown interaction of the two isoforms. If this were the case ill vivo then podocytes 
would die under normal conditions, which is not the case. This suggests that of the two VEGF 
isoforms VEGF165b expression dominates at maturity. If the splicing switch of the isoforms 
were at the time of podocyte differentiation this would explain a massive amount of podocyte 
death seen in culture when podocytes are thermo-switched to induce differentiation. This may 
also be applicable in vivo when podocytes begin to differentiate because there would probably 
be an overproduction of immature podocytes, whilst they were still proliferative. When 
podocytes differentiate in vivo they take up a lot more capillary surface area and hence there 
may not be enough space for all of the podocytes to differentiate. An increase in apoptosis, 
due to the temporary presence of both VEGF isoforms, would therefore decrease podocyte 
number surplus to requirement. It is vital to investigate whether VEGF165b is solely expressed 
in vivo at maturity, post-differentiation, to fully understand the effects of physiological effects 
of VEGF165b. 
The VEGF family of proteins in the mature glomerulus are undoubtedly part of a complex 
feedback system of growth factors and natural inhibitors controlling angiogenesis, 
permeability, survival and maintenance of the glomerular filtration barrier. Without knovAng 
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the physiological expression levels of all of these proteins and how they relate to each other it 
is very hard to predict the effect of individual growth factors, but it seems likely that 
imbalance in this system may contribute to the progression of glomerular disease. 
11.1.2 Pathological relevance 
VEGF has been implicated in many types of renal disease. In the past authors have tried to 
generalise glomerular VEGF expression to renal disease, but there have been many conflicting 
reports. This is probably because VEGF can induce an effect in glomerular endothelial cells, 
mesangial cells and podocytes, therefore a change in VEGF expression may have a different 
effect depending on which cell type is being studied. The type of renal disease may also affect 
VEGF expression and of course the effect of VEGF will change depending on whether 
VEGF165 or VEGF165b is being investigated. The key to protection of the glomerulus from 
many glomerular diseases may be to protect the mature state of the glomerulus. VEGF165b 
expression is switched to that of VEGF165 in renal carcinomas (Bates et al., 2002), making it a 
more exaggerated, developmental environment. The expression of podocyte VEGF receptors 
in disease states has not yet been considered in detail in the literature, but this is another 
variable that would affect VEGF signalling in the glomerulus. The state of the cells in 
pathology also needs to be considered. They may lose their function under sclerotic 
conditions, therefore levels of VEGF expression may change during the course of some 
diseases. Finally, the effects of VEGF need to be considered as part of an entire system within 
the glomerulus, particularly with expression of angiopoiefins and their receptors. 
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11.1.3 Future work 
11.1.3.1 VEGF, 65b expression in the glomerulus 
Future considerations as a result of this investigation should be channelled into confirming 
VEGF165b expression and function in mature podocytes. Firstly, confirmation of sole 
expression of VEGFi65b at maturity would ensure that investigations could concentrate on the 
effects of VEGF165b on podocyte biology, rather than a combination of VEGF165 and 
VEGF165b isoforms. This would be carried out using a primer designed specifically towards 
VEGF exon 8b, together with a primer designed towards VEGF exon 8a against cDNA 
reverse transcribed from mRNA extracted from both hCIPs and human isolated glomeruli. 
The splicing switch from VEGF165 to VEGF165b at differentiation could also be confirmed by 
investigating the semi -quantitative expression of both isoforms throughout hCIP 
differentiation, from 331C to 14 days at 37*C by PCR. It would be interesting to examine 
whether in diseased glomerular tissue the same splicing switch is seen as with renal 
carcinomas.. 
11.1.3.2 Interaction of VEGF with its receptors on podocytes 
A lot of the assumptions made on VEGF signalling in podocytes is based on speculation of 
VEGF-VEGF receptor interaction and receptor hetero- and homo-dimerization. These 
interactions need to be clarified, and may be best studied in cells that do not normally express 
VEGF or its receptors, such as CHO cells. Each receptor could be transfected by itself and the 
interactions with VEGF165 and VEGF165b studied using immunoprecipitation techniques. The 
receptors could then be double transfected under different combinations and their interactions 
re-evaluated. Once preliminary data has been collected using an artificial system then 
interactions could be examined in cultured podocytes. This could be done, again, using 
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immunoprecipitation studies. When it has been established which receptors are involved in 
VEGF binding to podocytes, then the signalling pathways could be clarified further. 
11.1.3.3 VEGF-C and VEGF165bfunction in podocyles 
Examination of the effects of VEGF-C and VEGF165b in cultured podocytes has only just 
begun. The signalling pathways should be studied in full, along the same lines as with the 
VEGF165 studies. Once these studies have been carried out then their function within the 
glomerular system should then be considered. 
11.1.3.4.4pplication of hypothesis in vivo 
There has been a lot of speculation made from the results of this investigation in application to 
physiology and pathology yet the results were obtained from an in vitro culture system. 
Therefore, experiments should be carried out to confirm that the same happens in vivo as in 
vitro. The simplest way of approaching this initially would be using an ex vivo system, 
namely isolated human glomeruli. Immunoprecipitation studies examining VEGF effects on 
nephrin phosphorylation would go a long way in confirming that VEGF promotes survival in 
podocytes in vivo via a nephrin mediated reduction in apoptosis. Various apoptosis methods 
could also be applied to glomeruli as a whole, including DNA fragmentation (ladder) detection 
and examination of cleaved caspase proteins using confocal microscopy in conjunction with 
an antibody towards a podocyte specific protein or Western Blotting. 
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